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Articular cartilage
Articular hyaline cartilage is a white, smooth structure covering the ends of bones 
in synovial joints, like in the hip and knee. Because of its unique stiff yet flexible 
properties, it distributes the loads, as a consequence of weight bearing and loco-
motion, over the surface of the joint and enables bones to smoothly glide over each 
other during movement. Besides in synovial joints, hyaline cartilage is also found 
in non-synovial joints where bones are connected via one cartilaginous structure 
providing load distribution and resilience, like between the vertebral bodies. 
Thus, hyaline cartilage enables us to walk, dance and run a marathon with low 
friction between our articulating bones, providing us quality of life. However, when 
damaged, it mostly fails to repair itself properly. Traumatic or degenerative articular 
cartilage defects may be chondral or osteochondral when the subchondral bone is 
involved too. Chondral lesions are painless and repair poorly due to the absence 
of a nervous and vasculature system within the cartilage (1, 2). When untreated, 
small cartilage lesions will slowly progress into full-thickness lesions of the cartilage 
layer and involving the underlying bone, resulting in pain, reduced mobility and 
decreased quality of life. Osteochondral lesions may heal by an initial inflammatory 
response followed by the formation of so-called fibrocartilage, which is of inferior 
mechanical quality (2, 3), resulting in early degradation and fragmentation and 
eventually the onset of osteoarthritis (OA).
Osteoarthritis 
Osteoarthritis is a common chronic joint disease with progressive cartilage deg-
radation as one of its major characteristics. Other aspects of OA involve changes 
in the subchondral bone, ligaments and synovium. It most frequently affects the 
knee, hip and hands. OA is related to age and has a high prevalence in the popula-
tion older than 60 years. Worldwide estimates are that 9.6% of men and 18.0% 
of women aged over 60 years have symptomatic osteoarthritis (data from World 
Health Organization, (4)). Moreover, the prevalence among younger age groups 
is increasing, partially due to the increase in overweight. Osteoarthritis is already 
one of the ten most disabling diseases in developed countries, 80% of patients 
with osteoarthritis will have limitations in movement and 25% cannot perform 
their major daily activities of life (WHO). The recently published Global Burden 
of Disease Study in The Lancet (5) estimated that the global years lived with dis-
ability because of OA increased by 64% over the period 1990-2010. Therefore, the 
economic burden of OA is high. 
12 Chapter 1
Current approaches in treatment of cartilage defects
Orthopedic surgeons currently use different nonoperative and operative tech-
niques to treat cartilage defects and OA. Nonoperative treatments include weight 
loss guidence, analgesics and physiotherapy. Operative approaches can be classi-
fied in roughly three groups, based on their principle:
1. Relieve of the damaged surface: osteotomy and knee joint distraction. An 
osteotomy is used to realign the axis of the limb to transfer the load from the 
damaged surface to a healthier part of the cartilage surface. With joint dis-
traction, an external fixation frame is bridging the knee joint, which in stages 
distracts the joint for 5 mm for several weeks inducing clinical improvement and 
decreasing the area of denuded bone (6). 
2. Replacement of the damaged surface: mosaicplasty and osteochondral 
plugs, total hip arthroplasty and total/unicompartmental knee arthroplasty. 
Osteochondral plugs are harvested from a non-weight-bearing surface of the 
ipsilateral joint and placed in a prepared cylindrical hole in the cartilage defect. 
In mosaicplasty multiple small osteochondral plugs are harvested and placed 
in a larger defect. However, both techniques induce morbidity to the donor site 
and only limited size defects can be treated (7, 8). Total or unicompartmental 
joint arthroplasty is used for severe joint degeneration. The joint is replaced 
by a prosthetic joint, resulting in relief of pain en (partially) regain of function. 
However, the lifespan of these prosthetic joints is limited and revision surgery is 
unfavorable. 
Previous mentioned nonoperative and operative treatments are mostly focused 
on relief of symptoms, particularly pain, and not focused on inducing cartilage 
repair or limiting progression of the disease. For the last decades, a lot of research 
worldwide has been focused on developing treatment techniques to regenerate 
the damaged cartilage into healthy hyaline cartilage with its unique biomechanical 
properties.
3. Regeneration of the damaged cartilage: microfracture, drilling and cell trans-
plantation techniques. Microfracture and drilling are techniques to penetrate 
the subchondral bone and establish access of blood flow and bone marrow. As 
a result, bone marrow stem cells and inflammatory factors enter the cartilage 
defect, initiating a repair response. However, often fibrocartilage is formed with 
inferior biomechanical properties than healthy hyaline cartilage (9). Cell trans-
plantation, like Autologous Chondrocyte Implantation (ACI), is a cell-based 
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repair strategy and was first described in 1994 by Brittberg (10). ACI involves 
harvesting cartilage from a healthy non-weight-bearing surface of the ipsilateral 
joint, isolating the cartilage specific cells, chondrocytes, in a laboratory, expand-
ing the chondrocytes in vitro and subsequently inserting them in the cartilage 
defect during a second surgery. To keep the cells in place, they can be covered 
with a membrane or can be pre-seeded in a matrix. The main purpose of ACI 
is to implant chondrocytes so that hyaline cartilage is formed which resembles 
normal hyaline articular cartilage. Good to excellent results have been obtained 
with this technique on the short-to-medium term of follow-up (11-13), but the 
use is limited to small traumatic cartilage defects in the younger patient and not 
suitable for the treatment of OA. The major complications are transplant failure, 
delaminiation of the transplant or graft hypertrophy (11, 14). 
The search for the ideal cartilage regeneration technique continues. Increasing 
interest is raised on improving the quality of the cartilage formed after cell trans-
plantation for example by using different cell sources (like stem cells) or optimizing 
the in vitro culture conditions during the expansion phase. However, the develop-
ment of a drug inducing hyaline cartilage repair in vivo in patients with OA is of 
course preferable and still desirable. For both goals, it is necessary to know what 
healthy articular cartilage is composed of and how it is formed. 
Formation and composition of articular cartilage
In vivo, cartilage is only formed during embryogenesis. Most skeletal tissues 
arise from mesenchymal (stem) cells, which have the ability to differentiate into 
fibrous tissue cells, fat cells, muscle cells, chondrocytes and bone cells. Specific 
transcription factors regulate the differentiation of mesenchymal cells into these 
different lineages. Formation of the skeleton can first be seen as a condensation 
of these mesenchymal cells, which differentiate into precartilagenous cells and 
finally a cartilage template is formed with chondrocytes expressing collagen type 
II and Sox 9. The mesenchymal cells give rise to two different kinds of cartilage: 
transient and permanent. In the limb, bone is formed by terminal differentiation of 
the transient chondrocytes into hypertrophic chondrocytes and mineralization of 
the tissue. However, when a joint needs to be formed, the precartilagenous tissue 
splits transversely and on either side of the joint permanent articular cartilage is 
formed, which does not terminally differentiate into bone. Additional condensa-
tion of mesenchymal cells forms the joint capsule, ligaments and tendons (15-17).
Articular cartilage has its unique properties related to the structure and composi-
tion of its extracellular matrix (ECM), which is mainly composed of proteoglycans 
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(PGs, like aggrecan) entangled in a network of collagen fibers (mainly collagen type 
II) and large amounts of water (18, 19). Water and inorganic salts represent the bulk 
mass portion (65-80%), while collagens, PGs and other (glyco-)proteins constitute 
only 20% of the tissue’s wet weight. Collagens represent 50-60% of cartilage’s dry 
weight, while proteoglycans, as second largest solid phase portion, account for 
5-10%. Only 1-5% of the cartilage volume consists of chondrocytes, the main cell 
type found in cartilage, embedded in the matrix (2, 18, 19)(Figure 1). The chon-
drocytes are responsible for maintenance of its surrounding matrix by a balance 
between synthesis and degradation of matrix-components.
Osmotic pressure in healthy and damaged articular cartilage
The extracellular matrix is crucial for the unique biomechanical properties of 
cartilage. Cartilage requires a high osmotic pressure to maintain its hydrostatic 
pressure and keep its visco-elastic properties. Proteoglycans (PGs) with negatively 
charged sulphated glycosaminoglycan (GAGs) side chains (20) attract mobile cat-
ions (mainly sodium) and water. An intact collagen network restricts swelling and, 
in combination with GAGs, determines the osmotic pressure (i.e. tonicity) of the 
extracellular fluid around chondrocytes, which ranges between 350 and 480 mOsm 
in healthy cartilage (21-23). The combination of intertwined collagens and PGs 
creates the tissue’s rigidity by entrapping solutes and water, giving cartilage its 
mechanical properties, enabling it to deform and undergo large compressive and 
shear forces without failing (19).
Figure 1. Schematic representation 
of extracellular matrix components in 
cartilage. Proteoglycans consist of a 
core protein (aggrecan) to which nu-
merous glycosaminoglycans (GAGs) 
are attached. Up to 100 proteoglycans 
are normally attached to a hyaluronic 
acid filament (not shown in the figure). 
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In healthy cartilage (Figure 2, Panel A), the osmotic pressure is lowest (±350 mOsm) 
in the superficial (S) zone and increases to ±480 mOsm in the deep (D) zone of 
the cartilage, where the collagen fibers are stiffest (more stretched) and PG con-
centration is highest (24). The osmotic pressure is dynamic and changes under 
(patho)physiological conditions. In loaded cartilage (Figure 2, Panel B), the matrix 
deforms, squeezing water out of the tissue, increasing cation concentration and 
thus the osmotic pressure. The deformation and increase in osmotic pressure are 
more prominent in the superficial (S) and middle (M) layers than in the stiffer deep 
(D) layers of the cartilage. In osteoarthritic cartilage (Figure 2, Panel C), collagen 
fibers are degraded. The initial effect of collagen degradation is more swelling 
of the cartilage matrix, since there is less resistence of the collagen fibers (25). If 
there is also proteoglycan and GAG degradation the osmotic pressure drops (24, 
26) as well as cartilage swelling and thus leading to a less stiff cartilage layer that 
becomes more susceptible for further degradation. 
However the osmolarity in the extracellular matrix can also be affected by the 
uptake or release of ions by the cells. Cells have an active control system using 
complex channels that can transport ions to keep their osmolarity within specific 
Figure 2. Illustration of the zonal regulation of osmotic pressure in healthy (A), loaded (B) and early 
stage of osteoarthritic (C) cartilage.
16 Chapter 1
boundaries. These transporters interact with various systems within and outside 
the cell.
Molecular mechanisms in response to changes in extracellular 
osmotic pressure
Molecular mechanisms involved in the response of human articular chondrocytes 
to changes in osmotic pressure are poorly understood. Extracellular hyperosmolar-
ity perturbs mammalian cells by causing osmotic efflux of water, resulting in cell 
shrinkage (27, 28). Cells react by a rapid uptake of ions, which increase cellular 
ionic strength (29) with potentially detrimental effects (30-32). The initial, rapid 
response is the activation of transporters that exchange these ions for compatible 
osmolytes (32, 33). This process is controlled by Nuclear factor of activated T-cells 5 
(NFAT5, also called Tonicity-responsive Enhancer Binding Protein, TonEBP), which 
mediates transcriptional activation of these transporters (32). NFAT5 is a member 
of the Nuclear factor of activated T-cells (NFAT) transcription factors (34) and was 
first discovered for its function in kidney cells. It targets sodium/myo-inositol 
cotransporter (SMIT) (35, 36), sodium/chloride-coupled acid transporters (BGT1/
SLC6A12)(35), aquaporin channels (AQP1 and AQP2) (37), and calcium-binding 
proteins (S100A4) (38-40). Upon hyperosmotic stress, transcription of NFAT5 itself 
is upregulated in several cell types (41-43), but the tonicity threshold and cell 
signaling pathways required to activate NFAT5 may be cell type specific (44). Until 
recently, nothing was known about the expression or function of NFAT5 in human 
articular chondrocytes.
Signaling pathways influencing chondrogenesis
In the search for targets to improve the quality of the cartilage formed after cell 
transplantation or to induce cartilage repair in vivo, signaling pathways involved in 
chondrogenesis during embryonic development are frequently studied. Pathways 
known to be involved in this process are multiple and complex and involve for 
example fibroblast growth factors, transforming growth factors and Wnt/β-catenin 
(16). Another signaling pathway involved in chondrogenesis is the Calcineurin 
(Cn) – NFAT pathway (Figure 3). Where NFAT5 is osmolarity-dependent, the other 
members of the NFAT-family (NFAT1-4) are dependent on activation by calcineurin, 
which can be regulated by FK506 (also known as Tacrolimus or Prograf). 
FK506 is an immunosuppressive drug discovered by Kino et al. in the 1980s (45, 
46). FK506 revolutionized transplant therapy because of its ability to suppress T-cell 
activation, without markedly affecting bone marrow cell differentiation and prolif-
eration (47). Through binding to FK506-binding proteins (FKBPs), FK506 inhibits 
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the activity of ubiquitously expressed calcium/calmodulin dependent Cn. As a 
consequence, the Cn-mediated dephosphorylation of transcription factors of the 
NFAT family (1-4) is inhibited (Figure 3).
Besides their role in T-cell activation, Cn and NFATs are now also known to play 
a role in physiological processes in many other cell and tissue types as well as 
in pathological conditions like cancer, degenerative brain diseases and cardiac 
hypertrophy (48). FK506 has proven to be useful in reducing inflammation and 
alleviating symptoms in patients with inflammatory (rheumatoid) arthritis (49-52). 
Interestingly, the Cn-NFAT signaling cascade is also reported to play a role in bone 
remodeling (53) and chondrogenesis (54, 55). FK506 has been shown to induce 
chondrogenic differentiation of murine chondroprogenitor cells (56, 57). This sug-
gests that patients with non-inflammatory joint diseases, like osteoarthritis (OA), 
also might benefit from a treatment with Cn inhibitors. 
Figure 3. Schematic representation of the Cn-NFAT signaling and the inhibition by FK506. Calcineu-
rin is activated by calmodulin and calcium from external and internal stores. Activated Calcineurin 
dephosphorylates the NFAT 1-4 transcription factors, which in turn translocate into the nucleus and 
induce gene transcription. FK506 inhibits the Calcineurin activity. 
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Aims
The research that is reported in this thesis was aimed at finding new potential 
targets or tools for improving cartilage matrix synthesis by chondrocytes, either in 
vitro for cell transplantation techniques or in vivo toward a cure for osteoarthritis. 
The studies focus on influencing the calcineurin-dependent NFAT1-4 pathway and 
the osmolarity-dependent NFAT5 pathway. 
The first aim was to provide further understanding in the processes that control 
chondrocyte differentiation. During in vitro expansion, required for cell-based 
therapies, loss of chondrocyte phenotype takes place (dedifferentiation). Chondro-
cytes convert into a flattened, fibroblast-like state, accompanied by a shift from col-
lagen type II to collagen type I expression, reducing the quality of the extracellular 
matrix (ECM). Chapter 2 focuses on Calcineurin (Cn) as potential target to improve 
chondrogenic phenotype of culture-expanded osteoarthritic chondrocytes. First, 
Cn activity was measured during dedifferentiation by serial passaging in monolayer 
and after redifferentiation with transforming growth factor β (TGFβ), a commonly 
used chondrogenic redifferentiation factor (58, 59). The second step was to in-
vestigate whether inhibition of Cn activity by FK506 would improve chondrogenic 
marker expression. Since Cn inhibitors are known to induce TGFβ in renal cells (60, 
61), we investigated whether FK506 exerts its effect on chondrocyte redifferentia-
tion through endogenous TGFβ production. 
The second aim of this thesis was to investigate effects of physiological osmolarity 
on expression of chondrogenic markers by chondrocytes in vitro. As mentioned 
before, during cartilage degeneration as in OA, the extracellular osmolarity de-
creases as a result of matrix breakdown. Several studies have shown that articular 
chondrocytes are osmolariy-responsive (62, 63) and react with changes in aggrecan 
and GAG synthesis when the osmolarity is below or above the physiological range. 
Interestingly, chondrocyte in vitro expansion is mostly performed in medium of 
non-physiological tonicity (270 +/- 10-20 mOsm), which corresponds to physi-
ological osmolarity of blood. However, for cartilage this level is non-physiological, 
since it normally has a much higher osmolarity. Chapter 3 describes the effects of 
chondrocyte isolation and expansion at physiological osmolarity of 380 mOsm, by 
adding sterile sodiumchloride to the medium. The effects on chondrocytic markers 
(aggrecan, Sox9, collagen type II and type I) were studied in osteoarthritic and 
healthy chondrocytes. In addition, the role of the NFAT5 transcription factor in 
osmolarity-induced chondrocytic marker expression was elucidated. 
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We also wanted to elucidate whether combining both treatments would give 
synergistic effects. In chapter 4 the results are described, and special attention in 
these studies was paid to increasing anabolic, but suppressing unwanted catabolic 
and hypertrophic markers. 
In chapter 5 the aim was to investigate the effects of physiological osmolarity on 
chondrogenic differentiation of chondroprogenitor cells and mesenchymal stem 
cells. Chondrogenic differentiation of progenitor cells plays an essential role during 
endochondral ossification for skeletal growth and bone fracture healing. Moreover, 
mesenchymal progenitor cells are also used as alternative cell source for cell-based 
cartilage regeneration. Therefore, new methodologies improving chondrogenic 
differentiation of mesenchymal progenitor and stem cells into chondrocytes are of 
interest for cartilage and bone regenerative medicine approaches. In these studies, 
the ATDC5 chondroprogenitor cell line and human bone marrow stem cells were 
used as in vitro models for chondrogenic differentiation. Again, the role of NFAT5 
in regulating osmolarity-induced chondrogenic differentiation was elucidated. 
Terminal differentiation of mesenchymal progenitor cells into hypertrophic 
chondrocytes and mineralization of the tissue is favorable for bone regenerative 
medicine, but unfavorable for cartilage purposes. Based on the results of chapter 
4 and 5, we wondered whether FK506 addition to physiological osmolarity medium 
would be able to inhibit hypertrophic differentiation of progenitor cells. The results 
are described in chapter 6.
The last and most exciting aim of this thesis was to test the potential therapeutic 
effects of FK506 in an in vivo animal model for OA. In Chapter 7 a recently estab-
lished novel method (64) was used to induce OA in rat knee joints, showing severe 
degradation of articular cartilage and prominent involvement of subchondral bone 
and synovial macrophages. This chapter compares in vitro effects of FK506 on col-
lagen and GAG synthesis on osteoarthritic cells to in vivo effects of FK506 on OA 
articular cartilage. In addition, effects of FK506 on subchondral bone and synovial 
macrophages were studied in this animal model for OA.
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Abstract
In-vitro chondrocyte expansion is required for several cell-based approaches for 
the repair of chondral lesions. During expansion, loss of chondrogenic phenotype 
takes place (dedifferentiation). The objective of this study was to investigate calci-
neurin as a potential target to improve chondrocyte phenotype for cartilage repair 
purposes. 
Calcineurin activity in human articular chondrocytes was significantly increased 
during dedifferentiation and decreased during redifferentiation in vitro. Inhibition 
of calcineurin activity by FK506 increased the expression of chondrogenic markers 
collagen type 2, aggrecan and SOX9 in culture expanded cells. Addition of FK506 
increased endogenous Transforming Growth Factor (TGF) β1 expression on both 
mRNA and protein level. The effect of FK506 on chondrogenic markers was abol-
ished by addition of anti-TGFβ1 antibody, indicating that the endogenous TGFβ1 
was necessary to increase chondrogenic marker expression. We also showed that 
chondrocyte redifferentiation by TGFβ requires calcium influx and does not de-
pend on changes in calcineurin activity. 
In conclusion, inhibition of calcineurin activity by FK506 increases the expression 
of chondrogenic markers via endogenous TGFβ1 production in human articular 
chondrocytes. Calcineurin inhibitors might be an alternative for the application of 
(recombinant) TGFβ, to promote chondrocyte phenotype for cell-based cartilage 
repair procedures. 
Calcineurin inhibitors induce chondrogenic marker expression 29
Introduction
In-vitro chondrocyte expansion is required for several cell-based approaches for 
the repair of chondral lesions. During expansion, loss of chondrogenic phenotype 
takes place (dedifferentiation). Chondrocytes convert into a flattened, fibroblast-
like state (1, 2), accompanied by a shift from collagen type II expression to collagen 
type I expression (2-4), which reduces the quality of the extra-cellular matrix. To 
improve the quality of cartilage generated by culture-expanded chondrocytes, re-
differentiation of chondrocytes towards their chondrogenic phenotype is required. 
The mechanisms that regulate and control chondrocyte phenotypes are still largely 
unknown. Insight into these processes may provide new targets to improve cell-
based cartilage repair procedures.
In this study, we focused on calcineurin (Cn), a calcium-dependent serine/threo-
nine phosphatase, as potential target to improve chondrocyte phenotype. It has 
been demonstrated that osteoarthritic chondrocytes express mRNA of the α- and 
β-isoforms of the catalytic subunit of calcineurin (5). Furthermore, targeted inhibi-
tion of calcineurin activity with the immunosuppressive drug cyclosporin A (CsA), 
dose-dependently increased the production of collagen type II (5). In an in-vivo 
mouse model for osteoarthritis (OA), inhibition of calcineurin activity increased col-
lagen type II expression and improved the regeneration of cartilage defects (5). In 
addition, inhibition of calcineurin activity by FK506 (Tacrolimus, Prograf®), another 
widely used immunosuppressive agent, has been reported to induce chondrogen-
esis in clonal mouse embryogenic carcinoma cells and in human synovial stromal 
cells (6, 7). Besides these stimulating effects on chondrogenesis by inhibiting 
calcineurin activity, an increase in calcineurin activity appeared to induce chon-
drogenesis in the rat calvaria chondrogenic cell line RCJ3.1C5.18 and in chicken 
mesenchymal cells (8, 9). Summarizing, the data suggest that calcineurin plays a 
role in embryonic chondrogenesis and in the progression of OA, and the effects 
seem to be cell type dependent. It seems likely that calcineurin is also involved in 
the phenotypical changes of adult human articular chondrocytes during expansion 
for cartilage tissue engineering procedures. 
The aim of this study is to investigate the possibility to improve the chondrogenic 
phenotype of culture-expanded articular chondrocytes by modulating calcineurin 
activity. We therefore conducted the following steps: First, the relation of human 
adult articular chondrocyte phenotype and calcineurin activity was studied. We 
measured calcineurin activity during dedifferentiation by serial passaging in mono-
layer and after redifferentiation in vitro with Transforming Growth Factor (TGF) β, a 
30 Chapter 2
commonly used redifferentiation factor (10-12). The second step was to investigate 
whether inhibition of calcineurin activity using FK506 would improve chondrogenic 
marker expression of culture-expanded chondrocytes. Finally, we gained more 
insight in the mechanism of chondrocyte redifferentiation by calcineurin inhibition. 
Since calcineurin inhibitors are known to induce TGFβ signaling in renal cells (13, 
14), vascular smooth-muscle cells (15) and lymphocytic B cells (16), we investigated 
whether addition of FK506 would stimulate endogenous TGFβ production by chon-
drocytes and whether the effect of FK506 on chondrogenic marker expression was 
due to TGFβ. In addition, we investigated whether chondrocyte redifferentiation 
by TGFβ is directly due to modulation of calcineurin activity, or whether calcineurin 
activity changes as a result of the redifferentiation. 
These studies will provide further insight in the processes that control chondrocyte 
phenotype and may identify calcineurin as potential target to improve cell-based 
cartilage repair procedures. 
Materials and Methods
Isolation of human adult articular chondrocytes
Human cartilage was explanted from macroscopically normal areas of the femoral 
condyles and tibial plateau of 12 patients (mean age 66 ± 6.2 years) undergoing 
total knee replacement surgery for osteoarthritis (with medical ethical approval 
MEC2004-322). Cartilage explants were washed with sterile physiological saline 
and incubated with 2 mg/mL protease XIV (Sigma-Aldrich, St. Louis, Missouri, 
USA) for 2 hours, followed by overnight incubation with 1.5 mg/mL collagenase 
B (Roche Diagnostics, Mannheim, Germany) in medium (Dulbecco’s modified 
Eagle’s medium (DMEM) with 4.5 g/L glucose, 10% fetal calf serum (FCS), 50 µg/
mL gentamycine and 1.5 µg/mL fungizone (all Invitrogen, Paisley, Scotland, UK)). 
Both enzymatic digestions were done at 37°C. After incubation, the undigested 
cartilage fragments were removed using a 100 µm filter, and the isolated primary 
chondrocytes were used for cultures.
Chondrocyte dedifferentiation
We studied calcineurin activity during chondrocyte dedifferentiation by serial 
passaging. To dedifferentiate chondrocytes, isolated primary chondrocytes were 
precultured in monolayer at a seeding density of 7,500 cells/cm2. For the experi-
ments, we seeded differentiated cells (without preculture: P0) and dedifferentiated 
cells after 1, 2 and 3 passages of monolayer culture (P1, P2 and P3 respectively) 
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in high-density monolayers (20,000 cells/cm2) and cultured for four days before 
harvesting for analysis of mRNA expression levels (quantitative PCR; QPCR) and 
calcineurin activity. Cells were cultured at 37°C in a humidified atmosphere of 
5% CO2 in medium. Experiments were performed in triplicate samples from two 
donors (n=6).
Chondrocyte redifferentiation
We studied calcineurin activity during chondrocyte redifferentiation in alginate 
culture with added rhTGFβ2 (R&D Systems, Abingdon, U.K.). Expanded P2 chon-
drocytes from two donors were suspended in 1.2% alginate in physiological saline 
(Keltone LV, Kelco, Chicago, USA), at a density of 4x106 cells/mL. Beads were 
prepared and cultured in six-well plates (Corning, New York, USA) with 18 to 20 
beads in 2 mL medium per well. Redifferentiation medium consisted of DMEM 
supplemented with 1:100 ITS (Becton Dickinson, Bedford, MA), 10 ng/mL IGF1 
(recombinant human, Boehringer Mannheim), 25 µg/mL L-ascorbic acid 2-phos-
phate (Becton Dickinson), 50 µg/mL gentamycin (Invitrogen), 1.5 µg/mL fungizone 
(Invitrogen) and 10 ng/mL rhTGFβ2 (R&D Systems, Abingdon, Oxfordshire, UK)(10-
12). After 21 days of culture, alginate beads were harvested for analyses of mRNA 
expression levels (QPCR) and calcineurin activity.
For greater convenience and higher throughput, we also investigated whether 
monolayer cultures could be used to induce these effects on chondrogenic marker 
expression. Passage 2 chondrocytes were seeded at a density of 20,000 cells/cm2 
and cultured for 10 days in redifferentiation medium. Culture of more than 10 days 
in monolayer increased the risk of contraction and loosening of the cell layer (own 
experience). Two concentrations of rhTGFβ2 were used: 2.5 and 25 ng/mL. Both 
experiments were performed in triplicate samples taken from two donors (n=6). 
Inhibition of calcineurin activity with FK506
To investigate the effects of the calcineurin inhibitor FK506 on chondrocyte marker 
expression, we cultured chondrocytes with FK506 up to 10 days. Second-passage 
chondrocytes from three donors were plated at a density of 20,000 cells/cm2 and 
maintained in medium with 10% FCS and with or without 50 or 500 ng/mL FK506 (60 
and 600 nM respectively; Astella Pharma, Meppel, NL). In previous experiments we 
had ascertained that FK506 did not affect cell proliferation and cell viability up to 
1000 ng/mL (data not shown). Cells were harvested after 4 and 24 hours to analyze 
calcineurin activity and after 24 hours and 10 days to analyze mRNA expression 
levels (QPCR). Experiments were performed in triplicate for three donors (n=9). 
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FK506 and induction of endogenous TGFβ
To evaluate the hypothesis that the effects of FK506 on chondrogenic markers 
are caused by endogenous TGFβ production, we measured TGFβ1 (NM_000660), 
TGFβ2 (NM_003238) and TGFβ3 (NM_003239) mRNA expression levels of P2 chon-
drocytes cultured with 50 or 500 ng/mL FK506. In addition, we measured TGFβ1 
protein levels in these experiments. To investigate whether the endogenous TGFβ1 
production is responsible for the FK506 effects on dedifferentiated chondrocytes, 
P2 chondrocytes were cultured for 10 days in medium with 50 ng/mL FK506 with 
or without 1 or 10 µg/mL anti-TGFβ1 antibody (Sigma-Aldrich, raised against a 
mixture of human TGF-β1, porcine TGF-β1.2, porcine TGFβ2 and recombinant, 
amphibian TGF-β5). To check for unwanted effects of this anti-TGFβ antibody on 
chondrogenic marker expression or cross-reactivity to human TGFβ2, we cultured 
cells with anti-TGFβ1 without FK506, and redifferentiated cells by adding rhTGFβ2 
in the presence of 10 µg/mL anti-TGFβ1. After 24 hours and 10 days, cells were 
harvested to analyze mRNA expression levels (QPCR). The experiments were per-
formed in triplicate for two donors (n=6).
Calcineurin activity after addition of TGFβ
Our next goal was to investigate whether redifferentiation by TGFβ addition is due 
to modulation of calcineurin activity or whether the calcineurin activity is modulated 
as result of redifferentiation. We therefore cultured P2 chondrocytes in redifferen-
tiation medium supplemented with 0, 2.5 or 25 ng/mL rhTGFβ2. We used rhTGFβ2 
in these experiments because this is the routine procedure in our laboratory for all 
studies to induce chondrocyte redifferentiation (10, 11, 17, 18). We analyzed mRNA 
expression and calcineurin activity after 4 and 24 hours (to analyze early modula-
tion of Cn activity) and after 3 and 10 days (to analyze Cn modulation in time and 
to achieve redifferentiation). The experiments were performed in triplicate samples 
from two donors (n=6)
It is known that TGFβ can induce an influx of intra-cellular calcium (19-23), which 
can subsequently increase calcineurin activity. To investigate this mechanism, P2 
chondrocytes were pretreated either with 5 mM ethylene glycol-bis(β-aminoethyl 
ether)-N,N,N′,N′-tetraacetic acid (EGTA) tetrasodium salt  (Sigma), or with 10 µM 
1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid tetrakis(acetoxymethyl 
ester) (BAPTA-AM; Sigma) for 15 min prior to the addition TGFβ2 (2.5 ng/mL)
(n=3). EGTA is a chelator of extracellular calcium, and thereby inhibits the calcium 
influx. BAPTA-AM is a selective Ca2+ chelator from intracellular stores, inhibiting an 
increase in intracellular calcium concentration from these intracellular stores. 
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Calcineurin activity
Cells from monolayer cultures were washed twice in physiological saline, before 
starting the cytoplasmatic extraction procedure (NE-PER Nuclear and Cytoplasmic 
Extraction Kit, PIERCE, Bonn, Germany). Concentrations of cytoplasmic proteins, 
isolated according to the supplier’s instructions, were quantified using the BCA 
Protein Assay Kit (PIERCE, Bonn, Germany) in a microplate reader (VersaMax, Mo-
lecular Devices Ltd, NL). All samples were stored at -80°C until further use.
Calcineurin activity was measured using the Calcineurin Cellular Assay Kit Plus 
(BioMol, Tebu-Bio, Heerhugowaard, NL). First, extracts were purified on a Micro 
Bio-Spin P-6 chromatography column (Bio-Rad Laboratories B.V., Veenendaal, 
NL). Calcineurin activity was measured colorimetrically as relative units of free 
phosphate in 5 µL purified extract (1.0-1.5 µg of total cytosolic protein per assay). 
OD620nm data were converted using a standard curve, and expressed as the amount 
(nmol) phosphate released per µg of total cytosolic protein.
TGFβ production
TGFβ1 secretion in the culture medium was measured in triplicate using a commer-
cially available sandwich ezyme-linked immunosorbent assay (ELISA) kit for TGFβ1 
(R&D Systems, Abingdon, Oxfordshire, UK). According to the manufacturers’ 
protocol samples were first activated with 1 N HCl and 1.2 N NaOH/0.5 M HEPES.
mRNA expression analysis
RNA was extracted as described earlier (24) and further purified using the RNeasy 
Micro Kit (Qiagen, Venlo, Netherlands) with on-column DNA-digestion. Total 
RNA was quantified accurately using NanoDrop ND-1000 UV-Vis (Isogen Life Sci-
ence, IJsselstein, Netherlands) spectrophotometer, prior to cDNA synthesis using 
RevertAid™ First Strand cDNA Synthesis Kit (#1622, MBI Fermentas, Germany). 
Expression levels of collagen type II (COL2) and type I (COL1), SOX9 and aggrecan 
(AGC1) were studied as markers for chondrogenic differentiation. In the experi-
ments with FK506, expression levels of TGFβ1, TGFβ2, TGFβ3 and collagen type X 
(COL10; marker for hyperthrophy) were studied. The TGFβ1 (NM_000660) specific 
primers HsTGFb1_F GTGACAGCAGGGATAACACACTG, HsTGFb1_R CATGAAT-
GGTGGCCAGGTC, and the FAM-labeled hydrolysis probe HsTGFb1_FAM ACAT-
CAACGGGTTCACTACCGGC were used at 200 nM (each) and 600 nM, respectively. 
The other QPCR assays (COL2, COL1, SOX9, AGC1, COL10 and glyceraldehyde 
3-phosphate dehydrogenase (GAPDH)) were used as reported earlier(24-26). Reac-
tions were performed as 20mL reactions using TaqMan® Universal PCR MasterMix 
(ABI, Branchburg, NJ, USA) or qPCRTM Mastermix Plus for SYBR® Green I (Euro-
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gentec, Maastricht, Netherlands) according to the manufacturer’s guidelines on an 
ABI PRISM® 7000 with SDS software version 1.7. Data were normalized to GAPDH, 
which was stably expressed across samples (data not shown), and relative expres-
sion was calculated according to 2-ΔCT method (27).
Statistical analysis
Statistical analysis was performed using SPSS 13.0 software (SPSS Inc., Chicago, IL, 
USA). Data were compared between groups by Kruskall-Wallis H test and post-hoc 
Mann–Whitney U test. Results represent mean ± standard deviation and p<0.05 
was considered to indicate statistically significant differences. 
Results
Chondrocyte phenotype and calcineurin activity
To investigate the relation between calcineurin activity and the phenotype of adult 
human chondrocytes, we first studied calcineurin activity during chondrocyte de-
differentiation by serial passaging. To confirm changes in chondrocyte phenotype 
resulting from serial passaging, we determined mRNA expression levels of collagen 
type II (COL2) and type I (COL1). During chondrocyte dedifferentiation, expres-
sion levels of COL2 significantly decreased, while that of COL1 increased (Figure 
1A). The collagen type II / type I (COL2/COL1) ratio strongly decreased from 13 in 
primary (Passage 0; P0) chondrocytes to 0.00005 in passage 3 (P3) chondrocytes. 
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Figure 1. Relative expression of chondrogenic markers and calcineurin activity during chondrocyte 
dedifferentiation. A. Expression of collagens type II (COL2) and type I (COL1) in primary (P0) chon-
drocytes compared to dedifferentiated (P1-P3) chondrocytes. B. Relative calcineurin activity per µg 
of total protein in primary (P0) chondrocytes compared to dedifferentiated (P1-P3) chondrocytes. All 
data are means ± SD. * indicates significant difference with P0 cells (p<0.05). 
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During chondrocyte dedifferentiation, calcineurin activity significantly increased 
with increasing passage number (Figure 1B). 
In addition, we studied calcineurin activity after chondrocyte redifferentiation in 
alginate culture, with addition of TGFβ2 for 21 days. COL2 mRNA expression levels 
strongly increased (Figure 2A), with an increased COL2/COL1 ratio from 0.0009 to 
3, indicating redifferentiation of the cells. Redifferentiation was accompanied by a 
strong decrease in calcineurin activity (Figure 2B). 
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Figure 2. Collagen type II mRNA levels and calcineurin activity of chondrocytes cultured in alginate 
or monolayer with TGFβ2. A. Expression of collagen type II (COL2) mRNA in chondrocytes in alginate 
culture with or without TGFβ2 for 21 days. B. Calcineurin activity per µg of protein in chondrocytes in 
alginate culture with or without TGFβ2 for 21 days. C. Collagen type II (COL2) mRNA in chondrocytes 
treated with or without TGFβ2 for 10 days in monolayer culture. D. Calcineurin activity per µg of pro-
tein after 10 days of monolayer culture with TGFβ2. All data are means ± SD. * indicates significant 
difference with untreated cells (p<0.05). 
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For greater convenience and higher throughput, we also investigated whether mono-
layer cultures (2D-cultures) could be used to induce the effects on chondrogenic 
marker expression. High (25 ng/mL) and low (2.5 ng/mL) concentrations of TGFβ2 
both significantly increased collagen type II mRNA expression levels (Figure 2C), lead-
ing to a 3-fold increase of the COL2/COL1 ratio. Calcineurin activity significantly de-
creased by addition of TGFβ2 in monolayer (Figure 2D). Although, mRNA expressions 
of chondrogenic markers were lower than in alginate (Figure 2A), a clear improvement 
in chondrocyte marker expression was visible in the monolayer cultures, indicating 
that monolayer cultures can be used for the follow-up experiments using inhibitors of 
calcineurin activity and experiments to investigate underlying mechanisms. 
Inhibition of calcineurin activity increases the expression of 
chondrogenic markers
As calcineurin activity increased during dedifferentiation and decreased during 
redifferentiation of chondrocytes, we investigated the effects of the calcineurin 
activity inhibitor FK506 on chondrogenic marker expression. 
We first confirmed that FK506 inhibited calcineurin activity in dedifferentiated chon-
drocytes (P2). After 4 and 24 hours of incubation with 50 or 500 ng/mL FK506 the 
calcineurin activity significantly dropped (Figure 3A). Both 50 and 500 ng/mL FK506 
significantly increased COL2, AGC1 and SOX9 expression levels after just 24 hours 
(Figure 3B). After 10 days of culture, the mRNA levels of COL2 were still significantly 
higher in the FK506-conditions than in the control condition (Figure 3C) and similar 
to the effects of TGFβ2 in monolayer culture (Figure 2C). Although the expression of 
COL1 was slightly upregulated by FK506, the COL2/COL1 ratio was increased by 2.5-
fold after addition of 500 ng/mL FK506 after 10 days (data not shown). In addition, 
the mRNA levels of SOX9 were also still significantly higher in the FK506-conditions 
than in the control condition (Figure 3C). COL10 expression was undetectable in the 
control and in all FK506 conditions (data not shown). We concluded that inhibition of 
calcineurin activity by FK506 induced expression of chondrogenic markers. 
FK506-induced expression of collagen type II via endogenous 
TGFβ1
To explain the effects of FK506 on chondrogenic markers, we investigated the ef-
fect of FK506 on TGFβ1, TGFβ2 and TGFβ3 mRNA levels. After 24 hours of culture, 
both 50 and 500 ng/mL FK506 significantly increased TGFβ1 mRNA levels (Figure 
4A), while the levels of TGFβ2 and TGFβ3 were not significantly altered (data not 
shown). In addition, TGFβ1 protein level was significantly increased after 48 hours 
and even more increased at day 7 (Figure 4B). 
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Therefore, we hypothesized that this endogenous TGFβ1 production might be 
responsible for the chondrogenic effects of FK506 on dedifferentiated chondro-
cytes. Neutralizing the activity of endogenous TGFβ1 with an anti-TGFβ1 antibody 
significantly decreased the FK506-mediated increase in COL2 expression after 10 
days (Figure 4C). While anti-TGFβ1 also inhibited the slight increase in AGC1 by 
FK506, it had no effects on SOX9 expression (data not shown). The anti-TGFβ1 
antibody had no effects on COL2 expression levels in cells treated with rhTGFβ2 
in redifferentiation medium, indicating that there was no cross-reactivity to TGFβ2 
and no inhibitory effect of the antibody on chondrocyte redifferentiation otherwise.
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Figure 3. Effects of FK506 on calcineurin activity and on the mRNA levels of chondrogenic markers. 
Chondrocytes were expanded in monolayer for two passages and subsequently cultured in mono-
layer with 0, 50 or 500 ng/mL FK506. A. Calcineurin activity per µg of protein in P2 cells treated with 
50 or 500 ng/mL FK506 for 4 and 24 hours, compared to untreated cells. B Relative mRNA levels of 
collagen type II (COL2), aggrecan (AGC1) and SOX9 after 24 hours of culture with FK506. C. Shown 
are mRNA levels of collagen type II (COL2), aggrecan (AGC1) and SOX9 after 10 days of culture. All 
data are means ± SD. * indicates significant difference with untreated cells (p<0.05). 
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Cn activity after addition of TGFβ
Next we investigated whether redifferentiation by TGFβ is directly due to modu-
lation of calcineurin activity. Culturing chondrocytes in redifferentiation medium 
with rhTGFβ2 (serum free), significantly decreased Cn activity after 3 days (data not 
shown) and 10 days (Figure 2D). Surprisingly, calcineurin activity increased after 24 
hours of treatment with TGFβ (Figure 5A). 
As calcineurin is a calcium-dependent phosphatase, we hypothesized that the 
short-term peak in Cn activity by TGFβ is mediated by an increase in calcium influx. 
TGFβ-mediated alterations in Cn activity were completely blocked by chelation 
of extracellular calcium with EGTA for 15 min and 24 hours. Figure 5B confirms 
that Cn activation by TGFβ is altered by influx of extracellular calcium. In addition, 
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Figure 4. Effect of anti-TGFβ1 antibody on FK506-induced collagen type II expression.
A. TGFβ1 mRNA levels in cells treated with 50 or 500 ng/mL FK506 for 24 hours. B. TGFβ1 protein 
levels measured by ELISA in the culture medium after 48 hours and 7 days of culture with FK506. C. 
Collagen type II mRNA levels after 10 days of culture with FK506 with or without anti-TGFβ1 antibody. 
All data are means ± SD. * indicates significant difference with untreated cells (p<0.05). # indicates 
significant difference with the FK506 condition without anti-TGFβ1 (p<0.05). 
Calcineurin inhibitors induce chondrogenic marker expression 39
EGTA completely blocked the TGFβ-mediated increase in collagen type II expres-
sion after 3 days (Figure 5C). Pre-incubation with the intracellular calcium chelator 
BAPTA-AM did not affect TGFβ-mediated Cn activity (data not shown), indicating 
that TGFβ-mediated Cn activity is not dependent on intracellular calcium stores. 
To determine whether the short-term peak in Cn activity is necessary for TGFβ-
induced redifferentiation, we cultured chondrocytes with TGFβ in redifferentiation 
medium supplemented with FK506. FK506 inhibits the short-term, TGFβ-induced 
peak in Cn activity. We found that the TGFβ-induced increase in COL2 expression 
increased by FK506 (Figure 5D).
0
1
2
3
4
5
Cn activity
- 2.5 25TGFβ
*
*
A
C
al
ci
ne
ur
in
 a
ct
iv
ity
(n
m
ol
 p
ho
sp
ha
te
 /
µµ µµ g
 p
ro
te
in
)
0
1
2
3
4 control
TGFβ (2.5 ng/mL)
Cn activityB
- - +EGTA
*
# #
+
C
al
ci
ne
ur
in
 a
ct
iv
ity
(n
m
ol
 p
ho
sp
ha
te
 /
µµ µµ g
 p
ro
te
in
)
0
1
2
3
4 control
TGFβ (2.5 ng/mL)
COL2C
- - + +
*
# #
EGTA
m
R
N
A 
le
ve
ls
0
2
4
6
8
10 control
TGFβ (2.5 ng/mL)
COL2D
- - +FK506 +
*
*
#
m
R
N
A 
le
ve
ls
Figuren artikel.pzf:Figure 5 - Thu Jan 12 15:50:37 2017
Figure 5. Effects of extracellular calcium chelation or calcineurin inhibition on TGFβ-induced col-
lagen type II expression. A. Calcineurin activity per µg of protein after 24 hours of culture with 2.5 or 
25 ng/mL TGFβ. Data are mean expressions relative to control (without TGFβ) ± SD means ± SD. * 
indicates significant difference with untreated cells (p<0.05). B. Calcineurin activity per µg of protein 
after chelation of extracellular calcium with 5 mM EGTA for 24 hours. Data are means ± SD. * indi-
cates significant difference with control (without TGFβ and EGTA). # indicates significant difference 
with the TGFβ/ without EGTA condition. C. Effect of EGTA on TGFβ-induced Collagen type II (COL2) 
mRNA expression after 3 days. Data are mean expressions relative to control (without TGFβ and 
EGTA) ± SD of values normalized for GAPDH. * indicates significant difference with control. # indi-
cates significant difference with TGFβ/ without EGTA condition. D. Effect of FK506 on TGFβ-induced 
Collagen type II (COL2) mRNA expression after 3 days. Data are mean expressions relative to control 
(without TGFβ and FK506) ± SD of values normalized for GAPDH. * indicates significant difference 
with control. # indicates significant difference with all other conditions. 
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In conclusion, chondrocyte redifferentiation by TGFβ is due to elevation of intracel-
lular calcium concentration upon influx of extracellular calcium. Redifferentiation 
by TGFβ is not dependent on modulations in calcineurin activity. 
Discussion
The present study provides evidence that FK506-induced inhibition of calcineurin 
activity in human adult articular chondrocytes increases the expression of chon-
drogenic markers via TGFβ1 signaling. Our results showed that calcineurin activity 
is strongly regulated during chondrocyte dedifferentiation and redifferentiation in 
vitro. Inhibition of calcineurin activity by FK506 increased the expression of chon-
drogenic markers COL2 , AGC1 and SOX9, indicating that the chondrocytes might 
shift towards a more chondrogenic phenotype without becoming hypertrophic. 
In addition to the results by Yoo et al. that inhibition of calcineurin activity pro-
tects from cartilage damage in experimental osteoarthritis (OA), we demonstrate 
that calcineurin inhibition can also be useful for Tissue Engineering purposes 
because of the anabolic effects on early differentiation of adult human articular 
chondrocytes in-vitro by increasing chondrogenic marker expression. Furthermore, 
we demonstrated that increased endogenous TGFβ1 production was responsible 
for the effects of calcineurin inhibition on collagen type II expression, by blocking 
endogenously produced TGFβ1. 
The FK506-induced expression of chondrogenic markers is consistent with earlier 
reported effects of FK506 in other cell types (6, 7). To exclude that the effects of 
FK506 on the expression of chondrogenic markers were caused by unspecific 
Figure 6. Schematic of FK506 signaling and TGFβ signaling in human articular chondrocytes. A. 
FK506 induces expression of chondrogenic markers via inhibition of calcineurin activity and TGFβ1 
gene and protein expression. B. The redifferentiation effects of rhTGFβ are mediated via an in-
creased calcium influx, leading to an increase in calcineurin activity. However, the effects of TGFβ 
on chondrocyte redifferentiation are not dependent on calcineurin activity modulation, suggesting 
that other calcium-sensitive enzymes might mediate TGFβ action. We hypothesize that improved 
chondrogenic marker expression by FK506 involves effect A, leading to effect B via paracrine or 
autocrine signaling. 
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effects of FK506 and not due to calcineurin inhibition, we also performed experi-
ments with a second calcineurin inhibitor: cyclosporine A (CsA). The effects of 1 
and 10 µM CsA on calcineurin activity, on the expression of chondrogenic markers 
and TGFβ isoforms were comparable with the effects of FK506 (data not shown). 
So far, we can conclude that both culturing with TGFβ and culturing with a calci-
neurin inhibitor induce chondrogenic marker expression. For many years, TGFβ 
has been the most commonly used chondrogenic factor to induce redifferentiation 
(10-12). A relation between calcineurin activity and TGFβ signaling could, at least 
partially, explain the effects of FK506. Our data strongly suggest that endogenous 
TGFβ1 is the most important TGFβ subtype responsible for the FK506-effects (Fig-
ure 6A), because the TGFβ1-antibody was specific for this subtype and blocked the 
effect of FK506 on collagen type II mRNA expression entirely. The relation between 
calcineurin inhibition and induction of TGFβ signaling has been described earlier in 
several other cell types, for example in renal cells (13, 14), vascular smooth muscle 
cells (15) and lymphocytic B cells (16) and is now also demonstrated to be present 
in adult human articular chondrocytes. 
There are different mechanisms reported by which FK506 and/or CsA induce en-
dogenous TGFβ. FKBP12, the 12-kDa FK506-binding protein, is a receptor for the 
immunosuppressant drug FK506 (28). FKBP12 occurs in high concentrations in all 
cells and is known to regulate fundamental aspects of cell biology (29, 30). One 
of its multiple biological functions, is the inhibition of TGFβ type I receptors (31, 
32). FKBP12 binds to the glycine-serine region of a ligand-free TGFβ type I recep-
tor, thereby blocking access to activators. FK506 blocks the FKBP12/TGFβ type I 
receptor interaction and enhances the ligand activity of the TGFβ type I receptor 
(31). This mechanism could explain the effects of FK506 on TGFβ signaling in our 
cultures, but does not explain the effects of CsA on endogenous TGFβ signaling. 
CsA, but not FK506, is reported to promote the release of preformed TGFβ by 
inducing apoptosis in human T cells (33). Next to this, there are indications that cal-
cineurin and the calcineurin-dependent nuclear factor of activated T-cells (NFATc) 
transcription factors can regulate the promoter activity of TGFβ1 (33, 34), which 
could be the explanation for the effects of FK506 and CsA in our experiments. It 
would be of interest to investigate whether this mechanism plays a role in human 
articular chondrocytes. 
Since we found this relation between calcineurin activity and endogenous TGFβ1, 
we also wanted to investigate whether the redifferentiation by addition of rhTGFβ2 
depends on modulation of calcineurin activity. Culturing chondrocytes with TGFβ 
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in redifferentiation medium (serum-free), significantly decreased calcineurin activ-
ity at the long term (from 3 days of culture up to 21 days of culture). Interestingly, 
we found a short-term peak in calcineurin activity between 24 hours and 3 days. As 
calcineurin is a calcium-dependent phosphatase, we hypothesized that the short-
term peak in Cn activity by TGFβ is mediated by an increase in intracellular calcium 
concentration. It is known that TGFβ can induce an increase of intra-cellular calcium 
in a variety of cell types (19-23). In rat mesengial cells, TGFβ mediated accumula-
tion of extracellular matrix (ECM) proteins via calcium influx and thereby activation 
of calcineurin (19-23). In our study, we also found that the short term increase in 
calcineurin activity by TGFβ2, was mediated via an increase in calcium influx. It is 
unlikely that the Ca2+ influx is specific for TGFβ2, as the role of TGFβ1 in inducing 
a Ca2+ influx has also been described (20, 21, 23). Addition of EGTA to block the 
calcium influx abolished TGFβ-mediated increase in COL2 expression, indicat-
ing that redifferentiation by TGFβ is due to entry of extracellular calcium (Figure 
6B). Inhibition of the early increase in calcineurin activity by FK506 did not inhibit 
the TGFβ-induced chondrogenic marker expression. This suggests that calcium-
sensitive proteins other than calcineurin might mediate TGFβ action. The short-
term increase in calcineurin activity by TGFβ is likely a side-effect of the increased 
calcium influx (Figure 6B). Linking figure 6A and 6B would indicate that when EGTA 
would be added together with FK506, the endogenously induced TGFβ effect 
would be inhibited and thereby FK506 would have no effect. This however was not 
experimentally tested because this would require long term culture (at least 7 days) 
with EGTA which would lead to too many negative side effects on cell behavior. We 
conclude that the effects of TGFβ on chondrocyte redifferentiation do not depend 
on modulations in calcineurin activity. The TGFβ-mediated decrease in calcineurin 
activity after 3 days is probably a consequence of chondrocyte redifferentiation. 
The aim of our study was to investigate calcineurin as potential target to improve 
chondrocyte phenotype for cartilage tissue engineering purposes. This study 
provides the first data on the relation between calcineurin activity and chondrocyte 
dedifferentiation and redifferentiation using gene expression as well accepted 
measures for chondrocyte phenotype (2, 4). In this study we used monolayer 
cultures of passaged adult human chondrocytes to show effects of calcineurin 
inhibitors on chondrogenic marker expression. Although monolayer cultures are 
a convenient system for studies on mechanisms of action, it is well accepted that 
chondrocyte phenotype is better supported in 3-dimensional systems. For future 
application the effects of calcineurin inhibition in 3D systems, analyses of collagen 
type II expression on protein levels as well as more advanced analyses on matrix 
assembly and effects on functional properties, would be required. Furthermore the 
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use of calcineurin inhibitors to control chondrocyte phenotype in-vivo deserves 
further investigation. As reported earlier, at the moment TGFβ is the most com-
monly used chondrogenic factor to induce redifferentiation in vitro (10-12). How-
ever, TGFβ has been implicated in fibrosis in many organs like eye, lung, heart, liver, 
kidney, skin and the synovial tissue in articular joints (35, 36). Multiple injections of 
high amounts (≥ 20 ng) of TGFβ in the knee induced synovial fibrosis and chondro-
osteophyte formation (36-39). The use of TGFβ as therapeutic agent for cartilage 
repair, and even the use of TGFβ in culture before implantation of a construct in 
vivo, is limited due to the risk of these side-effects. Calcineurin inhibition by FK506 
or CsA leads to a relatively low, sustained release of endogenous TGFβ1, which 
might limit the risks of fibrosis in vivo. Cyclosporine A (CsA) and FK506 are systemi-
cally used as primary immunosuppressants in hepatic and cardiac transplantation. 
Although systemic application of these calcineurin inhibitors is also reported to 
dose-dependently induce fibrosis of mainly the kidney (40-43), the dosage to be 
used for local application of FK506 or CsA in the joint is much lower. CsA has been 
reported as an effective treatment strategy for OA in a mouse model, without any 
reported side-effects such as fibrosis (5). Next to this, CsA has been reported to 
promote TGFβ transcription by synovial cells in-vitro, without displaying a profibro-
genic effect in an inflamed environment (44). 
Local administration of FK506 or CsA in the joint might have another advantage 
because of the immunosuppressive effects of these agents. Both CsA and FK506 
are already used as disease-modifying antirheumatic drugs (45). They inhibit the 
secretion of cytokines such as interleukin (IL) -2, IL-3, IL-4, tumor necrosis factor 
(TNF)-α and interferon-γ from T-lymphocytes (46, 47). In tissue engineering proce-
dures the use of cells and scaffolds might evoke inflammatory and immunological 
reactions that will negatively affect the performance of tissue engineered con-
structs (see April 2008 issue of Semin Immunol). Furthermore, in at least 50% of the 
patients with OA inflammation in the synovial membrane is documented (48). This 
inflammatory response exhibits features of a T cell immune response and several 
studies support the idea that T cells may play an important role in the pathogen-
esis and progression of OA (48). Therefore, the immunosuppressive effect of local 
administration of calcineurin inhibitors might be beneficial for the treatment of 
OA. Further animal studies are needed to investigate the beneficial and possible 
disadvantageous effects of calcineurin inhibitors applied during the in-vitro culture 
period to prepare constructs or when applied directly in the joint.
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In conclusion, calcineurin inhibitors stimulate endogenous TGFβ1 production and 
might be a good alternative for the application of recombinant TGFβ both in-vitro 
and in-vivo, to promote cartilage tissue engineering and other cell-based therapies. 
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Abstract
Chondrocytes experience a hyperosmotic environment compared to plasma 
(280 mOsm) due to the high fixed negative charge density of cartilage. Standard 
isolation of chondrocytes removes their hyperosmotic matrix, exposing them to 
non-physiological conditions. During in-vitro expansion, chondrocytes quickly lose 
their specialized phenotype, making them inappropriate for cell-based regenera-
tive strategies. We aimed to elucidate the effects of osmolarity during isolation and 
in-vitro expansion on chondrocyte phenotype. 
Human articular chondrocytes were isolated and subsequently expanded at control 
osmolarity (280 mOsm) or at moderately elevated, physiological osmolarity (380 
mOsm). The effects of physiological osmolarity on chondrocyte proliferation and 
chondrogenic marker expression were evaluated. The role of Tonicity-responsive 
Enhancer Binding Protein (TonEBP/NFAT5) in response to physiological osmolarity 
was investigated using NFAT5 RNA interference.
Moderately elevated, physiological osmolarity (380 mOsm) did not affect chondro-
cyte proliferation, while higher osmolarities inhibited proliferation and diminished 
cell viability. Physiological osmolarity improved expression of chondrogenic mark-
ers and NFAT5 and its target genes, while suppressing dedifferentiation marker 
collagen type I and improving type II/type I expression ratios >100-fold. Effects 
of physiological osmolarity were similar in osteoarthritic and ‘normal’ (non-os-
teoarthritic) chondrocytes, indicating a disease-independent mechanism. NFAT5 
RNA interference abolished osmolarity-mediated effects and revealed that NFAT5 
positively regulates collagen type II expression, while suppressing type I.
Physiological osmolarity provides a simple, yet effective, means to improve pheno-
typical characteristics during cytokine-free isolation and in-vitro expansion of hu-
man articular chondrocytes. Our findings will lead to the development of improved 
cell-based repair strategies for chondral lesions and provides important insights 
into mechanisms underlying osteoarthritic progression.
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Introduction
Hyaline articular cartilage is a connective tissue covering the ends of bones in 
joints and is composed of specialized cells, chondrocytes, that produce a large 
amount of extracellular matrix. This matrix is crucial for the unique biomechanical 
properties of this tissue and is composed of a collagen fiber network, providing 
tensile strength and flexibility, and abundant ground matrix rich in proteoglycans 
(1). The glycosaminoglycan (GAG) side chains of the proteoglycans are sulfated 
and responsible for a characteristic high fixed negative charge density (2) which 
binds mobile cations (mainly sodium). This determines the physiological osmolarity 
(tonicity) of the extracellular fluid around chondrocytes in vivo, but the osmolarity 
indirectly also largely depends on the quality of the collagen network. Extracellular 
osmolarity in healthy cartilage ranges between 350 and 480 mOsm (3, 4). In vivo, 
osmolarity of the extracellular fluid is dynamic and changes due to alterations in 
matrix hydration (5). During cartilage degeneration, i.e. in osteoarthritis (OA), col-
lagen matrix degrades and GAG concentration diminishes, resulting in a severity-
depending decreased osmolarity of between 280 and 350 mOsm (3, 6). Currently, 
chondrocyte isolation and in-vitro expansion culture are performed in medium 
of non-physiological osmolarity (270±20 mOsm). Several studies already showed 
that chondrocytes are osmolarity responsive (7-9) and react with changes in matrix 
synthesis (4, 8, 10, 11), but focused on aggrecan (AGC1) core protein mRNA levels, 
AGC1 promoter activity and GAG production.
Molecular mechanisms involved in the hyperosmotic response of human articular 
chondrocytes (HACs) are poorly understood. Hyperosmolarity perturbs cells by 
causing osmotic efflux of water, resulting in cell shrinkage (12, 13). Cells react by 
a rapid uptake of ions, which increase cellular ionic strength (14) with potentially 
detrimental effects (15-17). The initial, rapid response is the activation of trans-
porters that exchange these ions for compatible osmolytes (16, 18). This process 
is controlled by Tonicity-responsive Enhancer Binding Protein (TonEBP/NFAT5) 
which mediates transcriptional activation of these transporters (16). NFAT5 is a 
member of the Rel family of transcription factors (19) and targets sodium/myo-
inositol cotransporter (SMIT) (20, 21), sodium/chloride coupled acid transporters 
(BGT1/SLC6A12) (20), aquaporin channels (AQP1 and -2) (22), and calcium-binding 
proteins (S100A4) (23-25). Upon hyperosmotic stress, transcription of NFAT5 itself 
is up-regulated several cell types (26-28), but the osmolarity threshold and cell 
signaling pathways required to activate NFAT5 may be cell type specific (29). Cur-
rently, nothing is known about the expression or function of NFAT5 in HACs. 
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Chondral lesions by e.g. trauma or overuse, can cause joint pain, immobility and 
eventually osteoarthritis (OA). The associated high prevalence (60% of all patients 
undergoing knee arthroscopy is diagnosed with a chondral lesion (30)) and loss of 
quality of life makes cartilage damage a major personal and economical burden. 
Treatment options of chondral lesions are limited and autologous chondrocyte 
implantation (ACI) is the currently most developed hyaline repair technique for 
the knee (31). Lately, characterized chondrocyte implantation (CCI), employing a 
phenotypical pre-screening prior to implantation, improved structural repair (32). 
Chondrocyte dedifferentiation during in-vitro expansion for ACI is detrimental, 
but almost inevitably in standard monolayer culture: spherical chondrocytes will 
gradually convert into fibroblast-like cells (33, 34). This morphological change 
is accompanied by a shift in collagen expression towards less collagen type II 
(COL2) and more collagen type I (COL1) (34, 35). Consequently, dedifferentiated 
chondrocytes produce fibrocartilage in vivo, with an extracellular matrix of inferior 
biomechanical properties due to higher collagen (especially type I) content and 
less proteoglycans compared to hyaline cartilage (36). Three-dimensional culture 
systems can partially prevent dedifferentiation, but are labor intensive and essen-
tially impair propagation. Chondrocyte dedifferentiation might also play a role in 
the pathogenesis of osteoarthritis (OA), as the ability of aging chondrocytes to 
produce and repair the extracellular matrix is compromised (37) and collagen type 
I is shown to be present in clusters of fibrillated areas in late stage OA, while it is 
absent in healthy cartilage (38).
Here we report that physiological osmolarity (380 mOsm) during isolation and 
monolayer expansion can suppress chondrocyte dedifferentiation and that ex-
pression of the extracelluar matrix components collagen types I and II as well as 
aggrecan is NFAT5-dependent. We further show that NFAT5 contributes to the 
differential regulation of both collagen types. This study provides a simple, yet 
novel and effective, means to improve cell-based repair strategies for chondral 
lesions and contribute to our understanding of osteoarthritic progression.
Materials and Methods
Cartilage and chondrocyte isolation 
After informed consent was obtained, human articular cartilage was explanted 
from macroscopically normal areas of the femoral condyles and tibial plateau of 
nine patients undergoing total knee replacement surgery for OA (medical ethical 
approval MEC2004-322). In addition to preparation of cartilage explants and isola-
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tion of human articular chondrocytes (HACs) under standard conditions (DMEM, 
280 mOsm) as described by Das et al. (39), medium osmolarity was also adjusted to 
380, 480 or 580 mOsm, respectively by addition of sterile NaCl. Enzymatic diges-
tion, removal of undigested fragments and subsequent chondrocyte culture are 
reported earlier (39). The 280 and 380 mOsm isolations were also performed with 
cartilage obtained from the femoral condyles and tibial plateau of two non-OA 
donors (further referred to as ‘normal’ donors), undergoing above-knee amputa-
tion surgery after trauma.
Chondrocyte proliferation and DNA measurements
Primary (passage 0; P0), P1, P2 and P3 HACs were monolayer expanded in medium 
corresponding to their isolation osmolarity (280, 380, 480 or 580 mOsm), with an 
initial seeding density of 6,000 cells/cm2. Cells were harvested daily for cell counts 
and DNA assay between day two and day six. Experiments were performed in 
duplicate from three OA donors (n=6). At each passage, growth curves were estab-
lished by cell counts using Trypan Blue (Sigma, cat. T8154) and DNA quantification. 
DNA measurements were performed according to Karsten et al. (40) with slight 
modifications (41). Doubling times within each passage were calculated from the 
trend line of the exponential growth phase using equation y = x(0) exp(kx(t)) with k 
= ln 2 / T (k = growth constant, T = doubling time). 
Chondrocyte expansion
Primary HACs were cultured for expansion in monolayer at a seeding density 
7,500 cells/cm2 in medium corresponding to their isolation osmolarity (280, 380, 
480 or 580 mOsm). Primary through P3 cells were seeded in high-density mono-
layers (20,000 cells/cm2) and cultured for additional five and seven days before 
analysis of mRNA (quantitative RT-PCR) and protein expression (Western Blot-
ting) respectively. Experiments were performed in triplicate from four OA donors 
(n=12). Additionally, experiments were performed in triplicate from two healthy 
donors (n=6), to investigate whether the hyperosmotic stress response is specific 
for pathologically altered cells. To exclude sodium or chloride specific effects, we 
performed experiments using NMDG-Cl or sucrose to adjust medium tonicity to 
380 mOsm.
Lentiviral NFAT5 gene knock-down
We used lentiviral vectors for non-transient shRNA-mediated gene silencing in 
primary chondrocytes (42). BamHI/MunI restriction fragments of the parental 
pLKO.1-puro vector, each containing the U6 promotor and one out of five differ-
ent, sequence-verified anti-human NFAT5 shDNAs (MISSION shRNA library; www.
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sigmaaldrich.com) were subcloned into corresponding restriction sites of recipient 
vector pRRL.PPT.PGK.GFPpre. This was kindly provided by L. Naldini (San Raffaele 
Telethon Institute for Gene Therapy, Milano, Italy) (43, 44) and optimized by A. 
Schambach (Department of Experimental Hematology, Hannover Medical School, 
Hannover, Germany) (45) to express eGFP from the phosphoglycerate kinase pro-
moter. Lentiviral particles were produced in HEK293T cells by transient transfection 
using a calcium phosphate protocol (46). Cells transduced with a lentiviral vector 
lacking the NFAT5-specific shRNA expression cassette served as controls. All cells 
were grown in monolayer. TRCN0000020020 was identified as best performing 
anti-NFAT5 shRNA clone by QPCR-based knockdown efficiency determination and 
used in subsequent experiments.
Passage 1 osteoarthritic HACs from two donors were seeded (15,000 cells/cm2) 
and cultured for four days in control medium (280 mOsm). Three hours prior to 
transduction, cells were deprived of antibiotics, transduced for ± 18 hours, re-
freshed with control medium with antibiotics and cultured for additional four days 
before harvesting for FACS analyses. Cells were resuspended in PBS with 10% FCS 
and antibiotics and washed. Cells were collected and stained with Hoechst 33258 
(1 mg/mL, Molecular Probes) to discriminate between dead and live cells. FACS 
was performed on FACSAria (Becton Dickinson) and eGFP expressing cells were 
collected (>50%, MOI~1) and re-analyzed for purity (> 95%) using Cell Quest Pro 
Software. 
EGFP expressing populations were seeded (10,000 cells/cm2) and cultured in 
control medium up to 80% confluency. Cells were then switched to medium of 380 
mOsm or kept on control medium for 24 hours prior to RNA analysis. 
RNA expression analysis 
RNA isolation, purification, quantification and cDNA synthesis are described else-
where (47). Expression levels of aggrecan (AGC1), SOX9 and collagen type II (COL2) 
were studied as chondrogenic markers, while collagen type I (COL1) was studied as 
dedifferentiation marker (34, 35, 48, 49). QPCR assays for COL2, SOX9, AGC1 and 
COL1 were reported earlier (50). To quantify expression of NFAT5 and its target 
genes, the following primers were tested for similar amplification efficiency and 
specificity according to Das et al. (39) and used as 20mL SYBR® Green I reactions: 
HsNFAT5_Fw, GGGTCAAACGACGAGATTGTG, HsNFAT5_Rv, TTGTCCGTGGTA-
AGCTGAGAA; HsS100A4_Fw, GTCCACCTTCCACAAGTACTCG, HsS100A4_Rv, 
TCATCTGTCCTTTTCCCCAAG; HsSLC6A12_Fw, ACACAGAGCATTGCACGGACT, 
and HsSLC6A12_Rv, CCAGAACTCGTCTCTCCCAGAA). Data were normalized to 
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an index of three reference genes (GAPDH, UBC, HPRT1) which were pre-evaluated 
to be stably expressed across samples (39). Relative expression was calculated ac-
cording to 2-ΔCT method (51).
Western Blot analysis
Cells seeded at high densities were washed twice with PBS and lysed in RIPA buffer 
(52) with addition of protease inhibitors. Total protein concentration was quantified 
by BCA assay according to the manufacturer’s protocol (Pierce, #23225). Ten µg 
aliquots were subjected to 10% SDS-polyacrylamide gel electrophoresis (PAGE) 
prior to electro-blotting onto nitrocellulose membranes (Protran BA83, Schleicher 
& Schuell). Blots were blocked in 5% low-fat dry milk in 1X PBS, 0.05% v/v NP-40, 
incubated with primary antibodies (anti-type II collagen and anti-type I collagen 
(both 1:100, SouthernBiotech, or 1:10,000 anti-α-Tubulin (Sigma)), washed, incu-
bated with secondary antibodies (both 1:1,000, Dako Cytomation) and chemilumi-
nescently detected. Signals were quantified using ImageJ 1.42 software. 
Statistics 
Statistical analysis was performed using SPSS 13.0 software (SPSS Inc., Chicago, IL, 
USA). Data were compared between groups by Kruskall-Wallis H test and post-hoc 
Mann–Whitney U test. Results represent mean ± standard deviation and p<0.05, 
p<0.01 and p<0.001 were considered to indicate levels of statistically significant 
difference. 
Results
Osmolarity influences proliferation and survival of chondrocytes
We first determined the influence of osmolarity on proliferation: osteoarthritic 
HACs (OA-HACs) isolated at 580 mOsm hardly attached nor proliferated (Figure 
1; photo D) and two days after seeding no viable cells were recovered. At 280, 380 
and 480 mOsm, respectively, cells did adhere but increasing osmolarity induced 
marked morphological changes: at 280 mOsm, cells appeared fibroblast-like 
stretched-out and flattened with long filopodia (Figure 1; photo A), while at 380 
mOsm cells were more sphere-shaped and had shorter filopodia (Figure 1; photo 
B). At 480 mOsm, cells showed few filopodia and appeared spherical (Figure1; 
photo C). The differences in appearance remained throughout dedifferentiation 
period (P0 to P3), but were most apparent at earlier passages. 
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Using cell counts and DNA assays, doubling times were calculated from growth 
curves established from each passage at three different osmolarities (280, 380 
and 480 mOsm). Throughout dedifferentiation, OA-HACs isolated at 480 mOsm 
showed severely inhibited proliferation compared to cells at 280 and 380 mOsm 
(Table 1). In contrast, doubling times of OA-HACs at 280 and 380 mOsm never 
significantly differed (Table 1). Therefore, all further experiments were performed 
at 380 mOsm (as high osmolarity condition) and compared to 280 mOsm (control 
condition). 
Figure 1. Hyperosmotic isolation and expansion of chondrocytes changes chondrocyte morphology. 
Representative images (200X) of chondrocytes cultured for 2 days at 280 (A), 380 (B), 480 (C) and 580 
(D) mOsm. 
Table 1. Proliferation of chondrocytes isolated and cultured at 280, 380 and 480 mOsm. Displayed 
are relative doubling times in percentage (%) of cells cultured at 280 mOsm. All data are means ± SD. 
The absolute doubling time ± SD in hours is displayed in brackets. n=6 *p<0.05
Culture condition P0 P1 P2 P3
280 mOsm 100 % (68 ± 28 hrs) 100 % (89 ± 54 hrs) 100 % (67 ± 48 hrs) 100 % (57 ± 11 hrs)
380 mOsm 113 ± 18 % 89 ± 25 % 99 ± 9 % 154 ± 41 %
480 mOsm 675 ± 405 % * 180 ± 24 % * 168 ± 28 % * 165 ± 81 % *
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Isolation and expansion of chondrocytes under hyperosmotic 
conditions improves their phenotype
Next, we set out to determine whether expansion culture in physiological osmolar-
ity improves the chondrocytic phenotype. Physiological osmolarity (380 mOsm) 
during isolation and subsequent passaging of OA-HACs significantly increased 
mRNA levels of both AGC1 (Figure 2A) and SOX9 (Figure 2B) at all passages. In 
expanded P3 chondrocytes in physiological culture, AGC1 levels were still higher 
than in unpassaged P0 chondrocytes cultured under the standard culture condi-
tions (280 mOsm). Physiological osmolarity also significantly up-regulated COL2 
levels from 8.5-fold in P0 to 11.6-fold in expanded P3 chondrocytes (Figure 2C) 
compared to controls. In contrast, COL1 expression was significantly suppressed 
in physiological conditions throughout culture. Consequently, we found a signifi-
cantly improved COL2/COL1 ratio during chondrocyte expansion (Figure 2D), from 
7-fold in P0 cells to 100-fold in expanded P3 cells. Physiological osmolarity also 
up-regulated COL2 protein expression (Figure 2E): levels significantly increased 
(between 1.5- and 2.2-fold) in P0, P1 and P2 chondrocytes. In contrast, physiologi-
cal osmolarity significantly decreased COL1 protein expression (Figure 2F), from 
2-fold in P0 cells to 13-fold in P1 cells. Physiological osmolarity also significantly in-
creased AGC1 (Figure 3A) and SOX9 (Figure 3B) mRNA levels in non-osteoarthritic 
HACs (NHACs). Furthermore, COL2 mRNA levels were significantly upregulated; 
from 5.8-fold in P0 cells to 270-fold in expanded P3 NHACs (Figure 3C). Like in 
OA-HACs, hyperosmolarity also down-regulated COL1 expression with increasing 
passage number in NHACs: the COL2/COL1 ratios increased during expansion 
(Figure 3D); from 6.8-fold in P0 cells to 355-fold in expanded P3 cells. Correspond-
ingly, COL2 protein levels increased under these conditions (4.8-fold in P1 cells and 
2.9-fold in P2 cells), while the amount of COL1 diminished (by 4.7-fold in P1 cells 
and 5-fold in P2 cells; Figure 3E, F). 
Osmolarity activates NFAT5 in human articular chondrocytes
Compared to 280 mOsm controls, NFAT5 mRNA levels were significantly increased 
in 380 mOsm OA-HACs cultures (Figure 4A), as was the expression of established 
NFAT5 target genes S100A4 (in all passages; Figure 4B) and SLC6A12 (until P2; 
Figure 4C). Similar effects were found in NHACs (data not shown).
NFAT5 knockdown inhibits osmolarity-induced chondrogenic 
marker expression
Upon transduction, sorted eGFP co-expressing OA-HACs were switched to 380 
mOsm for 24 hours. In controls, not expressing NFAT5-specific shRNAs, a ~2-fold 
increase in NFAT5 mRNA levels was observed (Figure 4A; P1) upon osmotic stimula-
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tion. In contrast, likewise challenged cells expressing anti-NFAT5 shRNAs showed 
a ~75% reduction in NFAT5 levels (Figure 5A). Following NFAT5 knockdown, also 
the NFAT5 targets, S100A4 and SLC6A12, were no longer osmotically inducible: 
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Figure 2. Hyperosmotic isolation and expansion increased marker gene expression in OA-HACs. 
Relative expression of AGC1 (A), SOX9 (B), COL2 (C) and COL2:COL1 ratio (D) in primary (P0) and 
passaged (P1-P3) chondrocytes cultured at 380 mOsm compared to 280 mOsm. COL2 protein ex-
pression (E) and COL1 protein expression (F) in P0 and P1 OA-HACs are shown. Protein levels are 
normalized to α-Tubulin. All data are means ± SD, n = 12. Differences with cells cultured at 280 
mOsm are indicated with * (p<0.05), ** (p<0.01) and *** (p<0.001).
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S100A4 expression decreased 2-fold and SLC6A12 was virtually undetectable upon 
NFAT5 RNAi (Figure 5A), confirming a functional NFAT5 knockdown. At 380 mOsm, 
NFAT5 RNAi also down-regulated chondrogenic markers: AGC1 by 80%, SOX9 by 
32% and COL2 by 84% as compared to non-RNAi controls (Figure 5B). Interestingly, 
expression of COL1 increased after NFAT5 RNAi in OA-HACs to ~300% of control 
levels (Figure 5B).
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Figure 3. Hyperosmotic isolation and expansion increased chondrogenic marker expression in 
NHACs. Relative expression of AGC1 (A), SOX9 (B), COL2 (C) and COL2:COL1 ratio (D) in pri-
mary (P0) and passaged (P1-P3) NHACs cultured at 380 mOsm compared to cells cultured at 280 
mOsm. COL2 (E) and COL1 (F) protein expression in P1 and P2 NHACs are shown and normalized 
to α-Tubulin. Data are means ± SD; n = 6. Differences to 280 mOsm controls are indicated with * 
(p<0.05) and ** (p<0.01).
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Discussion
Isolation and expansion of adult human articular chondrocytes under physiological 
osmolarity (380 mOsm) improves expression of chondrogenic markers on mRNA 
and protein level. While other studies partially confirm that non-human chondro-
cytes respond to osmolarity with altered aggrecan and SOX9 expression (4, 8, 10), 
we are reporting beneficial effects of isolating and expanding human normal and 
osteoarthritic articular chondrocytes at physiological levels (380 mOsm). In addi-
tion, we also studied collagen type II expression, generally acknowledged to be 
the most important chondrogenic marker. As fibrocartilaginous collagen type I and 
hyaline collagen type II expression are differentially regulated in chondrocytes (34), 
analyzing the collagen type II/type I expression ratios is informative of chondrogenic 
potential (50). Interestingly, NFAT5 seems to be crucially involved in this differential 
regulation upon osmotic challenge: it positively regulates collagen type II, while 
suppressing collagen type I (Figure 5B). Fibrocartilage, occurring in areas subject 
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Figure 4. Hyperosmotic conditions activate NFAT5 in OA-HACs. Relative expression of NFAT5 (A) 
and its target genes S100A4 (B) and SLC6A12 (C) in primary (P0) and passaged (P1 to P3) chondro-
cytes cultured at 380 mOsm compared to 280 mOsm. All data are means ± SD, n = 12. Differences 
are indicated with * (p<0.05), ** (p<0.01) and *** (p<0.001).
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to frequent stress like intervertebral discs and tendon attachment sites, is more rich 
in collagen type I than hyaline cartilage (53). Osmolarity may thus provide a simple 
means to manipulate expression of these two collagens for broader applications 
than regenerative chondrocyte implantations (ACI or CCI) alone (54). 
Under our conditions, COL2 mRNA abundances measured by QPCR nicely cor-
related with protein synthesis as determined by Western Blots (Figure 2 and 3). The 
same holds for COL1 expression in the early passages, but not for COL1 expression 
in the later passages. 
Hyperosmolarity-induced increase in NFAT5 abundance and protein synthesis rate 
were found to be proportional to the increase in mRNA in MDCK (28) and mIMCD3 
cells (27). NFAT5 mRNA is expressed abundantly in chondrocytes throughout pas-
sages and is further induced by osmolarity. However, we failed to show NFAT5 
protein expression by Western blotting. Whether this is due to low protein abun-
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Figure 5. NFAT5 knockdown inhibits osmolarity-induced chondrogenic marker expression. 
(A) Relative expression of NFAT5 and its target genes S100A4 and SLC6A12 in transduced chondro-
cytes either expressing (NFAT5 shRNA) or not expressing (control) NFAT5-specific shRNAs, 24 hours 
after increasing osmolarity to 380 mOsm. (B) Effects of NFAT5 knockdown on chondrogenic markers 
AGC1, SOX9, COL2 and COL1. All data are means ± SD, n = 6. Differences to cells transduced with 
control virus are indicated with * (p<0.05) and ** (p<0.01).
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dance in our cells or technical issues like poor extraction efficiency of this very large 
transcription factor has to be elucidated in future experiments.
Hyperomolarity induces cell shrinkage which may activate Na+, K+, or 2Cl- co-
transport allowing cellular accumulation of NaCl and KCl. The beneficial effects 
on chondrogenic marker gene expression therefore could have been caused by 
accumulation of specific inorganic ions or specific channel activity rather than 
primarily osmolarity-mediated effects. We used NMDG-Cl, a bulky substitute for 
small cations that is impermeable to almost all known channels (55), and sucrose 
to exclude sodium or chloride specific effects. We were not able to detect any 
significant differences in gene expression patterns between the NaCl, NMDG-Cl 
or sucrose means of osmolarity alteration (data not shown). 
As our initial studies concerned adult human articular chondrocytes obtained from 
osteoarthritic knee joints, we aimed at eliminating interpretation bias due to the 
pathological state of these cells. Using identically challenged non-osteoarthritic 
cells (NHACs), we showed that these chondrocytes react similarly to the same 
order of osmolarity with respect to our marker genes: 380 mOsm significantly 
delayed the phenotypical deterioration of NHACs as observed in control medium. 
This may imply that physiological osmolarity, postulated to be around 380 mOsm 
for chondrocytes, is sensed by osteoarthritic and ‘normal’ cells in a similar fashion. 
We observed a slightly faster decrease in AGC1 and COL2 mRNA levels in P2 
and P3 NHACs as compared to OA-HACs. Late stage osteoarthritic chondrocytes 
from fibrillated areas are dedifferentiated, flattened cells. The loss of a proper 
spherical shape as an integral part of the chondrocytes phenotype (56, 57) involves 
cytoskeletal changes (58). Exposing these cells to physiological osmolarity as re-
differentiation stimulus likely induces a more enduring response as compared to 
spherical, normal’ chondrocytes. Cell based therapies using the latter are usually 
restricted to younger individuals after traumatic insults. Autologous chondrocyte 
implantation employing osteoarthritic cells may benefit relatively more from a 
hyperosmotic treatment protocol.
The precise molecular mechanism by which osmolarity is sensed by cells is still 
poorly understood. Hyperosmolarity-increased NFAT5 mRNA abundances have 
been shown for other cell types (26-28). NFAT5 is thus accepted as key transcription 
factor participating in the mammalian hyperosmotic stress response. Our study 
is the first showing the functional expression of NFAT5 in human articular chon-
drocytes. In both, osteoarthritic and ‘normal’ chondrocytes, cellular NFAT5 mRNA 
levels are increased by 380 mOsm. In addition, mRNA levels of generally accepted 
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NFAT5 target genes, S100A4 and SLC6A12 (20, 59), were induced accordingly after 
osmotic challenge, underscoring an involvement of NFAT5. It has recently been 
suggested that guanine nucleotide exchange factors near the plasma membrane 
may be activated through cytoskeleton changes or by changes in interactions with 
putative osmosensors at the cell membrane in other cells (60). Sensation of such 
basic responses might not be different in chondrocytes than in other cells. Rho-
type small G proteins (61) and p38 kinases (62, 63) might act upstream of NFAT5 in 
chondrocytes, too. In IMCD cells, p38 MAPK signaling was recently also shown to 
be involved in the NFAT5-mediated hyperosmotic induction of the osmosensitive 
(64, 65) serine-threonine protein kinase Sgk-1 (66, 67). As p38 MAPK plays important 
roles in chondrocytes and seems to be necessary for NFAT5 expression (20), further 
experiments employing pharmacological inhibition or knockdown experiments in 
HACs will hopefully shed more light into this signaling cascade in chondrocytes. 
Increase in NFAT5 mRNA is usually transient with a cell type depending time course 
and a 2- to 4-fold upregulation (26, 28) which fits with our data. NFAT5 mRNA 
abundance might rapidly increase upon hypertonic stress by a transient increase in 
its mRNA stability, mediated by its 5’-UTR (27). Whether 380 mOsm is a sufficiently 
high osmolarity to explain our increase in mRNA by this phenomenon or whether 
active transcription is involved, has to be addressed in other studies. Interestingly, 
recently Tew et al. (68) showed that the mRNA of SOX9, an important regulator of 
COL2 expression, is stabilized by supra-physiological osmolarity. Therefore, 380 
mOsm might also directly contribute to SOX9 mRNA stability and abundance in 
our experiment, rather than elevating promoter activity. COL2 regulation could 
thus be an indirect effect of osmolarity. 
Interestingly, AGC1 seems to be more stably expressed in cultures maintained at 
280 mOsm compared to 380 mOsm, with a lower overall expression in the for-
mer condition. Effects of osmolarity on promoter activity and mRNA stability of 
AGC1 are incompletely understood. Other groups described the complexity of 
osmotic stress on gene expression (69, 70). It is tempting to speculate that gene 
expression may be influenced by morphological changes between our conditions: 
while cells cultured at 380 mOsm are rather round, cells cultured in monolayer 
at 280 mOsm are rather flat and more fibroblast-like (see Figure 1). Although we 
did not investigate actin stress fiber formation in this study, they are usually more 
pronounced in fibroblastic cells and have been shown to suppress SOX9 mRNA 
levels in chondrocytes (49). However, aggrecan expression has been reported to 
be influenced by both hyper- and hypo- osmolarity (4, 8). The promoter regions of 
both collagen type II and aggrecan contain a plethora of potential other binding 
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sites for transcriptional enhancers and suppressors, such as SOX5/6 (71, 72), Barx2 
(73), β-catenin (74), c-Maf (75), PIAS (76), TRAP230 (77), Bapx1 (78), and C/EBP and 
NF-kB (79). Chondrogenic differentiation and SOX9-dependency of aggrecan and 
collagen expression may also be differentially modulated by these transcriptional 
co-factors under different osmolarities. Interestingly, while SOX9 dependency of 
COL2A1 expression has been unequivocally shown, it may not actually be a key 
regulator of COL2A1 promoter activity in human adult articular chondrocytes (80). 
Of note, the human aggrecan promoter sequence has been shown to contain a 
conserved NFAT5 binding site (81). In nucleus pulposus cells, SOX9 mediated 
aggrecan expression has recently been shown to critically depend on PI3K/AKT 
signalling (82). Moreover, while high NaCl rapidly activates p38 MAPK, its action 
can be isoform specific and may exert opposing effects on NFAT5 (83), which in 
turn may influence COL2A1 and AGC1 transcription differently in a osmolarity-
dependent manner. We are therefore currently looking into the underlying mo-
lecular mechanisms regulating aggrecan and collagen type II expression in both 
conditions. 
With respect to regenerative medical applications, the high-end hyperosmotic 
conditions used by Tew et al. can be considered a limitation of that study. In our 
hands, these osmolarity levels (≥480 mOsm) induced chondrocyte death within 48 
hours (Figure 1D) and are not likely applicable for chondrocyte expansion culture. 
To ensure sufficient cell numbers for cell-based repair techniques, proliferation 
capacity of the isolated chondrocytes should not be compromised. Cell numbers 
generally need to be increased during two passages (>4-10 times) for clinical appli-
cation (84, 85). We found that supra-physiological conditions (480 and 580 mOsm) 
clearly compromised survival rates, which is in agreement with data by Racz et al. 
(17). From our data, we conclude that about 380 mOsm is optimal for both isolation 
and in vitro expansion culture of HACs. NFAT5 knockdown down-regulates its own 
transcription by 75% and compromises target gene induction (Figure 5), being in 
line with a functionally active NFAT5 in chondrocytes. Constitutive homodimeric 
NFAT5 molecules encircle DNA rather independently of osmolarity in solution (86), 
enabling NFAT5 to exert its biological activity over a wide osmolarity range (87, 88). 
It is thus reasonable to assume that NFAT5 activity is not generally compromised at 
380 mOsm. However, other aspects are involved in the regulation of NFAT5 as well 
as its target genes. Like other proteins larger than 50kDa (89), NFAT5 dependents 
on nuclear localization and export sequences for its nuclear translocation (26, 86, 
89). In most cells, NFAT5 is equally distributed between cytoplasm and nucleus 
at physiological osmolarity (±300 mOsm), whereas at 500 mOsm most of it local-
izes to the nucleus (19, 26, 87). To demonstrate that the hyperosmolarity-induced 
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chondrogenic marker expression was indeed mediated by NFAT5, we used RNAi 
to confirm that knockdown of NFAT5 significantly i) inhibited hyperosmotic induc-
tion of its own transcription as discussed before, (ii) suppressed the osmolarity-
mediated induction of known NFAT5 targets, and (iii) most importantly, eliminated 
the hyperosmolarity-mediated mRNA expression of chondrogenic marker genes 
(COL2, AGC1, SOX9 and COL1).
Conclusions
We have shown that isolation and expansion of adult human articular chondrocytes 
in culture medium of physiological osmolarity (380 mOsm) improves chondrogenic 
marker expression and extracellular matrix production through NFAT5. We identi-
fied NFAT5 as a novel molecular target preserving chondrocytic marker expression. 
Our data provide valuable insights for the development of strategies for cell-based 
repair of chondral lesions and contributes to the understanding of mechanisms 
involving osteoarthritis.
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Abstract
The physiological interstitial osmolarity (tonicity) of healthy articular cartilage (350-
480 mOsm) is lowered to 280-350 mOsm in osteoarthritis. This results in loss of 
tissue pre-stress, altered compressive behavior and thus inferior tissue properties. 
We aimed at determining potential synergistic effects of physiological osmolarity 
in combination with inhibiting calcineurin activity by FK506 on human articular 
chondrocytes and explants in vitro.
Osteoarthritic chondrocytes and explants and non-osteoarthritic chondrocytes 
were cultured in cytokine-free medium of 280 and 380 mOsm with or without 
calcineurin inhibition by FK506. Chondrogenic, hypertrophic and catabolic marker 
expression was evaluated on mRNA, protein and activity level.
Culturing osteoarthritic chondrocytes at 380 mOsm increased mRNA expression 
of chondrogenic markers (e.g. COL2, ~13-fold, p<0.001) compared to 280 mOsm, 
while suppressing COL1 (~0.5-fold, p<0.01). Inhibiting calcineurin activity under 
physiological osmolarity further enhanced expression of anabolic markers on mRNA 
(COL2, ~50-fold, p<0.001; AGC1, ~2-fold, p<0.001; SOX9, ~3.5-fold, p<0.001) and 
protein (COL2, ~6-fold, p<0.001) level. Calcineurin inhibition suppressed relevant 
collagenases as well as hypertrophy and mineralization markers on mRNA and 
activity level. Aggrecanase-1 and -2 expression was not influenced by osmolar-
ity or FK506 alone, but the combination suppressed both, by ~50% (p<0.05) and 
~40% (p<0.001) respectively. Generally, similar anabolic and anti-hypertrophic 
effects were observed in ex-vivo cartilage explant cultures and non-osteoarthritic 
chondrocytes. 
Calcineurin inhibition at physiological osmolarity exerts a superior effect than 
physiological osmolarity or FK506 alone: increasing anabolic, while suppressing 
hypertrophic and catabolic markers. Our data may aid in developing improved 
cell-based chondral repair and osteoarthritis treatment strategies.
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Introduction
Articular cartilage has unique properties related to the structure and composition 
of its extracellular matrix (ECM), which is mainly composed of proteoglycans (PGs, 
e.g. aggrecan, AGC1) entangled in a network of collagen fibres (i.e. collagen type II, 
COL2) and large amounts of water (1). Water and inorganic salts represent the bulk 
mass portion, while collagens, PGs and other (glyco-)proteins constitute only 20% 
of the tissue’s wet weight. Collagens represent 50-60% of cartilage’s dry weight, 
while proteoglycans, as second largest solid phase portion, account for 5-10%.
In normal cartilage there is a balance between matrix synthesis and degradation. 
Depletion of aggrecan from articular cartilage by metalloproteinase (MMP) and 
aggrecanase (ADAMTS) action, is an essential early pathophysiological event in 
osteoarthritis (OA) (2-4). This decrease in PG content can result in reduced visco-
elastic properties and increased deformation of cartilage under load, causing in-
directly increased protease, but decreased tissue inhibitor (TIMP) production (5-7).
Cartilage requires a high osmotic pressure to maintain its hydrostatic pressure and 
keep its visco-elastic properties. The glycosaminoglycan (GAG) side chains of PGs 
are sulfated and responsible for the characteristic high fixed negative charge density 
(8) which binds mobile cations (sodium, calcium and potassium). The combination 
of intertwined collagens and PGs creates the tissue’s rigidity by entrapping solutes 
and water, giving cartilage its unique mechanical properties, enabling it to deform 
and undergo large compressive and shear forces without failing (9). An intact col-
lagen network restricts swelling and, in combination with GAGs, determines the 
tonicity (i.e. osmotic pressure) of the extracellular fluid around chondrocytes, which 
ranges between 350 and 480 mOsm in healthy cartilage (10-11). Catabolic events 
in the course of OA deplete PGs and degrade the collagen matrix, resulting in a 
severity-depending decreased osmolarity of between 280 and 350 mOsm (10, 12) 
and biomechanical inferiority.
Several studies have shown the presence of ‘abnormal’ collagens in OA car-
tilage: COL1 appears to be present in clusters of fibrillated areas in late stage 
OA, while COL10 (a hypertrophic marker) is expressed in moderately to severely 
affected osteoarthritic cartilage (5). COL1 expression is also increased during in-
vitro chondrocyte expansion for several cell-based approaches, like Autologous 
Chondrocyte Implantation (ACI), to repair chondral lesions. During expansion, loss 
of chondrogenic phenotype occurs (dedifferentiation): chondrocytes convert into 
a flattened, fibroblast-like state, accompanied by a shift from COL2 expression 
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to COL1 expression (13), which reduces extracellular matrix quality. Chondrocyte 
dedifferentiation during in-vitro expansion for ACI is detrimental, but almost inevi-
tably in standard monolayer culture. 
Previously, we identified calcineurin (Cn), a calcium-dependent serine/threonine 
phosphatase, as a potential target to improve chondrocyte phenotype, by showing 
that Cn activity is strongly regulated during chondrocyte differentiation. Inhibition 
of Cn activity by FK506 increased the expression of the chondrogenic markers 
AGC1, COL2 and SOX9, indicating that chondrocytes might shift towards a more 
chondrogenic phenotype (13). We further showed that isolation and expansion of 
adult human articular chondrocytes (HAC) in culture medium of physiological os-
molarity (380 mOsm) improves chondrogenic marker expression and extracellular 
matrix production through NFAT5 (14).
The aim of the current study was to elucidate whether combining physiological 
osmolarity with inhibiting Cn activity has a synergistic effect and thereby exceed 
the anabolic effects of each treatment alone. In the present study, we paid special 
attention to suppressing unwanted hypertrophic and catabolic markers. Finally, we 
also performed experiments with non-osteoarthritic chondrocytes to investigate 
whether our culture method holds the potential to develop strategies for cell-
based repair of chondral lesions.
Materials and Methods
Cartilage and chondrocyte isolation
After informed consent (MEC2004-322), human articular cartilage was explanted 
from macroscopically normal areas of femoral condyles and tibial plateaus of 
thirteen patients undergoing total knee replacement surgery for OA and of five 
patients undergoing (non-osteoarthritic) trauma surgery. Isolation of primary os-
teoarthritic human articular chondrocytes (OAHAC) and non-osteoarthritic human 
articular chondrocytes (NHAC) from cartilage tissue under standard conditions 
(cytokine-free, 280 mOsm DMEM) was described earlier (13, 15). In contrast, osmo-
larity of the isolation and culture media was adjusted to 380 mOsm by addition of 
sterile NaCl (14). 
Chondrocyte expansion
Briefly, 7,500 cells/cm2 were expanded in cytokine-free 280 mOsm or 380 mOsm 
DMEM, corresponding to their isolation osmolarity. Passage 1 (P1) and P2 cells were 
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seeded at 20,000 cells/cm2 prior to adding 0, 50 or 500 ng/ml FK506 to the medium 
after 24 hours. Cells were then cultured for six days prior to mRNA (quantitative 
RT-PCR) and protein (Western Blotting) analyses. Experiments were performed at 
least in technical duplicates from five OA donors for mRNA analysis and from three 
OA donors for protein analysis (OAHAC). 
In addition, experiments were performed with three non-osteoarthritic donors for 
mRNA analysis (NHAC).
Chondrocyte pellet culture (3D)
In addition to 2D culture, P2 OAHAC from three donors were isolated at 280 mOsm 
and cultured as triplicate pellets (2x105 cells/pellet) according to Hellingman et 
al.(16), but for 21 days in DMEM medium of 280 mOsm or 380 mOsm with addition 
of FK506 (50 ng/mL). The same experiments were performed with P2 NHAC from 
three donors. COL2 and GAG staining intensities of NHAC pellets were quantified 
using ImageJ 1.42 software (http://rsb.info.nih.gov/ij/download.html).
Cartilage explants
Six mm diameter full-thickness explants from femoral condyles and tibial plateaus 
of three OA donors were pooled prior to culturing at least two randomly taken 
explants per group for three days in 24-well plates with 330 µl medium per explant. 
Explants were cultured in DMEM at 280 mOsm or 380 mOsm, with or without addi-
tion of 50 ng/mL of FK506 for 24 hours and 7 days. RNA was extracted as described 
earlier (15).
RNA expression analysis 
RNA purification, quantification and cDNA synthesis are described elsewhere (15). 
Expression levels of AGC1, SOX9 and COL2 were studied as chondrogenic mark-
ers, while COL1 was studied as dedifferentiation marker as previously described 
(14). To investigate terminal chondrocyte differentiation, COL10 and MMP13 were 
used as hyperthrophic markers and alkaline phosphatase (ALPL) as mineralization 
marker. MMP-1 ,-3, -8, -13, ADAMTS-4 and -5 and tissue inhibitors (TIMP-1 and -2) of 
the aforementioned were studied. While most QPCR assays were reported earlier 
(14-15, 17-18), ALPL expression was detected using the following primers (5’ - 3’): 
ALPL-Fw GACCCTTGACCCCCACAAT, ALPL-Rv GCTCGTACTGCATGTCCCCT 
(200nM each) and ALPL hydrolysis probe FAM-TGGACTACCTATTGGGTCTCTTC-
GAGCCA-TAMRA (600nM), respectively. Data were normalized to an index of at 
least three reference genes (GAPDH, UBC, HPRT1), which were pre-evaluated to 
be stably expressed across samples, and relative expression was then calculated 
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according to 2-ΔCT method (19). Averaged replicates per patient and condition were 
used to calculate the relative expression, normalized to the 280 mOsm P1 control.
Western Blotting and (immuno)histochemistry
Protein extraction, quantification, loading of SDS-polyacrylamide gels, electro-
blotting, detection and quantification is described in detail by van der Windt et al 
(14). The anti-GAPDH antibody (1:1000) was purchased from Cell Signaling Tech-
nology (Boston, MA, USA). Replicate data per patient and passage were averaged 
and normalized to the 280 mOsm condition.
(Immuno)histochemical staining for COL2 and GAG content of triplicate 3D pellet 
cultures from OAHAC and NHAC (three donors each) was performed as described 
earlier by our group (16). 
Alkaline phosphatase activity and DNA assay
After washing human OAHAC in 1X PBS (8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 
0.24 g KH2PO4 per liter distilled H2O; pH 7.4 ), alkaline phosphatase (ALPL) activity 
was determined by the colorimetric method of Lowry et al. (20) with modifications 
described by Janssen et al. (21). Briefly, cell lysates in 1X PBS/0.1% (v/v) Triton X-100 
were heparin and RNase A (50 mg/ml in PBS) treated for 10 minutes at 37°C with 
gentle agitation and stored at -80°C until further use. Duplicates of 50 µl of each 
sample or lysis buffer (blank) were mixed with equal volumes of Substrate Solution 
(#P4744 Sigma-Aldrich; 20 mM p-nitrophenyl phosphate, 0.1M glycine, 1mM ZnCl2, 
1mM MgCl2, pH 9.6), incubated for 10 min at 37oC in the dark and stopped by add-
ing 125 µl of 0.1M NaOH. Samples were measured at 405nm in a standard micro-
plate reader against a standard curve of p-nitrophenol (pNP, #1048, Sigma-Aldrich, 
Zwijndrecht, The Netherlands). ALPL activity was calculated from pNP standard 
curve and corrected for the amount of DNA per culture well (21). Measurements of 
triplicate samples from three OA donors per condition were analyzed.
MMP13 activity
MMP13 activity in OAHAC was determined using the SensoLyte® Plus 520 MMP13 
Assay Kit (AnaSpec #71156, San Jose, CA) according to the manufacturer’s instruc-
tions. Cell-free culture media were collected and stored at -80°C until activity of 
immobilized MMP13 was determined by its ability to cleave a FRET peptide sub-
strate. Proteolysis separates the fluorophore from the quencher, with the resulting 
fluorescence (Ex/Em=490nm/520nm) being proportional to the MMP13 activity in 
the sample. Fluorescence was measured in a SpectraMAX Gemini plate reader 
using black, m-clear flat-bottom 96-well plates (Greiner Bio-one, Alphen a/d Rijn, 
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Netherlands; #655090) and expressed as relative fluorescence units (RFU). Hence, 
samples were corrected for DNA content and displayed as n-fold RFU of the con-
trol condition. Measurements of replicate samples per condition were analyzed 
from three OA donors.
Calcineurin (Cn) activity
Cn activity was determined colorimetrically in triplicate using the Calcineurin Cellu-
lar Assay Kit Plus (BioMol, Tebu-Bio, Heerhugowaard, NL) as described earlier (13).
Statistics
Statistical analysis was performed using SPSS 13.0 software (SPSS Inc., Chicago, IL, 
USA). We used the replicate raw expression data of multiple donors and tested for 
the effect of our experimental conditions using Linear Mixed Model (LMM) regres-
sion. We therefore accounted for the correlation in the data that exists within each 
donor. We further incorporated ‘donor’ as a random effect to correct for basal 
differences in expression between patients; p-values are reported as p< 0.05, 0.01 
and 0.001.
Results
FK506 inhibits Cn activity at 280 and 380 mOsm to a similar 
extent
Dose-dependent inhibition of Cn activity in OAHAC cultured at 380 mOsm (data 
not shown) was not significantly different from that in 280 mOsm (13).
Physiological osmolarity and FK506 synergistically increase 
expression of chondrogenic markers of OAHAC in vitro
Culturing P1 and P2 osteoarthritic chondrocytes (OAHAC) in medium of physiologi-
cal osmolarity (380 mOsm) significantly increased mRNA expression of chondro-
genic markers COL2, AGC1 and SOX9 when compared to control osmolarity (280 
mOsm), but significantly decreased COL1 expression (Fig. 1), thereby confirming 
our earlier results (14).
Calcineurin inhibition enhanced anabolic effects of physiological osmolarity: FK506 
dose-dependently increased chondrogenic marker expression to a much greater 
extend than in the 280 mOsm controls (Fig. 1B and D). While physiological osmo-
larity has a general, passage-dependent suppressive effect on COL1 expression, 
addition of FK506 did not alter COL1 gene expression and had no effect at 280 
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mOsm either; except for P2 cells in which the highest concentration of FK506 (500 
ng/mL) slightly suppressed COL1 mRNA levels (Fig. 1A, on log scale). In contrast, 
COL2 mRNA levels increased up to 13-fold in P1 chondrocytes at physiological 
osmolarity and increased further up to 49-fold after co-stimulation with FK506 (Fig. 
1B, on log scale). At 380 mOsm, AGC1 mRNA levels increased up to 2.1-fold and 
SOX9 expression up to 3.4-fold in P2 chondrocytes after co-stimulation with FK506 
(Fig. 1 C and D, respectively). 
Physiological osmolarity increased COL2 protein levels at least 3-fold in P1 and P2 
(Fig. 2A) chondrocytes. Addition of FK506 increased COL2 protein levels up to 6.0-
fold in P1 and up to 5.2-fold in P2 chondrocytes (Fig. 2A). Physiological osmolarity 
did not affect COL1 protein levels in P1 chondrocytes, but addition of FK506 to 
the 380 mOsm medium significantly decreased COL1 protein levels (Fig. 2B). In P2 
chondrocytes physiological osmolarity decreased COL1 protein levels by 35% and 
up to 40% when FK506 was added. 
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Figure 1. FK506 mediated effects on chondrogenic marker expression during isolation and expan-
sion of OAHAC. Relative mRNA expression of (A) COL1 (log scale), (B) COL2 (log scale), (C) AGC1, 
(D) SOX9 in human osteoarthritic P1 and P2 monolayer chondrocytes from five donors, cultured at 
physiological (380 mOsm, black bars) or at control (280 mOsm, grey bars) omolarity with or without 
50 or 500 ng/mL FK506. Data are means ± standard deviation. Differences per passage are indicated: 
*p < 0.05, **p < 0.01, ***p < 0.001 (compared to 280 control), #p < 0.05, ##p < 0.01, ###p < 0.001 
(compared to 380 control).
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As inhibition of Cn activity under physiological osmolarity decreased the de-
differentiation rate of chondrocytes in 2D monolayer culture, we next evaluated 
this treatment in 3D micro-tissue culture (i.e. pellets) in vitro: COL2 protein and 
GAG abundance were again increased in the 380 mOsm condition with addition of 
FK506 as compared to the 280 mOsm control (Fig. 2C).
FK506 inhibits osmolarity-induced expression of hypertrophic and 
catabolic markers of OAHAC in vitro.
Next, we investigated the effects of FK506 at physiological osmolarity on the syn-
thesis of terminal differentiation markers (COL10, ALPL), ECM-degrading enzymes 
(MMPs, ADAMTSs) and their inhibitors (TIMPs). 
Physiological osmolarity also slightly increased mRNA levels of hypertrophy 
markers COL10 and MMP13 and mineralization marker ALPL (Fig. 3A) in P1 chon-
drocytes. Addition of FK506, however, inhibited these unwanted tonicity-induced 
effects. Moreover, FK506 exerted similar effects on the expression of collagenases 
MMP1 and -8 (Fig. 3B). Interestingly, aggrecanases ADAMTS4 and -5 were not 
significantly influenced by 380 mOsm or FK506 alone, while the combination sig-
nificantly decreased their expression: ADAMTS4 by 50% and ADAMTS5 by 40% 
(Fig. 3C). The expression of tissue inhibitors of metalloproteinases, TIMP1 and -2, 
was increased by 380 mOsm (2.5-fold and 1.5-fold, respectively). Although FK506 
had limited effects on TIMP expression at 280 mOsm, it increased their expression 
Figure 2. Improved collagen and GAG expression in expanded OAHAC. Western blot analyses 
of (A) COL2 and (B) COL1 levels of P1 and P2 OAHAC. Cells from three donors were cultured at 
physiological tonicity (380 mOsm, black bars) with or without 500 ng/mL FK506 or at control medium 
omolarity (280 mOsm, grey bars). Representative blots are shown (on bottom) next to densitometry 
data; data are means ± standard deviation. Significant differences per passage are indicated: *p < 
0.05, **p < 0.01, ***p < 0.001 (compared to 280 control), ##p < 0.01 (compared to 380 control). (C) 
Representative images of 21-day 3D cultures showing COL2 immunostaining (on top, in red) and 
GAG thionin staining (on bottom, in blue) of pellets from three donors cultured at 280 mOsm or 380 
mOsm + FK506 (50 ng/mL). (Original magnification x 40).
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at 380 mOsm almost 4-fold (TIMP1) and 2.5-fold (TIMP2) (data not shown). Overall, 
the combination of FK506 and physiological osmolarity showed similar trends in 
expression levels of hypertrophic and catabolic markers in P2 chondrocytes (data 
not shown). 
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Figure 3. Treatment effects on hypertrophic and catabolic markers in OAHAC. Relative mRNA ex-
pression of (A) hypertrophic markers COL10, ALPL, MMP13 and (B,C) catabolic markers MMP1, 
MMP3, MMP8 and ADAMTS4 and -5. P1 OAHAC from five donors were cultured in monolayer at 
physiological (380 mOsm, black bars) or control (280 mOsm, grey bars) medium omolarity with or 
without 50 or 500 ng/mL FK506. Data are means ± standard deviation. Differences are indicated: 
*p < 0.05, **p < 0.01, ***p < 0.001 (compared to 280 control), #p < 0.05, ##p < 0.01, ###p < 0.001 
(compared to 380 control).
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Physiological osmolarity also significantly increased ALPL activity in all three 
donors, while addition of FK506 to 380 mOsm medium significantly reduced 
osmolarity-induced ALPL activity (Fig. 4A). Although elevated osmolarity increased 
MMP13 activity in one patient (Fig. 4B), addition of even small doses of FK506 
always suppressed its activity. Moreover, higher FK506 concentrations (500 ng/mL) 
suppressed MMP13 activity to, or below, control (280 mOsm) levels.
Synergistic effects of FK506 and physiological osmolarity in OA 
cartilage ex vivo. 
Chondrocytes in vivo are embedded in an extensive ECM. For potential clinical 
applications it is essential to investigate whether chondrocytes embedded in this 
ECM are reacting similarly to osmolarity and FK506 as those in monolayer culture. 
To address whether the ECM of cartilage interferes with osmolarity-mediated re-
sponses of chondrocytes, we next performed experiments with cartilage explants. 
Stimulation of cartilage explants with physiological osmolarity for 24 hours increased 
expression of chondrogenic markers COL2, AGC1 and SOX9, while the expression 
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Figure 4. FK506 mediated effects on hypertrophic marker activity of OAHAC. Relative activity of (A) 
ALPL and (B) MMP13 in P1 monolayer cultures of OAHAC from three donors at physiological (380 
mOsm, on right) or control (280 mOsm, on left) omolarity with or without 50 or 500 ng/mL FK506. 
Data are means ± standard deviation, normalized to 280 control. Differences are indicated: *p < 0.05, 
***p < 0.001 (compared to 280 control), ##p < 0.01, ###p < 0.001 (compared to 380 control).
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of COL1 decreased (data not shown). Physiological osmolarity or FK506 had no 
apparent effect on hypertrophic marker expression (COL10, ALPL and MMP13) on 
the short term (data not shown). After seven days of culture, the sole osmolarity-
induced upregulation of the chondrogenic markers was reduced to baseline levels 
(Fig. 5A), while addition of 50 ng/mL of FK506 to this medium ensured a prolonged 
transcriptional abundance of all tested chondrogenic markers (Fig. 5A). Osmolar-
ity, however, also induced expression of COL10 in explants, while no significant 
effects were found on ALPL and MMP13 levels (Fig. 5B). Strikingly, FK506 was able 
to suppress COL10 to baseline levels not only in monolayer cultures but also in 
cartilage tissues in vitro. Although physiological osmolarity did not increase ALPL 
expression in explants within 7 days, addition of FK506 under these conditions 
suppressed ALPL mRNA levels (Fig. 5B). 
Synergistic effects of FK506 at physiological osmolarity in NHAC 
in vitro.
Finally, we evaluated our approach on NHAC from a limited number of non-os-
teoarthritic donors. In monolayer culture, NHAC reacted similarly to physiological 
osmolarity as did OAHAC: expression trends of chondrogenic and hypertrophic 
markers were congruent (Fig. 6), but the magnitude of the FK506 mediated expres-
sional change was different. In both cell types, standard expansion increased COL1 
expression (Fig. 6A vs. 1A) while 380 mOsm generally suppressed COL1 levels, 
although in NHAC only significantly in P2. Trends in COL2 expression in response 
to osmolarity were the same in NHAC and OAHAC (Fig. 6A vs. Fig. 1B, both log 
scale). P2 NHAC showed a relatively larger increase in COL2 levels by elevated 
osmolarity than P1 NHAC or OAHAC did (Fig. 6A vs. 1B), mainly due to a more 
profound suppression of COL2 expression at 280 mOsm in P2 NHAC. In NHAC, 
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Figure 5. Treatment effects on chondrogenic and hypertrophic markers in OA cartilage explants. 
Relative expression of (A) COL1, COL2, AGC1 and SOX9 and (B) hypertrophic markers COL10, ALPL 
and MMP13 in human osteoarthritic articular cartilage explants from three donors. Explants were 
cultured in physiological (380 mOsm, black bars) or control (280 mOsm, grey bars) medium with or 
without 50 ng/mL FK506. Data are means ± standard deviation. Significance is indicated by *p < 0.05, 
**p < 0.01 (compared to 280 control) and #p < 0.05, ##p < 0.01 (compared to 380 control).
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the trends towards synergy between elevated osmolarity and FK506 were less 
prominent on COL2 expression and had a more profound effect on AGC1 mRNA 
levels, when compared to OAHAC (Fig. 6A). Interestingly, in NHAC, the overall 
expression of SOX9 dropped in a rather passage- than stimulus-dependent man-
ner at both osmolarities, while elevated osmolarity had a similar stimulating effect 
in both passages (Fig. 6A). 
As OAHAC and NHAC showed similar trends in response to basal osmolarity on 
chondrogenic marker expression, we next analyzed their hypertrophic response. 
COL10 transcripts were low abundant in NHAC and only considerably expressed 
by two out of three donors, but in those showed the same trend in response to 
osmolarity and FK506 as in OAHAC (Fig. 6B). MMP13 transcripts were virtually 
absent in NHAC (data not shown). In P1, OAHAC and NHAC, revealed almost 
identical responses in ALPL expression (Fig. 3A, Fig. 6B), with FK506 suppressing 
the up-regulation of ALPL expression in response to 380 mOsm. 
NHAC pellet cultures revealed a consistent trend of improved COL2 protein and 
GAG content (65% and 44% respectively, data not shown) upon inhibition of Cn 
activity under physiological osmolarity after 21 days (Fig. 6C).
Discussion
In OA, the ECM of cartilage degrades and the extracellular osmolarity drops 
considerably compared to healthy cartilage (10-11), resulting in a biomechanically 
inferior tissue. Physiological osmolarity is chondroprotective in vitro and ex vivo 
(14, 22-23), while Cn inhibition exerts pro-chondrogenic effects (13, 24). We now 
showed that Cn inhibition at physiological osmolarity exerts a superior effect: 
improving anabolic, while suppressing catabolic and hypertrophic markers.
Adding FK506 to medium of physiological osmolarity dose-dependently enhanced 
chondrogenic markers to a much greater extend than FK506 at 280 mOsm or than 
physiological osmolarity alone (Fig.1B-D). The already ~13-fold solely osmolarity-
dependent increase of COL2 mRNA levels in P1 cells was tripled to ~50-fold 
upon co-stimulation with FK506 (500 ng/mL, Fig.1B). Furthermore, physiological 
osmolarity suppressed unwanted COL1 expression more efficiently than FK506 
did (Fig.1A). Tew et al. found that osmolarity regulates SOX9 and COL2 expres-
sion post-transcriptionally, but stabilizing SOX9 mRNAs while destabilizing COL2 
transcripts (25). In our study, SOX9 up-regulation by osmolarity revealed a sub-
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stantial FK506-dependency. We did not aim to elucidate the underlying molecular 
mechanism in this study, but rather confirmed the beneficial treatment effect on 
protein level (Fig.2). In both 2D and 3D cultures, COL2 mRNA and protein expres-
sion profited relatively more from osmolarity and FK506 than AGC1 expression 
and GAG content did. As the maximum gain in COL2 expression diminishes in 
P2 compared to P1 in both OAHAC and NHAC (Fig.1B, 6A and Fig.2), our data 
indicate that synergism between osmolarity and Cn inhibition cannot ultimately 
prevent, but only delay, chondrocyte de-differentiation in monolayer culture. It is 
important to realize that normal adult articular chondrocytes in vivo do not divide, 
while in our study they did. Maintaining proliferation capacity and chondrogenic 
marker expression is excellent for clinical applications of cell-based therapies (14).
Aggrecanases ADAMTS4 and ADAMTS5 were not significantly influenced by 380 
mOsm or FK506 alone, but the combination decreased their expression (Fig. 3). Ex-
pression of TIMP1 and TIMP2 was increased at 380 mOsm and further up-regulated 
upon co-stimulation with FK506 (data not shown), adding to a PG-protective effect 
of FK506. TIMP3 transcripts were very low abundant (data not shown). Hiyama et 
al. (26) suggested that AP1, Sp1, and NFAT5 transcription factors control GAG 
synthesis in nucleus pulposus cells and we recently showed that NFAT5 is a key 
mediator of osmolarity responses in HAC, too (14). Although being controversial, 
NFAT5 expression seems to be modulated in a Cn-dependent manner in some cells 
(27). FK506-induced Cn inhibition likely involves several MAP kinases (28) which 
may contribute to an AP1/NFAT-mediated promoter activation of certain prote-
ases. Promoter–reporter assays recently identified the promoter region of human 
ADAMTS4 as a potential downstream target of NFAT and Runx2 (29) and similar 
transcription factor binding sites were identified in the promoter regions of MMP13 
(30) and other MMPs. The cellular context is, however, important: FK506 induces 
chondrogenesis in murine ATDC5 cells and human synovial stromal cells, but Cn 
activity is necessary for chondrogenesis of mesenchymal cells (24, 31). We found 
that physiological osmolarity also slightly increased mRNA levels of unwanted 
hypertrophy markers like COL10, MMP13 and ALPL (Fig. 3). Animal models of OA 
revealed crucial roles of MMP3, MMP13 and ADAMTS5 in cartilage degradation. 
At 380 mOsm, FK506 had a suppressing effect on these hypertrophic markers and 
proteases while increasing their inhibitors, TIMP1 and TIMP2, respectively. Other 
Cn inhibitors have been shown to suppress MMP13 and ADAMTS5 expression in 
cytokine-stimulated cartilage explants, although possibly not through blocking 
NFAT signaling (32). Our data are in agreement with cyclosporine A (CsA) inhibiting 
MMP1 and MMP3 expression in chondrocytes, while increasing COL2, TIMP1 and 
TGFβ as shown in a murine OA collagenase model (33). The cellular specificity of 
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FK506 action may, however, depend on selective interactions with specific isoforms 
of calcineurin or the existence of cell-type specific substrates. A possible role 
of TGFβ in calcineurin-mediated chondrogenic effects (13) may be mediated by 
FK506-binding immunophilins (34). MMP13 suppression in our study may involve 
p38γ mediated hypertonicity-induced NFAT5 activation (35-37). Hydrostatic pres-
sure may also directly act on chondrocytes membrane transporters to activate 
AGC1 and COL2, although this was yet only shown for higher tonicities (38-39).
For a better prediction of the clinical applicability of our treatment, we evaluated its 
effect on cartilage explants. After seven days of explant culture, the sole osmolarity-
induced up-regulation of the chondrogenic markers was reduced to baseline levels 
(Fig. 5A), while addition of 50 ng/mL of FK506 to this medium ensured a prolonged 
transcriptional abundance of all tested chondrogenic markers. Like in monolayer 
cultures, FK506 was able to suppress COL10 and ALPL mRNA levels. The ionic 
environment of chondrocytes is unusually rich in cations, while anion concentration 
is low (40). It is tempting to speculate that differences in ion gradients between 
cells and explants in vitro may also contribute to differences in gene regulation at 
both osmolarities. GAG synthesis may involve MEK-ERK or integrin signaling (41), 
which might explain the slightly different responses between explants and isolated 
cells. Overall, both responded remarkably similar to our treatment. 
Finally, we evaluated the potential of our approach for improving cell-based strate-
gies for chondral lesion repair using ‘normal’, non-osteoarthritic (NHAC) rather 
than osteoarthritic cells. Generally, expression trends of chondrogenic and hyper-
trophic markers in OAHAC and NHAC monolayer cultures were similar in response 
to physiological osmolarity. However, the synergistic effects of 380 mOsm and 
FK506 on COL2 and SOX9 mRNA levels were less prominent in NHAC, while the 
effects on AGC1 expression were more prominent. OAHAC and NHAC revealed 
almost identical responses to the treatment with respect to ALPL expression, while 
MMP13 transcripts were virtually absent in NHAC. COL10 transcripts were less 
abundant in NHAC than in OAHAC and virtually absent in one donor, but showed 
the same trends in response to tonicity and FK506 in the remaining samples (Fig. 
6B). However, we were not able to perform statistics on the isolated data and 
therefore merged NHAC and OAHAC data for LMM expression analysis of this 
gene to determine whether the pathologic state of the cells is a significant factor 
affecting its mRNA levels in chondrocytes in response to the treatment. Osmolarity 
still significantly increased COL10 mRNA levels (p<0.01) in the merged data, with 
FK506 also still inhibiting the osmolarity-induced upregulation (p<0.05). After the 
relatively short three week culture period, COL2 staining in OAHAC pellets seems 
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to profit relatively more from our treatment than in NHAC pellets. During OA, 
chondrocytes are activated and undergo phenotypic modulation, including altered 
COL2 regulation (42-43), possibly sensitizing OAHAC to osmolarity-induced COL2 
synthesis. The combined data from NHAC monolayer and pellet cultures together 
indicate that FK506 supplementation under physiological osmolarity holds po-
tential to improve the quality of non-osteoarthritic chondrocytes, although to a 
lesser extent when compared to OAHAC. To this end, the small number of NHAC 
donors may compromise the predictability of the LMM model, which is a limitation 
of the present study. As other statistical tests, LMM becomes less appropriate with 
decreasing numbers of donors even with a large number of observations on each 
donor. 
During in vitro expansion, chondrocytes rapidly become more fibroblast like and 
this likely alters their response to osmolarity, which may explain absolute differences 
between cells and explants. A similar modulation of the chondroyte phenotype is 
commonly observed in OA chondrocytes (44), including altered gene expression 
regulation and subsequent changes in ECM protein synthesis and morphology (45). 
Chondrocytes regulate their volume upon hyperosmolarity by activating regulatory 
volume increase, which is altered during cell isolation involving collagenases treat-
ment (46). Cell shape is an integral part of the chondrocyte’s phenotype (47-48) and 
influenced, among others, by cytoskeletal structures (49). This may also account 
for some passage-dependent effects and differences between isolated cells and 
explants as observed in our study, but likely also contributes to different responses 
in NHAC as compared to OAHAC. 
Conclusion
Using physiological osmolarity improves chondrogenic marker expression in 
osteoarthritic chondrocytes and cartilage explants, but to a lesser extent in non-
osteoarthritic chondrocytes in-vitro. Adding Cn inhibitor FK506 to the culture 
medium improves anabolic, while suppressing catabolic and hypertrophic markers. 
Our current data aid in the development of novel cell-based therapies for chondral 
lesion repair and might alter future strategies to treat osteoarthritis.
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Abstract
Previous studies have shown that human articular chondrocytes in vitro are 
osmolarity-responsive and increase matrix synthesis under cartilage-specific 
physiological osmolarity. The effects of increased osmolarity on chondrogenesis 
of progenitor cells in vitro are largely unknown. We therefore aimed to elucidate 
whether hyperosmolarity facilitates their chondrogenic differentiation and whether 
Nfat5 is involved.
ATDC5 cells and human bone marrow stem cells (hBMSCs) were differentiated in 
the chondrogenic lineage in control and increased osmolarity conditions. Chon-
drogenic outcome was measured by gene and protein expression analysis. RNAi 
was used to determine the role of Nfat5 in chondrogenic differentiation under 
normal and increased osmolarity. 
Increasing the osmolarity of differentiation medium with 100 mOsm resulted in 
significantly increased chondrogenic marker expression (Col2a1, Col10a1, Acan, 
Sox9, Runx2 and GAGs) during chondrogenic differentiation of the two chon-
droprogenitors, ATDC5 and hBMSCs. Nfat5 knockdown under both control and 
increased osmolarity affected chondrogenic differentiation and suppressed the 
osmolarity-induced chondrogenic induction. Knockdown of Nfat5 in early differen-
tiation significantly decreased early Sox9 expression, whereas knockdown of Sox9 
in early differentiation did not affect early Nfat5 expression. 
Increasing the osmolarity of chondrogenic culture media by 100 mOsm significantly 
increased chondrogenic gene expression during the course of chondrogenic dif-
ferentiation of progenitor cells. Nfat5 may be involved in regulating chondrogenic 
differentiation of these cells under both normal and increased osmolarities and 
might regulate chondrogenic differentiation through influencing early Sox9 ex-
pression.
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Introduction 
Chondrogenic differentiation of progenitor cells plays an essential role during 
endochondral ossification for skeletal growth and bone fracture healing (1, 2). 
Moreover, progenitor cell-based cartilage regeneration is a rapidly evolving field 
and methodologies promoting chondrogenic differentiation of mesenchymal 
progenitor and stem cells to chondrocytes are of interest to improve cartilage and 
endochondral bone regenerative medicine approaches.
Chondrogenic differentiation during endochondral ossification is a multi-step 
developmental process during which mesenchymal progenitor cells condensate, 
differentiate into extracellular matrix (ECM) producing chondrocytes and ultimately 
terminally differentiate into hypertrophic chondrocytes (1, 3). This process is ac-
companied by a stage-dependent expression of chondrogenic makers: while for 
example Sox9 (SRY (sex determining region Y)-box 9) is a primary determinant of 
differentiation from early stages onwards (4, 5), its transcriptional targets collagen 
type 2 (Col2a1) and aggrecan (Acan) are prominently expressed by more mature, 
ECM producing chondrocytes. Collagen type 10 (Col10a1) and its main transcrip-
tion factor Runx2 (Runt-related transcription factor 2) are specifically expressed by 
hypertrophic differentiating chondrocytes (4, 5). 
The large amount of ECM produced by chondrocytes is mainly composed of 
proteoglycans (PG; like aggrecan) which are entangled in a network of collagens 
(mainly Col2a1) and further contains a lot of matrix-retained water (6). The glycos-
aminoglycan (GAG) side chains of the PGs are sulphated and responsible for a high 
fixed negative charge density, which attracts mobile cations and water from the 
ECM-environment (7, 8). This, together with the quality of the collagen network, 
determines the osmolarity of the extracellular fluid and provides strength and flex-
ibility to the tissue. The extracellular osmolarity of healthy articular cartilage ranges 
between 350 and 480 mOsm and is thus markedly higher than that of standard 
culture medium (9, 10), which ranges around plasma levels (280 mOsm) (11, 12). 
Several studies have shown that articular chondrocytes in vitro are osmolarity-
responsive and increase their ECM synthesis under chondrocyte-physiological 
osmolarity (10, 13-15). The nuclear factor of activated T-cells 5 (Nfat5/TonEBP) plays 
an important role in this response (14). Nfat5 is a member of the Rel family of 
transcription factors (16) and mediates transcriptional activation of ion transporters 
like the sodium/myo-inositol transporter encoded by Slc5a3 (17, 18) and calcium 
binding proteins like S100a4 (19, 20) upon hypertonic stress in several cell types, 
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including human articular chondrocytes (14). Collectively, the Nfat5-activated trans-
porters exchange intracellular ions for compatible osmolytes and thereby regulate 
intracellular ionic strength and cell volume upon hypertonic stress (21). However, 
a growing body of evidence indicates that Nfat5 can also be regulated indepen-
dently of osmolarity (22) and has diverse osmolarity-independent transcriptional 
functions in cell proliferation/survival (23) , carcinogenesis (24) and many others. 
To the best of our knowledge, no literature is available describing the effects of 
increased osmolarity on chondrogenic differentiation of progenitor cells in vitro. 
In addition, the expression and a potential (osmolarity-independent) function of 
Nfat5 during chondrogenic differentiation remains elusive. We therefore hypoth-
esized that Nfat5 is involved in in vitro chondrogenic differentiation of progenitor 
cells during endochondral ossification and that the differentiation process can be 
enhanced by increasing the osmolarity of the culture medium possibly via an Nfat5 
dependent mechanism. 
In the present study we used ATDC5 cells and human bone marrow stem cells 
(hBMSCs) as in vitro models for chondrogenic differentiation and provide evidence 
that Nfat5 expression is indeed regulated during chondrogenic differentiation 
independently of osmolarity status, but also responds to increased osmolarity dur-
ing chondrogenic differentiation. Furthermore, we show that increased osmolarity 
improves chondrogenic differentiation of progenitor cells in vitro and that, at least 
in part, this is regulated via Nfat5-mediated transcriptional regulation of Sox9.
Material and methods
ATDC5 cell culture
ATDC5 cells were cultured in proliferation medium under a humidified atmosphere 
at 37ºC, 5% CO2. Proliferation medium consisted of DMEM/F12 (Invitrogen, Carls-
bad, CA, USA), 5% FCS (PAA, Pasching, Austria), 1% antibiotic/antimycotic (mixture 
of 10,000 U/ml penicillin, 10,000 µg/ml streptomycin and 25 µg/ml amphotericin B; 
Invitrogen) and 1% NEAA (non-essential amino acids; Invitrogen) and was changed 
every two days. Differentiation medium comprised proliferation medium supple-
mented with 10 µg/ml insulin (Sigma, St. Louis, MO, USA), 10 µg/ml transferrin 
(Roche Applied Science, Indianapolis, IN, USA) and 30 nM sodium selenite (Sigma, 
St. Louis, MO, USA). Cells were plated at approximately 6400 cells/cm2 in cell cul-
ture dishes, allowed to adhere overnight and the following day chondrogenesis 
was initiated by changing the proliferation medium to differentiation medium. Dif-
ferentiation medium was changed every two days (day 0-10) and daily (from day 10 
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on). The osmolarity of the ATDC5 differentiation medium was determined to 310±5 
mOsm using an Osmomat 030 (Gonotec GmbH, Germany). The osmolarity of this 
medium was increased with 100 or 200 mOsm, respectively, by adding sterile NaCl 
from day 0 in differentiation. For RNAi-experiments an Nfat5 siRNA-duplex (sense: 
5’-CCAGUUCCUACAAUGAUAACACU-3’, antisense: 5’-AGUGUUAUCAUUGUAG-
GAACUGG-3’), a Sox9 siRNA duplex (sense: 5’- GACUCACAUCUCUCCUAAUTT-3’, 
anti-sense: 5’- AUUAGGAGAGAUGUGAGUCTT-3’) and a scrambled siRNA-duplex 
(indicated by “Mock”) were used (Eurogentec). ATDC5 cells were seeded at ap-
proximately 25,000 cells/cm2 and transfection with siRNAs (30 nM) was performed 
using ICAfectin 442 (Eurogentec) according to manufacturers’ protocol. Knock-
down was allowed for 1 day prior to the initiation of chondrogenic differentiation 
and knockdown for longer timeframes was accomplished by retransfection of the 
respective siRNA duplex. 
hBMSC isolation and culture
Human bone marrow mesenchymal stem cells were obtained from iliac crest bone 
marrow aspirate from young, genetically healthy individuals (Medical ethical com-
mittee MUMC approval 08-4-056). BMSCs were isolated using Ficoll-Paque PLUS 
(Amersham Pharmacia, Diegem, Belgium) and plated on culture plates. Unbound 
cells were removed after 48 hours, and bound fraction was expanded in culture 
medium to five passages under a humidified atmosphere at 37ºC, 5% CO2. Culture 
medium consisted of DMEM high glucose (Invitrogen), 10% FCS (PAA), 1% anti-
biotic/antimycotic and 1% NEAA. Chondrogenesis was performed in monolayer 
by plating the cells at approximately 30,000 cells/cm2 one day prior to initiating 
chondrogenesis with differentiation medium (proliferation medium supplemented 
with 1% ITS (Invitrogen), 50 mg/ml L-ascorbic acid-2-phosphate (Sigma) and 1 ng/ml 
TGFβ3 (R&D)) (25). The osmolarity of the differentiation medium was determined 
using an Osmomat 030 (Gonotec GmbH, Germany) and was measured to be 285±5 
mOsm. When indicated, osmolarity of the differentiation medium was increased 
with 100 mOsm by adding sterile NaCl from day 0 in differentiation. Throughout 
the hBMSC differentiation, medium was changed every two days.
RT-qPCR
For RNA isolation, cells were washed 3 times with 0.9% NaCl w/v and disrupted with 
500 µl Trizol (Invitrogen). RNA isolation, RNA quantification by UV-spectrometry 
(Nanodrop, Thermo Scientific), and cDNA synthesis were performed as described 
before (26, 27). Real time quantitative PCR (RT-qPCR) was performed using Me-
sagreen qPCR mastermix plus for SYBR® Green (Eurogentec, Seraing, Belgium). 
An Applied Biosystems ABI PRISM 7700 Sequence Detection System was used 
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for amplification using the following protocol: initial denaturation at 95ºC for 10 
minutes, followed by 40 cycles of DNA amplification (denaturing for 15 seconds at 
95ºC and annealing for 1 minute at 60ºC) followed by a dissociation curve. Data 
were analysed using the standard curve method, mRNA expression was normal-
ized to a reference gene (β-actin for ATDC5 and 28S rRNA for hBMSCs) and gene 
expression was calculated as fold change as compared to day 0 (t=0 in graphs). 
Primer sequences are depicted in Table 1. 
Immunoblotting
Cells were washed three times with 0.9% NaCl and lysed in RIPA buffer (150 mM 
NaCl, 1% NP-40, 0.5% Sodium deoxycholate, 0.1% SDS, 50 mM Tris pH 8.0, 5.0 mM 
EDTA pH 8.0, 0.5 mM dithiothreitol and 1 mM phenylmethylsulfonylfluoride). Ex-
tracts were sonicated on ice using the Soniprep 150 (MSE, London, UK) at amplitude 
10 for 14 cycles (1 second sonication and 1 second pause). Insoluble material was 
Table 1. Oligonucleotide sequences for RT-qPCR. The 5’ to 3’ forward and reverse oligonucleotide 
sequences used for RT-qPCR are listed in the Table.
Oligo sets 
mouse
Forward Reverse
Col2a1 ‘5-TGGGTGTTCTATTTATTTATTGTCTTCCT-3’ ‘5-GCGTTGGACTCACACCAGTTAGT-3’
Col10a1 ‘5-CATGCCTGATGGCTTCATAAA-3’ ‘5-AAGCAGACACGGGCATACCT-3’
Col1a1 ‘5-CTGACTGGAAGAGCGGAGAGTAC-3’ ‘5-CCATGTCGCAGAAGACCTTGA-3’
Sox9 ‘5-AGTACCCGCACCTGCACAAC-3’ ‘5-TACTTGTAGTCCGGGTGGTCTTTC-3’
Runx2 ‘5-GACGAGGCAAGAGTTTCACC-3’ ‘5-GGACCGTCCACTGTCACTTT-3’
Acan ‘5-CATGAGAGAGGCGAATGGAA-3’ ‘5-TGATCTCGTAGCGATCTTTCTTCT-3’
Nfat5 ‘5-GGGTCAAACGACGAGATTGTG-3’ ‘5-TTGTCCGTGGTAAGCTGAGAA-3’
Slc5a3 ‘5-CACTTCTGTCATTGGAGCGCT-3’ ‘5-ATGGCAATGTCTGCTGTGTCC-3’
S100a4 ‘5-GTCCACCTTCCACAAGTACTCG-3’ ‘5-TCATCTGTCCTTTTCCCCAAG-3’
Β-Actin ‘5-GACAGGATGCAGAAGGAGATTACTG-3’ ‘5-CCACCGATCCACACAGAGTACTT-3’ 
Oligo sets 
human
Forward Reverse
COL2A1 ‘5-TGGGTGTTCTATTTATTTATTGTCTTCCT-3’ ‘5-GCGTTGGACTCACACCAGTTAGT-3’
COL10A1 ‘5-ATGATGAATACACCAAAGGCTACCT-3’ ‘5-ACGCACACCTGGTCATTTTCTG-3’
COL1A1 ‘5-TGTGCCACTCTGACTGGAAGA-3’ ‘5-AGACTTTGATGGCATCCAGGTT-3’
SOX9 ‘5-AGTACCCGCACCTGCACAAC-3’ ‘5-CGCTTCTCGCTCTCGTTCAG-3’
RUNX2 ‘5-TGATGACACTGCCACCTCTGA-3’ ‘5-GCACCTGCCTGGCTCTTCT-3’
ACAN ‘5-GCAGCTGGGCGTTGTCA-3’ ‘5-TGAGTACAGGAGGCTTGAGGACT-3’
NFAT5 ‘5-GGGTCAAACGACGAGATTGTG-3’ ‘5-TTGTCCGTGGTAAGCTGAGAA-3’
28SRNA ‘5-GCCATGGTAATCCTGCTCAGTAC-3’ ‘5-GCTCCTCAGCCAAGCACATAC-3’ 
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removed by centrifugation (13.000 x g, 4ºC). Protein concentration was determined 
using the BCA protein assay (Sigma). Polypeptides were separated by SDS-PAGE 
(samples were equally loaded) and subsequently transferred to nitrocellulose 
membranes by electroblotting. Primary antibodies for immunodetection were 
polyclonal goat anti-Col2a1 (Southern Biotech, Birmingham, AL, USA), polyclonal 
goat anti-Col1a1 (Southern Biotech, Birmingham, AL, USA), polyclonal rabbit anti-
Col10a1 (Calbiochem, Darmstadt, Germany), polyclonal rabbit anti-Sox9 (Abcam), 
mouse monoclonal anti-α-Tubulin (Sigma, Saint Louis, MO, USA), polyclonal rabbit 
anti-Gapdh (Cell Signaling) and polyclonal rabbit anti-Nfat5 [43]. Bound primary 
antibodies were detected with rabbit anti-goat, swine anti-rabbit or rabbit anti-
mouse immunoglobulins conjugated with horseradish peroxidase (DakoCytoma-
tion, Glostrup, Denmark) and visualized by enhanced chemiluminescence (ECL). 
ECL signals were quantified using ImageJ 1.46f software, and relative differences, 
corrected for background and housekeeper, were determined as compared to 
control conditions.
Cell proliferation
Cell proliferation was assessed by crystal-violet (Sigma, Saint Louis, MO, USA) 
staining. Cells were washed two times with 0.9% NaCl and subsequently fixed 
with 4% paraformaldehyde in phosphate buffered saline for 10 minutes at room 
temperature. Fixed cells were washed 6 times with water and air dried for storage. 
Cells were incubated with 0.1% crystal-violet for 30 minutes at room temperature. 
Cells were washed six times with water to remove excess crystal-violet and allowed 
to air-dry in the dark overnight. crystal-violet was extracted from the cells by incu-
bation with 10% acetic acid for 15 minutes under continuous agitation. Extracted 
crystal-violet was determined spectrophotometrically at 590 nm using a plate 
reader (Biorad, Hemel Hempstead, UK). 
Alcian blue staining
GAG deposition was detected by Alcian blue staining. Cells were washed two times 
with 0.9% NaCl and subsequently fixed with 4% paraformaldehyde in phosphate 
buffered saline for 10 minutes at room temperature. Fixed cells were washed 6 
times with water and air dried for storage. Fixed cells were incubated overnight 
with 1% Alcian blue (Acros Organics, Geel, Belgium) in 0.1 M HCl at room tem-
perature. Cells were washed six times with water to remove excess Alcian blue and 
allowed to air-dry in the dark overnight. Alcian blue was extracted from the cells 
by incubation with Guanidine-HCl (6 M) for 2 hours under continuous agitation. 
Extracted Alcian blue was determined spectrophotometrically at 645 nm using a 
plate reader (Biorad, Hemel Hempstead, UK). 
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Statistics
Statistical significance was determined by two-way ANOVA (with Bonferroni post 
hoc test) for ATDC5 experiments and two-tailed student t-tests for hBMSC experi-
ments using Graphpad PRISM 5.0 (La Jolla, CA, USA). To test for normal distribution 
of the input data, D’Agostino-Pearson omnibus normality tests were performed. 
All quantitative data sets presented passed the normality tests.
Results 
Increased osmolarity improves chondrogenic marker expression in 
differentiating progenitor cells
To determine whether increased osmolarity improves chondrogenic marker expres-
sion in differentiating progenitor cells (14), the chondroprogenitor cell line ATDC5 
(28, 29) was differentiated under control conditions and increased osmolarity 
(+100 mOsm and +200 mOsm). Under control conditions ATDC5 cells acquired a 
chondrogenic phenotype from day 7 in differentiation as determined by increased 
expression of collagen type II (Col2a1), aggrecan (Acan) and Sox9 (Figure 1A). From 
day 14 in differentiation these cells also express increased levels of the hypertro-
phic markers collagen type X (Col10a1) and Runx2. Collagen type I (Col1a1) is only 
slightly induced during ATDC5 differentiation. Protein expression of the above 
collagens at day 14 in differentiation was confirmed by immunoblotting (Figure 
1B). Increased osmolarity (+100 mOsm) significantly increased mRNA expression 
of Sox9 (1.9 fold, p=0.0005), Col2a1 (2 fold, p=0.0001), Acan (1.4 fold, p=0.0018), 
Runx2 (1.5 fold, p=0.0061) and Col10a1 (2.5 fold, p=0.0001) during the course of 
differentiation when compared to the control condition (Figure 1A). Differentiation 
in + 100 mOsm conditions further clearly increased COL2A1 protein expression. 
Expression of Col10a1 did not increase as much at protein level as at mRNA level 
(Figure 1B). The decreased Col1a1 mRNA (p=0.0035 at t=14 days) and protein 
expression (Figure 1B) is in line with our previous findings (14). Chondrogenic 
differentiation was inhibited when osmolarity of the differentiation medium was 
further increased to +200 mOsm, as the expression of all markers was significantly 
lower when compared to the control condition (at day 14 Sox9: p=0.0004, Col2a1: 
p=0.0184, Acan: p=0.0002), Runx2: p=0.0014 and Col10a1: p=0.0004) (Figure 1A/B).
Besides mRNA and protein expression of important differentiation markers, 
glycosaminoglycan (GAG) content is another hallmark of chondrogenic differen-
tiation. At 14 days in differentiation, ATDC5 cells increased total GAG content 
by 3.2 fold (Figure 1C). Similar to mRNA and protein expression of chondrogenic 
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marker genes, +100 mOsm significantly increased GAG content by another 2.7 
fold (control versus +100 mOsm, p=0.0018), whereas +200 mOsm did not increase 
GAG content compared to t=0. As cell proliferation is another important element 
in chondrogenic differentiation of ATDC5 (28) and e.g. in cartilage fracture callus 
development, differences in cell numbers between the conditions were deter-
mined. Increasing the osmolarity with 100 mOsm did not influence the increasing 
cell numbers during differentiation (Figure 1D), while culturing under +200 mOsm 
conditions lead to significantly lower cell numbers (reduction by ± 50%, p=0.0001) 
Figure 1. Increased osmolarity improves chondrogenic differentiation of ATDC5 cells. ADTC5 cells 
were differentiated under control osmolarity conditions (control, white bars), +100 mOsm (black bars) 
and +200 mOsm (grey bars). A. Induction of Sox9, Col2a1, Aggrecan, Runx2, Col10a1 and Col1a1 
mRNA expression was determined by RT-qPCR at day 0, 7, 10 and 14 in differentiation. B. Protein 
expression of Col2a1, Col10a1 and Col1a1 in day 14 samples, α-tubulin was used as loading control. 
Molecular weight markers (kDa) are depicted on the left of immunoblots. Quantifications of ECL 
signals (corrected for the complementary α-tubulin signals and set relatively to control condition) are 
depicted on top of all immunoblots. C. Glycosaminoglycans (GAGs) were stained by Alcian Blue and 
fold change of t=14 samples was calculated as compared to t=0 samples. D. Differences in prolifera-
tion speed between conditions were determined by crystal-violet staining. Fold change (DNA) from 
samples from t=14 was calculated relatively to day 0. In graphs, error bars represent mean ±s.e.m.. * 
indicates p < 0.05, and is determined for control compared to +100 or +200 mOsm.
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compared to the control condition. Overall, increasing osmolarity with 100 mOsm 
resulted in an enhanced chondrogenic marker expression during differentiation 
of ATDC5 cells, while further increasing the osmolarity with another 100 mOsm 
inhibited overall ATDC5 differentiation. 
To further substantiate the pro-chondrogenic effect of increased osmolarity dur-
ing chondrogenic differentiation of progenitor cells, we differentiated human 
bone marrow derived mesenchymal stem cells (hBMSCs) from three individuals 
towards the chondrogenic lineage in control medium and +100 mOsm conditions. 
As described earlier (26), chondrogenic/hypertrophic marker expression in these 
cells is detected around day 21 in differentiation. Increased osmolarity (+100 
mOsm) resulted in increased COL2A1 (p=0.0005), ACAN (p=0.0012) and COL10A1 
(p=0.0001) mRNA and protein expression when compared to control conditions 
(Figure 2A/B). Gene expression of their respective transcription factors SOX9 and 
RUNX2 was also increased in +100 mOsm conditions: SOX9 1.5 fold (p=0.0449) 
and RUNX2 2.1 fold higher (p=0.0010) (Figure 2A). COL1A1 mRNA expression at 
day 21 in differentiation was only marginally induced in the control condition, but 
was found to be suppressed under increased osmolarity (p=0.0021) (Figure 2A). 
Decreased COL1A1 protein expression was also observed under increased osmo-
larity conditions (Figure 2B). Therefore, hBMSC responded similarly to increased 
osmolarity as ATDC5 cells. 
Taken together, we found that the magnitude of chondrogenic differentiation of 
chondroprogenitor cells is sensitive for the osmolarity of the culture environment, 
providing the overall indication that chondrogenic marker expression by these 
cells benefits from osmolarity values in the range of that of articular cartilage. 
Nfat5 is involved in chondrogenic gene expression under normal 
and increased osmolarity 
Nfat5/TonEBP is a key regulator of the cellular response to hypertonic conditions 
and its expression increases during human articular chondrocyte expansion culture 
in 380 mOsm conditions (14). We determined the expression of Nfat5 during chon-
drogenic differentiation of ATDC5 cells under control and +100 mOsm conditions. 
Nfat5 mRNA expression was found to be upregulated during normal differentiation 
under control conditions (3.4 fold at day 7 and 5 fold at day 10 and day 14, respec-
tively) (Figure 3A). When differentiated in +100 mOsm conditions, the expression 
of Nfat5 was significantly higher as compared to the control condition (p=0.0445 
for t=7, p=0.0474 for t=10 and p=0.0195 for t=14 days) (Figure 3A), indicating 
the osmolarity-responsiveness of Nfat5 also during chondrogenic differentiation. 
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Figure 2. Increased osmolarity improves chondrogenic differentiation of hBMSCs. hBMSCs from 3 
individual donors were differentiated in the chondrogenic lineage under increased osmolarity. A. 
Induction of SOX9, RUNX2, COL2A1, COL10A1, ACAN and COL1A1 mRNA expression was deter-
mined by RT-qPCR at day 0 and 21 in differentiation (control, white bars and +100 mOsm black bars) 
B. Protein expression of COL2A1, COL10A1 and COL1A1 in day 21 samples. α-Tubulin was used as 
loading control. Molecular weight markers (kDa) are depicted on the left of the immunoblots. Quan-
tifications of ECL signals (corrected for the complementary α-tubulin signals and set relatively to con-
trol condition) are depicted on top of all immunoblots. In graphs, bars represent the average value 
of 3 individually averaged values of 3 individual samples per hBMSC isolate and error bars represent 
mean ±s.e.m.. * indicates p < 0.05, and is determined for control versus +100 mOsm.
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Similarly, NFAT5 mRNA expression in hBMSCs was significantly increased after 21 
days of chondrogenic differentiation and also further enhanced under +100 mOsm 
conditions at day 21 in differentiation (p=0.0100) as compared to control condi-
tions (Figure 3B). Confirming Nfat5 activation upon hyperosmolarity in ATDC5, the 
expression of the established Nfat5 target genes Slc5a3 and S100a4 specifically 
increased in +100 mOsm cultures as compared to control cultures (p=0.0360 for 
Slc5a3 at t=14 days and p=0.0175 for S100a4 at day 14) (Figure 3C) (14).
To functionally study the involvement of Nfat5 in chondrogenic differentiation 
under control and +100 mOsm conditions, Nfat5 expression was targeted using 
RNAi. Transfection of a target-specific siRNA duplex (30 nM) resulted in a 50% 
knockdown of Nfat5 mRNA expression in both osmolarity conditions at day 0 
Figure 3. Nfat5 expression during chondrogenic differentiation. A. In similar ATDC5 samples from 
Figure 1A, Nfat5 mRNA expression was determined under control (white bars) and +100 mOsm 
(black bars) conditions. B. In similar hBMSC samples from Figure 2A, NFAT5 mRNA expression was 
determined under control (white bars) and +100 mOsm (black bars) conditions. In graphs, bars rep-
resent the average value of 3 individually averaged values of 3 individual samples per hBMSC isolate 
and error bars represent mean ±s.e.m.. C. In samples from (A) expression of established Nfat5 target 
genes (Slc5a3 and S100a4) was determined. In graphs, error bars represent mean ±s.e.m.* indicates 
p < 0.05, and is determined for control versus +100 mOsm.
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(p=0.0287), 7 (p=0.0415 for control and p=0.0252 for +100 mOsm) and 10 (p=0.0275 
for control and p=0.0225 for +100 mOsm) in differentiation (Figure 4A; black versus 
white bars and dark grey versus light grey bars). Functional Nfat5 knockdown under 
+100 mOsm conditions was confirmed by immunoblotting (Figure 4B), as well as 
prevented the upregulation of Nfat5 target genes Slc5a3 (p=0.0334 at day 14) 
and S100a4 (p=0.0091 at day 14) under increased osmolarity (Figure 4C; dark grey 
versus light grey bars). Knockdown of Nfat5 under control conditions resulted in a 
significantly suppressed upregulation of chondrogenic markers genes Sox9 (63%, 
p=0.0047), Col2a1 (59%, p=0.0038), Acan (51%, p=0.0033), Runx2 (36%, p=0.0132) 
and Col10a1 (53%, p=0.0350) as compared to Mock conditions (scrambled siRNA) 
during chondrogenic differentiation (Figure 4D; black versus white bars and Figure 
4E). As increased osmolarity not only induced Nfat5 expression (Figure 3A/B), but 
also correlated with increased chondrogenic marker expression (Figure 1), we 
further tested the possibility whether this osmolarity-induced chondrogenic induc-
tion may be mediated by Nfat5. Knocking down the expression of Nfat5 under 
+100 mOsm conditions indeed suppressed the osmolarity effect on chondrogenic 
gene expression back to normal osmolarity conditions for most of the measured 
chondrogenic genes (at day 10 Sox9: p=0.0134, Col2a1: p=0.0056, Acan: p=0.0065, 
Runx2: p=0.0324 and Col10a1: p=0.0328) (Figure 4D; dark grey versus light grey 
bars and Figure 4F). The osmolarity-induced suppression of Col1a1 mRNA and 
protein expression was also abrogated by Nfat5 knockdown, where it was ex-
pressed even higher than in normal osmolarity conditions (Figure 4D; dark grey 
versus white bars and Figure 4E/F). Together, these findings indicate that Nfat5 
is involved in chondrogenic differentiation of ATDC5 cells and that the increased 
expression of chondrogenic markers during chondrogenic differentiation under 
+100 mOsm conditions is, at least in part, dependent on Nfat5. 
Nfat5 is involved in Sox9 function during chondrogenic 
differentiation
To further explore the possibility whether osmolarity induces the increased chon-
drogenic marker expression via the key chondrogenic transcription factor Sox9 and 
to explore potential cross-talk between Nfat5 and Sox9, we determined whether 
osmolarity-driven chondrogenic marker expression can be abolished by interfering 
with Sox9 expression. Expression of Sox9 was targeted by siRNA transfection (30 
nM) in ATDC5 and resulted in a knockdown efficiency of 58% at mRNA level at 
day 0, 7 and 10 in differentiation under both control and +100 mOsm conditions 
(p=0.0398 at t=0, p=0.0025 at t=10 control and p=0.0123 at +100 mOsm) (Figure 
5A/C; black versus white bars and dark grey versus light grey bars). Upon Sox9 
knockdown under control conditions, expression of the important Sox9 targets, 
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Figure 5. Osmolarity-enhanced chondrogenic differentiation is Sox9 dependent. Sox9 siRNA du-
plexes were retransfected under control and +100 mOsm conditions to investigate whether the os-
molarity effect on chondrogenic differentiation is depending on Sox9. A. Knockdown of Sox9 was 
confirmed at mRNA level at day 0, 7 and 10 in differentiation. White bars represent normal osmolarity 
conditions (control) transfected with a scrambled siRNA (“Mock”) and black bars normal osmolarity 
conditions transfected with the Sox9 siRNA. Light grey bars represent increased osmolarity condi-
tions (+100 mOsm) transfected with a scrambled siRNA (“Mock”) and black bars increased osmolar-
ity conditions transfected with the Sox9 siRNA. B. The effect of the Sox9 knockdown under control 
and +100 mOsm conditions on chondrogenic differentiation was established by measuring Col2a1 
and aggrecan mRNA expression. C. Protein expression of Sox9 and Col2a1 from day 10 samples 
in Mock and Sox9 knockdown cells under control and +100 mOsm. In graphs, error bars represent 
mean ±s.e.m.. * indicates p < 0.05, and is determined for Mock versus Sox9 siRNA under control 
osmolarity conditions and under +100 mOsm conditions, respectively.
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Col2a1 and aggrecan, was significantly decreased (p=0.0046 for Col2a1 and 
p=0.0076 for Acan at t=10 days) (Figure 5B; black versus white bars and Figure 5C; 
left panel), showing that expression of these genes under control culture condi-
tions is regulated through Sox9. The osmolarity-induced chondrogenic marker ex-
pression under +100 mOsm was also significantly affected by the Sox9 knockdown 
(p=0.0023 for Co2a1 and p=0.0092 for Acan at t=10 days) (Figure 5B; dark grey 
versus light grey bars and Figure 5C; right panel), showing that the osmolarity-
induced chondrogenic marker expression functionally depends on Sox9. We next 
aimed at elucidating potential cross-talk and pathway hierarchy between Nfat5 and 
Sox9, which might explain how Nfat5 influences chondrogenic differentiation. We 
analyzed Sox9 expression early in ATDC5 differentiation (26) at 24 hours after Nfat5 
knockdown and Nfat5 expression upon Sox9 knockdown at the same moment in 
ATDC5 differentiation as well. Functional interference with Nfat5 expression was 
confirmed by decreased expression of the Nfat5 targets Slc5a3 and S100a4 (Figure 
6A; 68% (p=0.0202) and 44% (p=0.0293), respectively). In addition, knockdown of 
Nfat5 efficiently decreased Sox9 mRNA (p=0.0404) and protein expression (Figure 
6A/C). In contrast, knockdown of Sox9 solely decreased Sox9 mRNA (p=0.0339) 
and protein expression, without further affecting Nfat5 mRNA levels or those of 
its target genes (Figure 6B/C). These data suggest that Nfat5 may determine the 
outcome of ATDC5 chondrogenic differentiation by transcriptionally influencing 
early expression of Sox9. 
In conclusion, increasing culture medium osmolarity from control levels (i.e. 285-310 
mOsm) with 100 mOsm significantly increased chondrogenic marker expression 
during the course of chondrogenic differentiation of progenitor cells (ATDC5 and 
hBMSCs). We further found evidence that Nfat5 may play a regulatory role during 
Figure 6. Nfat5 influences Sox9 expression. Signalling hierarchy between Nfat5 and Sox9 was deter-
mined early (24 hours) in ATDC5 differentiation by siRNA transfections. A. Expression of Nfat5, Sox9, 
Slc5a3 and S100a4 mRNAs in differentiating ATDC5 transfected with Mock or Nfat5 siRNAs in control 
osmolarity conditions. B. Same as (A) but with Mock or Sox9 siRNAs. Data is presented as percent-
age to control condition. C. Sox9 protein expression at 24 hours in ATDC5 differentiation after Mock, 
Nfat5 or Sox9 siRNA transfection. In graphs, error bars represent mean ±s.e.m.. * indicates p < 0.05, 
and is determined for Mock versus Nfat5 or Sox9 siRNA.
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(osmolarity-induced) chondrogenic differentiation of these cells, at least in part, 
through influencing Sox9 expression.  
Discussion
Several studies have shown that human articular chondrocytes in vitro are 
osmolarity-responsive and increase matrix synthesis under cartilage-physiological 
osmolarity with Nfat5 being involved in this response. The potentially beneficial 
effects of increased osmolarity on chondrogenic differentiation of progenitor cells 
are largely unknown. In addition, the expression and function of Nfat5 during this 
process have never been described. We here report that chondrogenic marker 
expression and chondrogenic extracellular matrix synthesis during differentia-
tion of the chondroprogenitor cell line ATDC5 and in human bone marrow stem 
cells (both sequentially expressing a chondrocyte and hypertrophic chondrocyte 
phenotype, respectively) positively respond to increased osmolarity. Expression 
of Nfat5 is upregulated during chondrogenic differentiation and its expression 
is further upregulated under increased osmolarity. Nfat5 is involved in regulating 
chondrogenic marker expression under normal and increased osmolarity and may 
regulate the osmolarity-induced beneficial effects on Col2a1 and Acan through 
key-chondrogenic transcription factor Sox9. 
In human articular cartilage the extracellular osmolarity ranges between 350-480 
mOsm (9, 10), due to the high fixed negative charge density of the sulfated GAG 
side chains in the proteoglycan network. It may therefore not be surprising that 
chondrocyte phenotypic preservation during isolation and culturing of articular 
chondrocytes in vitro benefits from increased osmolarity in the culture medium 
(14). However, the osmolarity levels in the direct environment of chondroprogenitor 
cells in vivo are poorly investigated. Amongst others, mesenchymal stem cells are 
found in the bone marrow, adipose tissue, muscle, blood and periosteum (30) and 
most of these tissues have a normal plasma level osmolarity of around 280 mOsm. 
It is therefore likely that progenitor cells residing in these tissues experience an 
environment that is close to plasma osmolarity in vivo. Yet, progenitor cells express 
similar chondrogenic markers (e.g. Sox9, Col2a1, Acan etc.) during chondrogenic 
differentiation as found in mature articular chondrocytes and may create a local 
self-sustaining hypertonic microenvironment by excretion of ECM components 
during their differentiation process. It seems therefore likely that the response of 
mesenchymal progenitor cells to increased osmolarity may be regulated through 
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similar molecular mechanisms that are also responsible for increased chondrogenic 
marker expression in mature chondrocytes.
We used established culture protocols for ATDC5 and hBMSC differentiation 
and thus their corresponding differentiation media had slightly different baseline 
osmolarities (310 and 285 mOsm, respectively), within the range of plasma level 
osmolarity [11, 12]. The relative cell type-specific quantity of the osmotic challenge 
was, however, identical for both cell types. Noteworthy, for ATDC5 we found that, 
as opposed to +100 mOsm, an osmotic challenge of +200 mOsm had deleterious 
consequences for the chondrogenic differentiation process. This suggests the ex-
istence of an optimal osmolarity-window for the outcome of ATDC5 differentiation. 
The +100 mOsm condition (i.e. ~410 mOsm) is within the range of physiological 
articular cartilage osmolarity [9, 10]. Higher osmotic pressures, as in the +200 
mOsm condition, are rather high end physiological and may exceed membrane 
transport capacities.
The molecular mechanism by which osmolarity is sensed by mammalian cells is only 
partially understood. Nfat5 is accepted as key transcription factor participating in 
the response to the deleterious effects of increased osmolarity (21, 31). The hyper-
tonic stress-induced increase in intracellular ionic strength is potentially genotoxic, 
inducing double-strand DNA breaks, growth arrest and apoptosis (32, 33). Nfat5 is 
activated by hypertonic stress to compensate for these deleterious effects through 
activation of compensatory mechanisms like e.g. activating osmolyte transporter 
gene transcription (e.g. Slc5a3 and S100a4) in order to reduce the intracellular ionic 
strengths (21, 34). However, little is known about the osmolarity threshold required 
to activate Nfat5 in specific cell types and several observations suggest that Nfat5 
is active already at plasma level osmolarity in tissues that normally are not exposed 
to a hypertonic environment (16). In addition, in our experiments knockdown of 
Nfat5 under plasma level osmolarity resulted in downregulation of Nfat5 target 
gene expression (Figure 4C), indicating that Nfat5 is functionally active under these 
conditions in the tested progenitor cells. Also, it is becoming increasingly evident 
that Nfat5 is involved in cellular processes unrelated to hypertonic stress, such 
as cell proliferation, differentiation or integrin-mediated cell migration (31, 35, 
36). Our present study shows that Nfat5 expression follows the course of normal 
chondrogenic differentiation and may play a regulating role during chondrogenic 
differentiation of progenitor cells. While osmolarity may enhance chondrogenic 
differentiation through Nfat5, its knockdown during chondrogenic differentiation 
under both plasma (control) osmolarity and increased osmolarity (+100 mOsm) 
resulted in suppressed expression of chondrogenic markers Col2a1, Acan, Sox9, 
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Col10a1 and Runx2 (Figure 4D-F), suggesting a regulatory function of Nfat5 during 
chondrogenic differentiation under both control culture conditions and increased 
osmolarity conditions. 
The mode of action by which Nfat5 may regulate chondrogenic differentiation of 
progenitor cells remains to be elucidated. Our data suggest that Nfat5 might act in 
this context through influencing the expression of key chondrogenic transcription 
factor Sox9. Regulation of Sox9 expression by osmolarity has been shown before. 
Stimulation of human chondrocytes with supraphysiological osmolarity not only 
induced SOX9 mRNA levels, but also increased SOX9 mRNA half-life (37). Post-
transcriptional stabilization of SOX9 mRNA is activated by p38 MAPK signalling 
(38), which is also known to be involved in the hypertonic activation and nuclear 
translocation of NFAT5 (39-41). Alternatively, we previously found that Sox9 expres-
sion during chondrogenic differentiation of progenitor cells in vitro is bi-phasic, 
with a first induction during the first hours of differentiation and a second peak 
expression later on in differentiation. Next to the well documented crucial role 
of Sox9 during ECM synthesis (late expression peak), we showed that the early 
and transient induction of Sox9 crucially determines the chondrogenic outcome 
of mesenchymal progenitor cell differentiation (26). Knockdown of Nfat5 resulted 
in decreased Sox9 expression (Figure 4D) on the long term, which could explain 
the decreased Col2a1 and Acan expression seen in these cultures. In addition, and 
relevant to the early Sox9 induction, Nfat5 knockdown during early chondrogenic 
differentiation (24 hours) affected early Sox9 expression, as well as known Nfat5 
target genes. Reciprocally, knockdown of early Sox9 expression did not influence 
the expression of Nfat5 or its target genes (Figure 6B/C), suggesting that Nfat5 
may act upstream of Sox9, through yet unknown (transcriptional) mechanisms. 
Conclusions
We have here shown that the magnitude of chondrogenic gene expression of dif-
ferentiating chondroprogenitor cells in vitro can be enhanced by increasing the 
osmolarity levels of the culture medium. The osmolarity responsive gene Nfat5 
seems to be part of the mechanism that underlies this effect and might influence 
chondrogenic differentiation via controlling the expression of key chondrogenic 
transcription factor Sox9. Future studies will focus on further elucidating the rela-
tion between Nfat5 and chondrogenic regulators. Increasing the osmolarity may be 
used as a relatively simple tool to modulate the formation of cartilaginous tissues 
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for progenitor cell-based cartilage and endochondral bone regenerative medicine 
approaches (42). 
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Abstract
Chondrogenic marker expression can be induced with osmotic stress in the range 
of 100 mOsm above plasma level. However, osmotic stress also induces hyper-
tophic differentiation of chondrocytes, an unwanted event in cartilage regenerative 
medicine. This study investigated the potential effects of FK506 (tacrolimus) on 
osmolarity-induced chondrogenic and terminal differentiation of chondroprogeni-
tor cells. 
ATDC5 cells, a murine chondroprogenitor cell line, were chondrogenically differ-
entiated under control plasma osmolarity of 312 mOsm and under a more cartilage 
specific physiological osmolarity (+100 mOsm). In addition, cells were costimulated 
with 0, 62 or 620 nM FK506 from day 7 in differentiation. Chondrogenic, hypertro-
phic and terminal differentiation was measured by gene expression analysis at day 
14. 
Cartilage physiological osmolarity (± 412 mOsm) increased chondrogenic (Sox9, 
Col2, Col9, Col11) and hypertrophic (Runx2, Tgm2, Col10, Vegf, Bmp2) marker 
expression of pre-chondrocytes, without affecting mineralization markers (Alpl, 
Spp1). FK506 further increased chondrogenic markers (Col9, Col11) but could not 
prevent hypertrophic and terminal differentiation at physiological osmolarity in this 
cell line. 
We showed that FK506 at physiological osmolarity promotes chondrogenic dif-
ferentiation of progenitor cells cultured at cartilage specific osmolarity, without 
altering or inhibiting differentiation to hypertrophic and calcified cells, as was 
found in earlier studies with osteoarthritic chondrocytes. These findings indicate 
that there might be a cell type dependent effect op FK506 or a timing effect during 
chondrogenic differentiation of ATDC5 cells. 
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Introduction
New methodologies promoting chondrogenic differentiation of mesenchymal 
progenitor cells are of interest to improve (cell based) repair of cartilage lesions 
in joint diseases such as osteoarthritis (OA). A clonal mouse embryonic cell line, 
ATDC5, has been identified to synchronously display the multistep differentiation 
process of mesenchymal progenitor cells during endochondral bone formation. 
The chondrogenic differentiation process starts with a mesenchymal condensation 
stage of progenitor cells, followed by differentiation into proliferating chondro-
cytes producing extracellular matrix (ECM), nodule formation and hypertrophic 
differentiation, and finally ends with matrix mineralization and apoptosis of the 
cells. These steps are resembled in vitro by ATDC5 cells as an established model 
to investigate regulation of chondrogenic differentiation (1, 2). 
FK506 (Tacrolimus, Prograf®) is an immunosuppressive drug discovered by Kino 
et al. (3, 4) in the 1980s, which is clinically used for a wide range of immunological 
disorders. The immunosuppressive agents FK506 and Cyclosporin A (CsA) revolu-
tionized transplant therapy because of their ability to suppress of T-cell activation 
without markedly affecting bone marrow cell differentiation and proliferation (5). 
FK506 and CsA bind to two different intracellular proteins, FKBP and Cyclophilin, 
but both thereby inhibiting the activity of the ubiquitously expressed calcium/
calmodulin dependent Calcineurin (Cn). As a consequence, the calcineurin-medi-
ated dephosphorylation of a specific group of transcription factors (NFATs, nuclear 
factor of activated T-cells) is inhibited (6, 7). 
Over the last 20 years, Calcineurin and NFATs are found to play a role in many other 
physiological processes in other cell types and the clinical application for FK506 
is still increasing. Two studies reported stimulating effects of FK506 on chondro-
genic differentiation of ATDC5 cells. Nishigaki et al. (8) showed that FK506, but not 
CsA, stimulates production of proteoglycan and type II collagen by ATDC5 cells. 
Nakamura et al. (9) suggested that FK506 predominantly promotes differentiation 
of ATDC5 cells into proliferating chondrocytes, without terminal differentiation to 
hypertrophic chondrocytes leading to calcified tissue.
Recently, we used osmotic stress to induce chondrogenic marker expression in 
human OA chondrocytes, ATDC5 cells and human bone marrow stem cells and 
elucidated a role for NFAT5 (a Calcineurin independent NFAT also known as 
TonEBP) in this osmotic stress response (10, 11). However, in both OA chondrocytes 
and progenitor cells, osmotic stress also increased expression of hypertrophy and 
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terminal differentiation markers (11, 12). The latter being a favourable event in 
improving endochondral regenerative medicine approaches, but unfavourable in 
improving cartilage regenerative medicine treatments. 
In human OA chondrocytes, FK506 was able to further enhance the osmotic stress 
induced anabolic marker expression (collagen type 2 (Col2) and aggrecan), while 
supressing unwanted catabolic and hypertrophic markers (collagen type 10 and 
matrix metalloproteases) (12). In the present study, we further explored these 
effects and investigated the potential effects of FK506 on osmolarity induced 
chondrogenic and terminal differentiation of the chondroprogenitor cells ATDC5. 
Materials and Methods
ATDC5 cell culture
ATDC5 cells were cultured in a monolayer using proliferation medium (DMEM/
F12 (Invitrogen, Carlsbad, CA, USA), 5% FCS, 0.1% (v/v) gentamycin, 0.6% (v/v) 
fungizione and 1% NEAA (nonessential amino acids; all Invitrogen)). Cells were 
plated at 6400 cells/cm2 in cell culture dishes, allowed to adhere overnight and the 
following day chondrogenesis was initiated by changing the proliferation medium 
to differentiation medium. Differentiation medium comprised proliferation medium 
supplemented with 1% ITS (B&D Bioscience). Differentiation medium was changed 
every two days (day 0 to 10) and daily (from day 10 on). It was shown before that at 
standard osmolarity conditions, ATDC5 cells acquire a chondrogenic phenotype 
from day 7 in differentiation with increased expressions of sex determining region 
Y box 9 (Sox9) and Col2 (11). The osmolarity of the standard ATDC5 differentiation 
medium was determined using an Osmomat 030 (Gonotec GmbH, Germany) and 
was 312±2 mOsm. To reach a cartilage specific physiological level, the osmolarity 
of this medium was increased with 100 mOsm by adding sterile NaCl (10) from day 
7 in differentiation. In addition, cells were co stimulated with 0, 62 or 620 nM FK506 
from day 7. Experiments were performed in replicates (n=7). Cells were harvested 
at day 0 and 14 in differentiation for analysis of mRNA and protein expressions.
To analyze direct effects of increased osmolarity on Nfat5 protein expression, cells 
were cultured on 8 well culture slides (BD Falcon) and stimulated with +100 or +200 
mOsm medium for 30 minutes. 
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RNA expression analysis 
RNA purification, quantification, cDNA synthesis and RT-qPCR are described 
elsewhere (13, 14). Data were normalized to an index of three reference genes 
(Gapdh, Hprt1, β-actin), which were pre-evaluated to be stably expressed across 
samples, and relative expression was then calculated according to 2-ΔCT method 
(15). Replicate values (n=7) were normalized to day 0. Collagen type 1, 2, 9 and 
11 and Sox 9 were studied as markers for chondrogenic differentiation (16). Col10 
and its main transcription factor runt-related transcription factor 2 (RunX2) as 
well as vascular endothelial growth factor (Vegf), transglutaminase 2 (Tgm2), and 
Mmp13 were used to evaluate induction of hypertrophic and terminal differentia-
tion of the cells (16, 17). Bone morphogenetic protein 2 (Bmp2) was evaluated as 
general inductor of chondrogenic and subsequent hypertrophic differentiation 
and endochondral ossification (18). The calcium binding protein A4 (S100a4) was 
evaluated as a negative regulator of mineralization (19) and Nfat5 target gene (10). 
In addition, expression levels of mineralization markers alkaline phosphatase (Alpl) 
and osteopontin (Spp1) (20) were studied. Primer sequences for Col2, Col1, Sox9, 
RunX2, Col10, Nfat5, s100A4 and β-actin (11), Col9 and Col11 (21), Mmp13 (14) and 
Vegf (22) are adopted from previous studies. Primer sequences for the other tested 
genes are listed in table 1. 
Calcineurin activity assay
FK506 is known to exert its immunosuppressive effects by inhibiting the calcineurin 
activity. Cells from monolayer cultures were washed twice with physiologic saline 
and lysed with Mammalian Protein Extraction Reagent buffer (Pierce, Bonn, Ger-
many) according to the supplier’s instructions. Samples were stored at minus 80°C 
until further use. Extracts were purified on a Micro Bio-Spin P-6 chromatography 
column (Bio-Rad Laboratories B.V., Veenendaal, NL) and protein concentrations 
were quantified using the BCA Protein Assay Kit (Pierce) in a microplate reader 
(VersaMax, Molecular Devices Ltd, NL). Calcineurin activity was measured using 
Table 1. Oligonucleotide sequences for RT-qPCR.
Oligo sets Forward Reverse
Hprt1 5’-TCAGTCAACGGGGGACATAAA-3’ 5’-GGGGCTGTACTGCTTAACCAG-3
Gapdh 5’-AGGTCGGTGTGAACGGATTTG-3’ 5’-TGTAGACCATGTAGTTGAGGTCA-3’
Tgm2 5’-GACAATGTGGAGGAGGGATCT-3’ 5’-CTCTAGGCTGAGACGGTACAG-3’
Bmp2 5’-GGGACCCGCTGTCTTCTAGT-3’ 5’- TCAACTCAAATTCGCTGAGGAC-3’
Alpl 5’-CCAACTCTTTTGTGCCAGAGA-3’ 5’-GGCTACATTGGTGTTGAGCTTTT-3’
Spp1 5’-GCAGCAGGAGGAGGCAGAGC-3’ 5’-AGTGAGTTTTCCTTGGTCGGCGT-3’
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the Calcineurin Cellular Assay Kit Plus (BioMol, Tebu-Bio, Heerhugowaard, NL) as 
described before (10).
Immunofluorescence
Next, we evaluated osmolarity-induced expression of Nfat5 protein in our experi-
ments. Immunofluorescence was essentially performed as described earlier (23), 
with the conditions and the anti-Nfat5 antibody reported elsewhere (24) and the 
normalization procedure using a histone H3-specific antibody reported earlier by 
us (25). 
Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics 20 software. The rep-
licate raw expression data was tested for the effect of osmolarity, FK506 dosis and 
the interaction between both treatments using a general linear model analysis. The 
effect of FK506 significantly differed between the two osmolarity groups for some 
of the tested genes. Therefore, the effect of FK506 was tested separately for the 
280 and 380 conditions, using univariate general linear model analysis followed by 
posthoc Bonferroni test. Differences were considered statistical significant when 
p< 0.05 and p<0.01. 
Results
Cartilage-specific physiological levels of osmolarity improve 
chondrogenic differentiation of pre-chondrocytes
When the medium osmolarity was increased with 100 mOsm (to reach cartilage 
specific osmolarity of 412 mOsm) from day 7 during differentiation, expression 
of the chondrogenic markers Sox9 and Collagen type 2 (Col2) was significantly 
increased at day 14 compared to control conditions (plasma level osmolarity of 
312 mOsm): Sox9 ± 2.0-fold and Col2 ± 1.2-fold (figure 1A,B). The +100 mOsm 
condition also increased the Col2:Col1 ratio by ± 1.5-fold (figure 1C). In addition, 
we analyzed the regulation of two other cartilage-specific collagens, collagen type 
9 (Col9) and type 11 (Col11). After 14 days of differentiation at control osmolarity, 
the expression of Col9 mRNA markedly increased by ± 290-fold and expression of 
Col11 by ± 55-fold (figure 1D,E). Their expression was further increased when the 
cells were stimulated with +100 mOsm: Col9 by 2.3-fold and Col11 by 1.8-fold. 
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Cartilage physiological osmolarity improves hypertrophic 
differentiation of ATDC5 cells
Besides its effects on chondrogenic marker expression, increasing the medium os-
molarity with 100 mOsm to cartilage physiological levels also significantly affected 
subsequent expression of hypertrophic and terminal differentiation markers. We 
studied the effects of our treatment on expression of runt-related transcription 
factor 2 (Runx2) and transglutaminase 2 (Tgm2), both regulators of terminal dif-
ferentiation. Both Runx2 and Tgm2 increased during the course of differentiation 
at control osmolarity and increased even further when the osmolarity was raised by 
100 mOsm (figure 2A,B). The hypertrophic marker Col10 increased by ± 4.6-fold 
upon osmotic stimulation, while Mmp13 decreased ± 2.0-fold (figure 2C,D). The 
terminal differentiation marker Vegf and Bmp2 both significantly increased by +100 
mOsm (figure 2E,F). 
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Figure 1. Increased osmolarity improves chondrogenic differentiation of ATDC5 cells and addition 
of FK506 further increased Col9 and Col10 expression. ATDC5 cells were differentiated under control 
osmolarity conditions for 14 days (grey bars) or at +100 mOsm from day 7 till day 14 (black bars). 
In addition, cells were co stimulated with 0, 62 or 620 nM FK506 from day 7. All experiments were 
performed in replicates (n=7). Induction of Sox9, Col2, Col2:Col1, Col9 and Col11 mRNA was deter-
mined by RT-qPCR at day 0 and day 14. Data are means ± standard deviation. Significant differences 
are indicated: ** p<0.01 between control and +100 mOsm conditions; # p<0.05 FK506 effect com-
pared to the iso-osmotic condition without FK506.
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Figure 2. Effects of cartilage physiological osmolarity and FK506 on hypertrophic differentiation 
markers. ATDC5 cells were differentiated under control osmolarity conditions for 14 days (grey bars) 
or at +100 mOsm from day 7 till day 14 (black bars). In addition, cells were co stimulated with 0, 62 
or 620 nM FK506 from day 7. All experiments were performed in replicates (n=7). Induction of mRNA 
was determined by RT-qPCR at day 0 and day 14. Data are means ± standard deviation. Significant 
differences are indicated: * p<0.05 and ** p<0.01 between control (grey bar) and +100 mOsm (black 
bar) conditions.
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Cartilage specific osmolarity (+100 mOsm) slightly increased the expression 
S100a4, a negative regulator of mineralization (figure 3A). Expression levels of min-
eralization markers Alpl and Spp1 were increased during differentiation at control 
osmolarity, but were not further altered by +100 mOsm (figure 3B,C). These data 
suggest that increasing the medium osmolarity to cartilage physiological levels 
promotes chondrogenic and hypertrophic differentiation of pre-chondrocytes 
(figure 1 and 2), without promoting mineralization (figure 3).
FK506 exerts dual effects on chondrogenic differentiation 
between different osmolarities
Supplementation of FK506 to ATDC5 cells in differentiation medium with control 
osmolarity from day 7 to 14 did not improve mRNA expression of the chondrogenic 
markers (figure 1). On the contrary, FK506 showed a decreasing trend in chon-
drogenic marker expression at control osmolarity, although only significant for the 
Col2:Col1 ratio and for Col9 in one of the two FK506 conditions. At +100 mOsm, 
FK506 showed clear effects. While there was no effect of FK506 on Sox9 and the 
Col2:Col1 ratio, a significant increased expression of Col9 (± 1.7-fold) by 62 nM 
FK506 and of Col9 (± 1.8-fold) and Col11 (± 1.5-fold) upon addition of 620 nM 
FK506 was observed (figure 1D,E). Although not significant, expression levels of 
Col2 showed the same increasing trend when the cells were stimulated with FK506 
in the +100 mOsm condition (figure 1B). 
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Figure 3. Mineralization markers were not altered by either increased osmolarity or FK506. ATDC5 
cells were differentiated under control osmolarity conditions for 14 days (grey bars) or at +100 mOsm 
from day 7 till day 14 (black bars). In addition, cells were co stimulated with 0, 62 or 620 nM FK506 
from day 7. All experiments were performed in replicates (n=7). Induction of mRNA was determined 
by RT-qPCR at day 0 and day 14. Data are means ± standard deviation. 
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FK506 has no effect on hypertrophic and terminal differentiation 
markers at both osmolarities
FK506 addition to medium of control or cartilage osmolarity (+100 mOsm) did 
not significantly alter any of the tested hypertrophic and mineralization markers 
(figure 2 and 3). There was a slightly increasing trend in Runx2, Col10 and Mmp13 
expression and a slightly decreasing trend in Tgm2, Vegf and Bmp2 expression by 
FK506. Currently, there is no evidence that FK506 significantly alters the osmolarity 
induced hypertrophic differentiation of ATDC5 cells.
Effect of FK506 on chondrogenic differentiation might be 
calcineurin independent 
Increased osmolarity is known to target Nfat5, which was shown earlier for mature 
chondrocytes (10). In the current experiments this was confirmed by a 1.5 fold 
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Figure 4. Correlation of Nfat5 expression and calcineurin activity. ATDC5 cells were differentiated 
under control osmolarity conditions for 14 days (grey bars) or at +100 mOsm from day 7 till day 14 
(black bars). In addition, cells were co stimulated with 0, 62 or 620 nM FK506 from day 7. Induction of 
Nfat5 mRNA was determined by RT-qPCR at day 0 and day 14 (A) and calcineurin activity was mea-
sured (C). Data are means ± standard deviation. ** p<0.01 between control and +100 mOsm condi-
tions; # p<0.05 FK506 effect compared to the condition without FK506 in the same osmolarity group. 
To analyse Nfat5 protein expression (B) cells were cultured on 8-well culture slides and stimulated 
with +100 or +200 mOsm medium for 30 minutes. 
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increase of Nfat5 mRNA expression (figure 4A). From the pattern of green colour 
in figure 4B it can be appreciated that, under plasma-level osmolarity (control), 
NFAT5 protein is more or less evenly distributed between cytoplasm and nucleus. 
At cartilage specific osmolarity (+100 mOsm, figure 4B), the intensity of green 
coloration accumulates in the nucleus. Further increasing the osmotic stress (+200 
mOsm, figure 4B) also increases the NFAT5-specific label intensity in the nucleus. 
NFAT5 mRNA expression appears to be independent of Cn activity in ATDC5 cells 
(4C), because it’s expression was not altered by FK506 (Figure 4A). At both osmo-
larity levels, FK506 significantly decreased the calcineurin activity (figure 4C), while 
it only affected some chondrogenic expression markers at increased osmolarity 
(Figure 1D,E).
Discussion
FK506 promotes osmolarity-induced terminal differentiation of the murine chon-
droprogenitor cell line ATDC5, an accepted model for terminal chondrogenic 
differentiation. The stimulating effect of cartilage physiological osmolarity on the 
expression of hypertrophy and terminal differentiation markers is a favourable 
event when aiming at improving endochondral regeneration medicine approaches. 
In contrast, it is unfavourable for cell-based cartilage regenerative medicine treat-
ments. In this study we investigated the potential effect of FK506 on osmolarity 
induced chondrogenic and terminal differentiation of ATDC5 cells. We hypoth-
esized that, like in human osteoarthritic chondrocytes (12), FK506 would be able to 
suppress the osmolarity/NFAT5 induced expression of the unwanted hypertrophic 
and terminal differentiation markers.
We found that cartilage physiological osmolarity (+100 mOsm; ± 412 mOsm) 
promoted chondrogenic and hypertrophic differentiation of pre-chondrocytes, 
without altering differentiation from hypertrophic chondrocytes to chondrocytes 
expressing mineralization markers. Expression levels of Sox9 and collagens type 2, 
9 and 11 all increased by +100 mOsm (figure 1) as well as the hypertrophic markers 
Tgm2, Runx2, Col10, Mmp13, Vegf and Bmp2 (figure 2). Mineralization markers 
Alpl and Spp1 (figure 3) were not further increased after stimulation by osmolarity. 
In previous studies, we have shown that the osmolarity induced expression of 
chondrogenic markers is, at least in part, regulated via Nfat5-mediated transcrip-
tional regulation of Sox9 (10, 11). Upon osmotic stress, transcription of Nfat5 is 
upregulated in several cell types (26, 27). The increased expression of Nfat5 on 
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mRNA level (figure 4A) by increased osmolarity support this thought. Like all tran-
scription (co-)factors, NFAT5 needs to be translocated to the nucleus to be active. 
In medulla cells, upon osmotic shock, NFAT5 rapidly translocates into the nucleus 
to induce its own transcription (27, 28). The newly synthesised NFAT5 proteins can 
then amplify the induction of cytoprotective proteins (28). We found that under 
plasma-level osmolarity conditions, NFAT5 protein is more or less evenly distrib-
uted between cytoplasm and nucleus (figure 4B). The additional osmotic trigger of 
100 mOsm stimulates transfer of NFAT5 to the nucleus (figure 4B, +100 and +200 
mOsm conditions), where it appears to be functionally active as derived from the 
subsequent induction of its own transcription (figure 4A). NFAT5 mRNA expression 
appears to be independent of Cn activity in ATDC5 cells (4A). 
FK506 seems to exert its effects on chondrogenic marker expression trough an-
other mechanism than increased osmolarity, as neither Nfat5 nor Sox9 are signifi-
cantly regulated by FK506 (figure 4A and 1A). FK506 inhibited Cn activity at both 
control and cartilage physiological osmolarity (figure 4C), but only improved some 
chondrogenic differentiation markers at physiological osmolarity (figure 1D,E). This 
indicates that there is an interaction between FK506 and the osmolarity, which was 
statistically confirmed for the FK506 effects on Col9 and Col11. These data also 
indicate that the effect of FK506 on differentiation of progenitor cells might be 
independent of Cn. This is in line with the study by Nishigaki et al. where FK506 but 
not CsA induced production of collagen type II and proteoglycan in differentiated 
ATDC5 cells (8). In that study, the effect of FK506 was antagonized by rapamycin, 
which competitively binds to FKBP. The authors concluded that FK506 induced 
chondrogenic differentiation of ATDC5 cells via a Cn independent mechanism 
after binding to FKBP. 
In human osteoarthritic chondrocytes cultured at control osmolarity we found 
that FK506 promoted chondrogenic marker expression via stimulation of en-
dogenous TGFβ1 production (13). Activated TGFβ induces gene transcription by 
phosphorylation of Smads (29, 30). In human synovial stromal cells FK506 induced 
glycosaminoglycan and Col2 production via Smad 1/5/8 and Smad 3 (31), likely 
by means of endogenous TGFβ induction. The FK506 binding protein, FKBP12, is 
known to inhibit TGFβ1 receptors (32). FK506 blocks this inhibition and enhances 
the ligand activity of the TGFβ1-receptor. This mechanism could explain the effects 
of FK506 on TGFβ signaling and chondrogenic differentiation of ATDC5 cells at 
cartilage physiological osmolarity. However, it does not explain why FK506 only 
increased some chondrogenic markers at physiological osmolarity and not at 
control osmolarity, like it does in human adult chondrocytes. Therefore, it would be 
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interesting to measure endogenous TGFβ production and Smad phosphorylation 
in our cultures. For now, this was beyond the scope of this paper, as our aim was 
to investigate whether FK506 would be able to suppress the osmolarity-induced 
expression of the unwanted hypertrophic markers.
Unfortunately, at both tonicities, we found that FK506 could not prevent or stimu-
late hypertrophic and terminal differentiation of progenitor cells at cartilage physi-
ological osmolarity (figure 2 and 3). Nakamura and colleagues (9) observed earlier 
that FK506 could promote the rate of cellular differentiation from pre-chondrocytes 
to proliferating and hypertrophic chondrocytes, without altering differentiation 
from hypertrophic to calcified chondrocytes. In metatarsals cultured with FK506 
for 5 days, FK506 predominantly promoted differentiation into proliferating chon-
drocytes without altering that from proliferating into hypertrophic and calcified 
chondrocytes. The authors also discovered that this regulation is not related to 
transactivation of Sox9 or RunX2. 
The results of this and of other studies indicate that FK506 promotes early chon-
drogenic differentiation of progenitor cells cultured at cartilage specific osmolar-
ity, without altering or inhibiting differentiation to hypertrophic and terminally 
differentiated cells. The latter is in contrast to the inhibiting effect of FK506 on 
osmolarity-induced hypertrophy in human osteoarthritic chondrocytes (12). We 
previously found evidence that FK506 may be therapeutically useful in repairing 
articular cartilage lesions or in joints with osteoarthritis (12, 13), where it can act on 
human adult chondrocytes. Future studies should investigate whether the effects 
of FK506 are cell type specific or whether changes in FK506 concentration and/or 
timing during chondrogenic differentiation of progenitor cells could achieve the 
same inhibiting effect on cell hypertrophy. This would make FK506 more useful for 
cartilage tissue engineering approaches using progenitor cells.
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Abstract
Osteoarthritis (OA) is a non-rheumatologic joint disease characterized by progres-
sive degeneration of the cartilage extra-cellular matrix (ECM), enhanced subchon-
dral bone remodeling, activation of synovial macrophages and osteophyte growth. 
Inhibition of calcineurin activity through tacrolimus (FK506) in in vitro monolayer 
chondrocytes exerts positive effects on ECM marker expression. This study there-
fore investigated the effects of FK506 on anabolic and catabolic markers of osteo-
arthritic chondrocytes in 2D and 3D in vitro cultures, and its therapeutic effects in 
an in vivo rat model of osteoarthritis.
Effects of high and low doses of FK506 on anabolic (QPCR/histochemistry) and 
catabolic (QPCR) markers were evaluated in vitro on isolated (2D) and ECM-em-
bedded chondrocytes (explants, 3D pellets). Severe cartilage damage was induced 
unilaterally in rat knees using papain injections in combination with a moderate 
running protocol. Twenty rats were treated with FK506 orally and compared to 
twenty untreated controls. Subchondral cortical and trabecular bone changes 
(longitudinal microCT) and macrophage activation (SPECT/CT) were measured. 
Articular cartilage was analyzed ex vivo using contrast enhanced microCT and 
histology.
FK506 treatment of osteoarthritic chondrocytes in vitro induced anabolic (mainly 
collagens) and reduced catabolic ECM marker expression. In line with this, FK506 
treatment clearly protected ECM integrity in vivo by markedly decreasing sub-
chondral sclerosis, less development of subchondral pores, depletion of synovial 
macrophage activation and lower osteophyte growth.
FK506 protected cartilage matrix integrity in vitro and in vivo. Additionally, FK506 
treatment in vivo reduced osteoarthritis-like responses in different articular joint 
tissues and thereby makes calcineurin an interesting target for therapeutic inter-
vention of osteoarthritis.
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Introduction
FK506 (Tacrolimus, Prograf) is an immunosuppressive drug discovered by Kino et 
al. in the 1980s (1). Since then, it has been used clinically for an increasing number 
of immunological disorders. FK506 exerts its therapeutic effects by suppression of 
T-cell activation, without markedly affecting bone marrow cell differentiation and 
proliferation (2). Through binding to FK506-binding proteins (FKBPs), FK506 inhibits 
the activity of ubiquitously expressed calcium/calmodulin dependent calcineurin 
(Cn). As a consequence, the calcineurin mediated dephosphorylation of transcrip-
tion factors of the nuclear factor of activated T-cells (NFATs) family (NFAT1-4) is 
inhibited. 
Besides their role in T-cell activation, Cn and NFATs are now also known to play a 
role in physiological processes in many other cell and tissue types and pathological 
conditions like cancer, degenerative brain diseases and cardiac hypertrophy (3). 
FK506 has proven to be useful in reducing inflammation and alleviating symptoms 
in patients with inflammatory (rheumatoid) arthritis (4, 5). Interestingly, the Cn/
NFAT signalling cascade is also reported to play a role in bone remodelling (6) 
and chondrogenesis (7). FK506 has been shown to induce chondrogenic differ-
entiation of murine chondroprogenitor cells (8). This suggests that patients with 
non-inflammatory joint diseases, like osteoarthritis (OA), also might benefit from a 
treatment with Cn inhibitors. 
OA is a complex progressive disease and a disturbed balance between anabolic 
and catabolic activity of chondrocytes is an early pathophysiological event leading 
to matrix degradation. Progression of OA finally results in severe deterioration of 
articular cartilage and involves pathological changes throughout the joint, like ex-
tensive subchondral bone remodelling (9) and activation of synovial macrophages 
(10). We reported earlier that FK506 treatment of monolayer cultured osteoarthritic 
cells enhanced expression of anabolic markers like collagen type II (COL2), but 
suppressed relevant catabolic, hypertrophy and mineralization markers (11, 12). 
Another Cn inhibitor, cyclosporine A (CsA) showed similar effects on anabolic 
and catabolic activity of OA chondrocytes and reduced cartilage damage in a 
collagenase induced OA mouse model (13). However, this study only measured 
macroscopical and microscopical cartilage damage ex vivo and did not investi-
gate possible effects of Cn inhibition on other tissues of the joint, like bone and 
synovium.
146 Chapter 7
Recently, we established a novel rat OA model using a combination of papain 
injections with a running protocol to induce severe knee joint articular cartilage 
degradation together with prominent involvement of subchondral bone and syno-
vial macrophages (14). The current study aimed to elucidate the effects of systemic 
FK506 treatment in this OA animal model. We first characterized whether both 
low and high concentrations of FK506 modulate anabolic markers in OA chondro-
cytes in monolayer cultures. Since chondrocytes reside in an extra-cellular matrix 
in vivo, we additionally investigated whether low dose FK506 treatment remains 
beneficial for extracellular matrix-embedded chondrocytes in ex vivo explants and 
pellet cultures. Finally, we tested modulating effects of FK506 in an animal model 
for severe cartilage degradation and analyzed articular cartilage (ex vivo µCT and 
histology), subchondral bone (in vivo µCT) and synovial macrophages activation (in 
vivo SPECT/CT) six and twelve weeks after induction of cartilage damage. 
Materials and Methods
FK506 effects on osteoarthritic chondrocytes in vitro
Human articular cartilage was explanted from macroscopically normal areas of 
femoral condyles and tibial plateaus of patients (N=9, between 55-82 years old) 
undergoing total knee replacement surgery for OA (MEC2004-322). Isolation of pri-
mary osteoarthritic human articular chondrocytes from cartilage tissue under stan-
dard conditions (cytokine-free Dulbecco’s modified Eagle’s medium (DMEM) with 
4.5 g/L glucose, 10% fetal calf serum (FCS), 50 µg/mL gentamycine and 1.5 µg/mL 
fungizone; all Invitrogen, Paisley, Scotland, UK, adjusted to 380 mOsm by adding 
sterile sodium chloride) and monolayer experiments were performed as described 
earlier (11). In short, passage 1 cells were seeded in 2D monolayer, stimulated with 
0, 62 or 620 nM FK506 after 24 hours and harvested for RNA analysis (quantitative 
RT-PCR) six days later. Experiments were performed at least in technical duplicates 
from four OA donors. In addition to 2D cultures, passage 2 cells from four OA 
donors were cultured as 3D pellets (2x105 cells/pellet) for 21 days in medium (380 
mOsm) with or without addition of 62 nM FK506 (11). 
To investigate the effects of FK506 on OA chondrocytes embedded in their ex-
tracellular matrix, six mm diameter full-thickness explants from femoral condyles 
and tibial plateaus of five OA donors were cultured as described before (11) and 
cultured in medium (380 mOsm) with or without 62 nM FK506 for 7 days.
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RNA and protein analysis by RT-QPCR and histology
RNA from monolayer and explant cultures was extracted, purified and quantified, 
and cDNA was synthesized and quantified by RT-QPCR reactions as described 
earlier (12, 15). RNA abundance was normalized to an index of the three most 
stable reference genes (GAPDH, HPRT1, 18sRNA or UBC) replicate values were 
averaged per condition per patient and gene expression was calculated as fold 
change of control condition (0 nM FK506) (11). Primer sequences for COL2, 
ACAN, MMP1, MMP13, MMP13, ADAMTS4 and ADAMTS5 were adopted from 
Uitterlinden et al (15), for COL1 from Das et al (16), and for VCAN/CSPG2 from 
Martin et al (17). To quantify expression of COL9 and COL11, the following prim-
ers were tested for similar amplification efficiency and specificity (16) , and were 
used as respectively 20 µl Taqman and SYBR® Green I reactions: HsCOL9A1_F 
GCAGCTCATGGCAAGTTTCTCT, COL9A1_R GCTTTGCTGTGCTGGGAAAA 
and COL9A1_FAM TGAAGTTCAAATGGAACAGAAACTTGAGGATTATCTG; 
HsCOL11a1_Fw AGGAGAGTTGAGAATTGGGAATC, COL11A1_Rv TGGTGAT-
CAGAATCAGAAGTTCG. 
The expression data are presented as 2-Ct values based on publication by Livak & 
Schmittgen (18). The cDNA abundances of each gene of interest were normalized 
to an index of three stable expressed reference genes to generate a normalized, 
so-called 2-Ct, value. Replicate values were averaged per condition, per patient, 
and finally expressed as fold change difference relative to the control condition (i.e. 
without FK506 treatment) and representing a 2-Ct value. The COL2/COL1 ratio, 
like the VCAN/CSPG2 ratio, relates the expression levels of both genes to one 
another. Relative higher COL2 expression, as compared to COL1, is indicative of a 
relatively better preserved chondrocyte-specific gene expression. This also holds 
for VCAN/CSPG2 ratios, and was used earlier as a measure of de-differentiation of 
chondrocytes (19, 20). 
(Immuno)histochemical staining for COL2 and GAG on 3D pellet cultures was 
performed as described before (21). Staining intensities of pellets were quantified 
using ImageJ 1.42 software (http://rsb.info.nih.gov/ij/download.html).
FK506 therapeutic effects in a rat model for severe osteoarthritis 
Forty 16-week-old male Wistar rats (Charles River Netherlands BV, Maastricht, the 
Netherlands) were housed in the animal facility of the Erasmus Medical Centre, with 
a 12-h light-dark regimen, at 21oC during the experimental period, and received 
standard food pellets and water ad libitum. OA-like articular destruction was in-
duced in all animals, which were then divided over two groups: twenty rats served 
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as untreated controls and twenty rats were treated during the experiment with 
FK506. FK506 treated animals received FK506 suspension (1 mg/kg) (22) through 
oral probing, five days a week, not on weekends. 
Severe cartilage damage was induced using intra-articular papain injections in the 
left knee joints combined with exposure to a moderate exercise protocol as de-
scribed before (14). In short, all animals received three intra-articular injection that 
consisted of 15µl 4% (w/v) papain solution (type IV, double crystallized, 15 units/mg, 
Sigma-Aldrich, St. Louis, MO, USA) with 15µl 0.03M L-cystein (Sigma-Aldrich) (23). 
Their contralateral knee joint served as an internal healthy control. All rats were 
forced to run on a motorized rodent treadmill (LE-8700; Panlab Harvard Apparatus, 
Barcelona, Spain) for six weeks covering a total distance of 15km (14). During the 
study all animals were longitudinally monitored at baseline, 6 weeks and 12 weeks 
with µCT to measure subchondral bone changes (24). At six and twelve weeks, 
ten rats in both groups were selected for a full analysis sequence. This sequence 
consisted of SPECT/CT to quantify in vivo macrophage activation (25), and ex vivo 
EPIC-µCT and histology to measure cartilage quality (26). The details of these pro-
cedures were described earlier (14). The animal ethic committee of the Erasmus 
Medical Center, Rotterdam, the Netherlands, approved all conducted procedures. 
A detailed planning scheme of all groups and conducted tests is given in figure 1.
Subchondral bone measurements on μCT scans
Both knees of all animals were µCT scanned under isoflurane anaesthesia, using a 
Skyscan 1176 in vivo µCT scanner (Skyscan, Kontich, Belgium). Ten minutes of scan 
time was required per knee at an isotropic voxelsize of 18µm, at a voltage of 65kV, a 
current of 385mA, field of view of 35mm, using a 1.0mm aluminium filter, over 198o 
with a 0.5 degree rotation step, and a 270 msec exposure time. All datasets were 
segmented with a local threshold algorithm (27). Cortical and trabecular bone were 
automatically separated using in-house software (28). Using Skyscan software, both 
subchondral plate thickness (Sb. Pl. Th. in µm) and subchondral plate porosity (Sb. 
Pl. Por. in mm3) of the medial and lateral compartment of the tibial plateau were 
measured (24). In the tibial epiphysis, the trabecular thickness (Tb. Th. in µm) and 
trabecular bone volume fraction (BV/TV), representing the ratio of trabecular bone 
volume (BV, in mm3) to endocortical tissue volume (TV, in mm3) were measured. 
Ectopic bone formation (mm3) was also quantified as a measure for osteophyte 
growth in these longitudinal µCT scans.
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Determination of activated macrophages by SPECT/CT using 111In-
EC0800
Activated macrophages express the folate receptor-β allowing monitoring mac-
rophages in-vivo using folate-based radiotracers (29, 30). Phosphate buffered 
saline (PBS, pH 6.5) DOTA-Bz-folate (EC0800, kindly provided by Endocyte Inc., 
West Lafayette, USA) (31) was labelled with 111InCl3 (Covedien, Petten, The Neth-
erlands) as described previously (14). Quality control was performed with ITLC-SG 
and revealed a radiochemical yield of ~91% at a specific activity of 50 MBq/µg. 
111In-EC0800 (55MBq) was administered via the tail vein twenty hours prior to scan-
ning. SPECT/CT scans were performed with a 4-head multiplex multi-pinhole small 
animal SPECT/CT camera (NanoSPECT/CT TM, Bioscan Inc., Washington DC, USA). 
All knee joints were scanned with both helical µCT (acquisition time 5min) and 
SPECT (acquisition time 30min). All scans were analyzed using InVivoScope pro-
cessing software (Bioscan Inc.). To reduce inter-individual variation, the absolute 
difference in measured radioactivity (kBq/mm3) of the OA knee joint compared to 
their internal control joint was calculated. This absolute difference was used when 
comparing means of untreated animals with FK506 treated animals.
Figure 1. Experiment design indicating analytical time points and methods for each experimen-
tal group. Forty 16-week-old male Wistar rats were injected with three papain intra-articular injec-
tions (P.I.) and forced to run 15km on a motorized treadmill. Animals were divided over two different 
groups: an untreated osteoarthritis (OA) group (n=20) and a FK506 treated group (n=20). During the 
experiment three longitudinal µCT scans were made to measure subchondral bone changes (24). At 
six and twelve weeks a full analysis sequence was done in ten animals per group (n†=10), consisting 
of: determination of activated macrophages using SPECT/CT in-vivo (25); and cartilage analysis with 
equilibrium partitioning of an ionic contrast agent using (EPIC-)µCT (26) and histology ex-vivo.
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Cartilage evaluation with contrast enhanced μCT and histology
Equilibrium partitioning of a contrast agent using µCT (EPIC-µCT) has a strong cor-
relation with cartilage sulphated-glycosaminoglycan (sGAG) content (26). Animals 
were euthanized directly after the last SPECT/CT scan and both knee joints were 
harvested for EPIC-µCT analysis. All specimens were incubated in 40% solution 
of ioxaglate (Hexabrix320, Mallinckrodt, Hazelwood, MO, USA) for 24 hours at 
room temperature (32). EPIC-µCT was performed on the 1176 in vivo µCT scanner 
(Skyscan), using the following scan settings: isotropic voxel size of 18µm, a voltage 
of 65kV, a current of 385mA, field of view 35mm, a 0.5 mm aluminium filter, 198o 
with a 0.5 degree rotation step, and a 235 msec exposure time. In all EPIC-µCT da-
tasets, X-ray attenuation (arbitrary gray values inversely related to sGAG content) 
and cartilage thickness (µm) was calculated for cartilage of the medial and lateral 
plateau of the tibia (14).
After EPIC-µCT, the separated parts of the knee joints were fixed in 3.7% phosphate 
buffered formaldehyde, decalcified with formic acid and embedded in paraffin. 
Sagittal sections were made at 300 µm intervals and stained with Safranin-O with 
a fast green counterstain to image the distribution of the GAGs. Sections were 
stained all at once, to minimize artifacts between different samples. 
Statistical analysis
Statistical analysis of vitro studies was performed as described before (11). Briefly, 
replicate raw expression data of multiple donors was tested for the effect of FK506 
using Linear Mixed Model regression and ‘donor’ was incorporated as a random 
effect to correct for basal differences in expression between donors (SPSS Inc., 
Chicago, USA).
For the in vivo study, differences between means of OA induced and healthy knee 
joints within the same animal were tested using paired t-tests at each time point for 
all outcome parameters (GraphPad Software, San Diego, California, USA). When 
comparing differences between means of untreated animals and FK506 treated 
animals, an unpaired t-test was used at each time point for all outcome parameters 
(GraphPad Software). Longitudinal data from in vivo µCT were additionally ana-
lyzed using generalized estimating equations (SPSS). For all tests, p values ≤ 0.05 
were considered significant.
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Results
In vitro effects of FK506 on human osteoarthritic chondrocytes
Inhibition of calcineurin activity by FK506 in monolayer cultured passage 1 osteoar-
thritic chondrocytes increased expressions of cartilage specific collagens. Both low 
and high concentrations of FK506 positively stimulated COL2/COL1 ratio (62 nM 
FK506 by ± 2-fold, p = 0.067; 620 nM by ± 3-fold, p = 0.001) and COL9 expression 
(62 nM FK506 by ± 1.8-fold, p= 0.037), while no effects were found on the ACAN/
VCAN ratio or COL11 expression (figure 2A). In cartilage explants, the osteoarthritic 
chondrocytes are embedded in a matrix, which might limit chondrocyte exposure 
to FK506. Despite the large standard deviations in the explants cultures, we found 
clear matrix-protective trends after FK506 treatment. A low dose of FK506 was 
enough to induce a similar trend of increased anabolic marker expression in ex-
Figure 2. RNA abundance of anabolic and catabolic markers was determined in samples from hu-
man osteoarthritic monolayer (A) and explant (B) cultures. Relative changes by FK506 (grey and black 
bars) as compared to control (no FK506) are shown, each bar represents the fold-change compared 
to the control condition. Error bars indicate standard deviations. Representative images of 21-day 
3D pellet cultures (C) show collagen type II immunostaining (on top, in red) and sGAG staining (thio-
nin; on bottom, in blue) of pellets cultured with or without 62 nM FK506. Staining intensity in FK506 
pellets is expressed as mean percentage (standard deviation) of that in control pellets *: p<0.05, **: 
p<0.01
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plants as seen in monolayer cultured chondrocytes (figure 2B). Moreover, the FK506 
induced changes in chondrogenic marker expression seem to be even higher in 
the explants. In line with our previous work on monolayer chondrocytes (11), FK506 
also reduced the expression of the catabolic MMPs and important aggrecanases in 
the explant cultures (figure 2B). 
The FK506 induced increase in collagen expression was confirmed by immuno-
histology on 3D pellets cultures of osteoarthritic chondrocytes. FK506 clearly 
increased COL2 protein expression (to 121.4% of control, p = 0.009) in chondrocyte 
pellet cultures, while no clear effect was seen on GAG staining (figure 2C).
In vivo effects of FK506 treatment
Bodyweight of all untreated rats at baseline was 416.4g (411.3 – 421.5g), during 
six weeks of treadmill running this decreased non-significantly to a mean weight 
of 408.3g (398.2 – 418.3g). During subsequent six weeks of rest, all rats increased 
in their mean bodyweight to 485.5g (473.0 – 498.0g). FK506 treated animals (mean 
weight at baseline was 413.6g; 409.4 – 417.8g) also did not increase in bodyweight 
during induction of OA-like articular destruction (mean weight after six weeks was 
418.5g; 412.9 – 424.1g). After twelve weeks their mean bodyweight was 507.1g 
(498.8 – 515.4g), which was significantly higher compared to untreated controls (p = 
0.004) (figure 3). During the course of the experiment, none of the animals showed 
signs of FK506-induced cytotoxicity, like weight or hair loss.  
Osteoarthritic changes of articular cartilage
Intra-articular papain injections combined with moderate exercise in untreated 
controls induced severe sGAG depletion from both medial and lateral cartilage 
Figure 3. Increase in rat bodyweight (gram) during the experiment of OA control (white circles) and 
FK506 treated (gray squares) animals. **: p<0.01, error bars indicate 95% confidence intervals.
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compartments of the tibia plateau. This sGAG depleted state persisted throughout 
the experiment (figure 4A-B). After the running protocol at six weeks, cartilage 
of the medial compartment was slightly reduced in thickness (figure 4C). Lateral 
cartilage thickness was severely degraded (figure 4D) and resulted in almost com-
pletely denuded subchondral bone (figure 4E). During subsequent six weeks of 
rest medial cartilage continued to degrade, in the lateral compartment an ongoing 
decline in cartilage thickness was absent (figure 4C). Representative medial and 
lateral cartilage images from safranin-O stained histology from untreated controls 
at six and twelve weeks are shown in figure 5.
Compared to untreated controls, FK506 treated animals had similar sGAG de-
pleted cartilage in medial and lateral compartments of the tibia plateau (figure 
4A-B). Lateral cartilage was reduced in thickness to similar extent as untreated 
controls (figure 4D). However, medial cartilage showed a trend towards thicker 
ECM compared to untreated control at six weeks, although this was not significant 
Figure 4. Cartilage quality and quantity was determined from untreated OA (circles) and FK506 
treated (squares) rats with equilibrium partitioning of an ionic contrast agent using (EPIC-)µCT (A-D). 
The amount of sulphated glycosaminoglycans (sGAG) (arbitrary gray values; A,B) and cartilage thick-
ness (µm; C,D) were measured of medial (A,C) and lateral (B,D) cartilage compartments of the tibia 
plateau harvested from healthy joints (blank boxes) and OA induced joints (gray boxes). Attenuation 
values from EPIC-µCT scans are inversely related to the sGAG content, meaning that a high attenu-
ation corresponds to low sGAG content. Coronal images from EPIC-µCT scans of the tibia plateau 
show the amount of cartilage (erosions indicated with q and dashed lines) and sGAG content (dis-
played in color). *: p<0.05, **: p<0.01, ***: p<0.001, error bars indicate 95% confidence intervals.
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(p = 0.15). In contrast to the progressive degradation of medial cartilage as seen 
in untreated controls at twelve weeks, medial cartilage thickness of FK506 treated 
animals remained constant and was significantly thicker at twelve weeks compared 
to untreated controls (p = 0.02) (figure 4C). 
Although lateral cartilage did not differ significantly in sGAG content or thickness 
between untreated and FK506 treated rats, we did observe a small difference 
between both groups. In four FK506 treated rats, but in none of the untreated 
rats, there were small and focal regions of lateral tibia cartilage that showed intact 
but totally sGAG depleted ECM (figure 4E). A difference that was also found on 
safranin-O stained histology sections as shown in figure 5.
Figure 5. Safranin-O stained histology sections of medial and lateral tibial plateau cartilage after six 
weeks and twelve weeks of follow up. Medial cartilage of untreated OA knee joints with depleted 
sulphated-glycosaminoglycan at six weeks and twelve weeks, and only mildly degraded extra-cellu-
lar matrix (ECM). Lateral cartilage ECM was almost totally eroded, only the calcified cartilage layer 
remained present and showed ECM denudation of cartilage ECM. Much less ECM degradation oc-
curred in FK506 treated animals. The lateral compartment cartilage was severely eroded, however 
4/10 rats showed focal regions with complete sGAG depleted but partially intact ECM.
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Subchondral bone changes
Subchondral bone plate thickness of medial tibia compartment in untreated con-
trols and FK506 treated rats was slightly reduced after six and twelve weeks of 
follow up (figure 6A), but did not differ between both groups (p = 0.83). Medial 
plate porosity did not increase in both experimental groups throughout the experi-
ment (figure 6B). Lateral compartment subchondral bone thickness of untreated 
OA joints was clearly increased compared to their healthy control joint at six weeks 
(p < 0.0001), and there was also more subchondral plate porosity (p = 0.02) (figure 
Figure 6. Subchondral bone changes analyzed with longitudinal in vivo µCT in untreated OA (circles) 
and FK506 treated (squares) animals. Subchondral plate thickness (Sb. Pl. Th.; A, C) and porosity (Sb. 
Pl. Por.; B, D) were measured in the medial (A,B) and lateral (C,D) compartment of the tibial epiphy-
sis. Changes in trabecular thickness (Tb. Th.; E) and trabecular bone volume fraction (BV/TV; F) were 
measured in tibial epiphyseal bone marrow. Representative sagittal images from binary µCT scans 
(G) show pore development (indicated with q) and development of subchondral sclerosis (indicated 
with dashed line and *). Three-dimensional top views of the tibial plateau at different time points 
(H) show subchondral pore (red color) development. *: p<0.05, **: p<0.01, ***: p<0.001, error bars 
indicate 95% confidence intervals.
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6C,G,H). Subchondral plate thickness further increased during subsequent six 
weeks of rest (p < 0.0001). Plate porosity also seemed to increase further, but there 
was no significant difference compared to internal healthy control joints. FK506 
treated animals also had a thicker subchondral bone plate at six (p < 0.0001) and 
twelve (p < 0.0001) weeks compared to their internal healthy control joints. When 
longitudinal subchondral bone changes in OA joints of both groups were analyzed 
with generalized estimating equations, FK506 treated rats had thinner lateral 
subchondral bone plates compared to untreated controls (p = 0.03) (figure 6C,G). 
FK506 rats did not develop subchondral plate porosity. This was significantly lower 
Figure 7. Macrophage activation determined in untreated OA animals (circles) and FK506 treated 
animals (squares) by injection of 111In-EC0800 using SPECT/CT. A: Quantified radioactivity in healthy 
joints (blank boxes) and OA joints (gray boxes) normalized to the size of the analyzed cylindrical 
region of interest (kBq/mm3). Absolute differences per animal were calculated (kBq/mm3) to reduce 
inter-individual variation (black boxes). A high radioactivity is related to more macrophage activa-
tion. B: Ectopic bone formation (mm3) as a measure for osteophyte development was quantified 
on longitudinal bone µCT scans. C: Sagittal SPECT/CT images of knee joints from representative 
animals. CT images shown in black and white were used for anatomical reference, the SPECT im-
ages are shown in color. Transaxial images from patellar bone extracted from binary µCT images 
show ectopic bone formation (red color). *: p<0.05, **: p<0.01, ***: p<0.001, error bars indicate 95% 
confidence intervals.
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at six weeks (p = 0.02), but not at twelve weeks anymore (figure 6D,H). After six 
weeks of treadmill exercise-mediated trabecular bone thickness (p = 0.05) and BV/
TV (p = 0.03) was lower in FK506 treated animals compared to untreated controls 
(figure 6E,F). Reduced trabecular thickness normalized during subsequent six 
weeks of rest, while the BV/TV ratio increased compared to untreated controls (p 
= 0.02). 
During six weeks of moderate running, FK506 treated animals formed less ectopic 
bone formation compared to untreated animals (p = 0.007) (figure 7B,C). This dif-
ference in ectopic bone formation between FK506 treated animals and untreated 
controls was still measured after the subsequent six weeks of rest (p = 0.04) (figure 
7B,C). 
Macrophage activation and osteophytes
Each animal received 54 ± 2 MBq of 111In-EC0800 under isoflurane anaesthesia. 
There were no significant differences of injected activity between experimental 
groups. After completion of the running protocol, both untreated and FK506 
treated rats revealed similarly increased radioactive uptake in their papain injected 
knee joints compared to their internal healthy control joints (figure 7A,C). After 
six subsequent weeks of rest, radioactive uptake in OA induced joints of FK506 
treated animals dropped to control levels. The absolute difference in radioactive 
uptake between OA induced and healthy control joints in FK506 treated animals 
was lower compared to the absolute differences measured in untreated controls 
(figure 7A,C). 
Discussion
Osteoarthritis is characterized by a loss of cartilage matrix, because chondrocytes 
cannot maintain tissue homeostasis due to a disturbed balance between anabolic 
and catabolic activities. Inhibiting calcineurin activity with immunosuppressive 
agents like cyclosporin A (13) or FK506 (11, 12) increases the anabolic, while sup-
pressing the catabolic, activity of osteoarthritic chondrocytes. In this study, we found 
that both high and low concentrations of FK506 improved the COL2/COL1 ratio 
and COL9 expression in monolayer cultured human osteoarthritic chondrocytes 
(figure 2A). Then, in 3D chondrocyte pellet cultures, FK506 clearly increased COL2 
content, while no effect was seen on sGAG staining (figure 2C). These data indicate 
that calcineurin inhibition through FK506 may protect the structural integrity of 
the ECM. Next, we studied the effects of low dose FK506 treatment in cartilage 
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explants, in which the chondrocytes are still embedded in their native extracellular 
matrix. The explants were harvested from macroscopically ‘healthy’ cartilage areas 
of the degenerated side. However, on microscopic level there might be still big 
differences in grade of degeneration between explants of the same donor. To limit 
the effects of these differences, explants were first pooled before assigning them 
to a certain culture condition. Despite the large standard deviations, we found 
a clear trend towards stimulated anabolic but reduced catabolic activities after 
FK506 treatment (figure 2B). 
Finally, we evaluated whether FK506 also exerts similar favorable effects in a severe 
OA in vivo model with a different response in medial and lateral compartments of 
tibia plateau cartilage (14). Six weeks of OA-like damage induction severely erodes 
lateral compartment cartilage and results in complete denudation of subchondral 
bone. Medial cartilage becomes sGAG-depleted with a slightly degraded ECM, a 
process that continued progressively during the course of the experiment (figure 
4 and 5). FK506 treatment in vivo did not increase sGAG levels nor did it protect 
against sGAG loss (figure 4A-B). However, it did protect against structural matrix 
degradation (figure 4C), which was in line with our in vitro results (figure 2). Loss of 
lateral cartilage matrix could not be prevented with FK506 treatment (figure 4D). 
Longitudinal µCT analysis showed reduced sclerotic bone formation in the lateral 
compartment of FK506 treated animals (figure 6C). Previous experiments with this 
severe OA model suggest that subchondral sclerosis might develop when cartilage 
is completely lost and subchondral bone is denuded (14). In some FK506 treated 
animals we found focal regions of cartilage on the lateral tibia plateau that showed 
totally sGAG depleted but partially intact ECM. This suggest, that FK506 might 
have delayed lateral cartilage matrix degradation and thus reduced formation of 
subchondral sclerosis. However, calcineurin inhibition is also known to modulate 
bone turnover (33) and therefore may have reduced sclerosis through direct 
modulation of osteoclast and osteoblast activity. CsA and FK506 have both been 
described to induce osteopenia through anti-anabolic effects on osteoblastic cells 
(34) and to reduce bone formation through inhibition of osteoblast differentiation 
(35, 36). This could be another explanation for the reduced development of sub-
chondral sclerosis in the lateral compartment, but has to be further investigated.
Another cell type that is modulated by FK506 are macrophages (37). We deter-
mined activated macrophages using 111In-EC0800 and quantitative SPECT/CT 
(figure 7A). During OA progression, macrophages become activated (25) and their 
TGFβ/BMP-2 production has previously been related to osteophyte development 
(38, 39). In our in vivo experiment, animals developed clear osteophytes at the 
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margins of the patella (figure 7B). FK506 treatment reduced osteophyte develop-
ment while the total amount of activated macrophages was equal after six weeks 
of follow up. This may suggest that FK506 treatment limits cytokine production 
by activated synovial macrophages and previous reports on calcineurin inhibition 
in macrophages showed reduced cytokine production (40-42). FK506 may initially 
activate Toll-like receptors (TLR) pathways in activated macrophages, which can 
enhance NFκβ activity (42) and stimulate expression of cytokines, like TNFα, IL1α, 
IL1β, IL12 and iNOS (40). However, prolonged exposure to calcineurin inhibitors 
has been shown to also secondarily inactivate this TLR induced pro-inflammatory 
cytokine expression by negative feedback loops (41). As such, continuous FK506 
exposure may eventually suppress NFκβ pathways, but activate caspases 3 and 9 to 
enhance macrophage apoptosis (42). Possibly, FK506 induced macrophage apop-
tosis may explain why radioactive folate uptake in our experiments was restored to 
levels comparable to healthy control joints (figure 7A). 
Osteoclasts are large multinucleated cells of the monocyte-macrophage hema-
topoietic lineage and are also influenced by FK506. During osteoclastogenesis 
macrophage colonoy-stimulating factor (M-CSF) and receptor activator of nuclear 
factor-κβ ligand (RANKL) stimulate precursor cells to acquire osteoclast characteris-
tics (43). NFATc1 is an essential terminal differentiation factor of osteoclastogenesis 
and can be blocked in a dose-dependent fashion using CsA or FK506 (44). CsA 
and FK506 treatment suppress RANKL stimulated osteoclastogenesis (45-47), and 
especially inhibits late stages of the osteoclast life cycle (48). By this mechanism 
Cn inhibition can diminish the activity of mature osteoclasts and reduce bone 
resorption (49-51). FK506 mediated suppression of osteoclast maturation and 
subsequently hindered subchondral bone resorption may therefore explain why 
less subchondral pores were measured in FK506 animals. 
Systemic FK506 treatment is known to induce toxic side effects (52). Throughout 
the experiment our animals gained weight (figure 3), and FK506 animals increased 
more in weight from 6 to 12 weeks of follow-up. However, this result could not 
clearly be related to side-effect of FK506, which usually results in a loss of weight. 
At the end of the twelve week experiment liver function (AST, ALT, alkaline phos-
phatase) and kidney function (creatinin and urea) were normal (figure 8A). Liver 
and kidney histology gave no indication that FK506 induced liver or kidney fibrosis 
(figure 8B-C). Despite these promising findings, systemic FK506 treatment cannot 
be translated towards clinical OA care directly. FK506 induced side effects are well 
described in patients after long term use and is unacceptable for a therapeutic 
strategy in human OA patients. To reduce toxicity, local intra-articular treatment 
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may be used, but repetitive intra-articular injections also increase the risk of iat-
rogenically arthritis should be avoided. FK506-coupled biodegradable delivery 
systems might be able to prolong intra-articular FK506 exposure and sustain long 
term therapeutic action (53), hopefully without systemic adverse effects.
Conclusion
Inhibition of calcineurin activity with FK506 stimulated anabolic activity, while 
reducing catabolic productivity of osteoarthritic human chondrocytes. Systemic 
treatment with FK506 in a rat model for severe osteoarthritis also protected against 
Figure 8. Toxicity analysis. Blood samples did not differ between experimental groups and gave no 
indication of liver or kidney toxicity (A). Liver (B) and kidney (C) histology showed no indication of 
FK506 induced toxicity. 
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cartilage extra-cellular matrix degradation. Additionally, there was also less devel-
opment of subchondral sclerosis, macrophage activation and osteophyte forma-
tion. Altogether, our data suggests that calcineurin inhibition with FK506 proves to 
be a promising candidate for therapeutic management of osteoarthritis.
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Hyaline (articular) cartilage enables us to walk, dance and run a marathon without 
friction between our articulating bones, providing us quality of life. However, when 
damaged it fails to repair itself properly. Because of the high economic burden 
of traumatic or degenerative articular cartilage defects, the search for the ideal 
cartilage regeneration technique continues. Improving the quality of the cartilage 
formed after cell transplantation for example by optimizing the in vitro culture 
conditions during the expansion phase, is therefore of great interest. However, the 
development of a drug inducing hyaline cartilage repair in patients with osteoar-
thritis or a traumatic defect is of course preferable and still desirable. 
The major aims of the research reported in this dissertation were to find new po-
tential targets or tools for improving cartilage matrix synthesis by chondrocytes, 
either in vitro for cell transplantation techniques or in vivo toward a treatment for 
osteoarthritis. As potential targets, the calcineurin-dependent NFAT1-4 pathway 
and the osmolarity-dependent NFAT5 pathway were studied. 
Main results and interpretation
Calcineurin as potential target to improve cartilage matrix 
synthesis by chondrocytes
In vitro chondrocyte expansion is required for several cell-based approaches for 
the repair of chondral lesions. During expansion, the chondrocytes loose their spe-
cific phenotype and dedifferentiate into more fibroblast-like cells. As a result the 
expression and synthesis of the cartilage specific collagen type II (COL2) decreases 
and that of collagen type I (COL1) increases, resulting in an inferior quality of the 
extracellular matrix (1-3). In chapter 2 we identified Calcineurin (Cn) as potential 
target to improve chondrocytic phenotype of culture-expanded adult osteoarthritic 
chondrocytes. Cn activity increased during chondrocyte dedifferentiation and de-
creased during redifferentiation by TGFβ. The question was if Cn inhibition could 
stimulate the redifferentiation process. We showed that this was indeed the case. 
FK506-induced inhibition of Cn activity increased the gene expression of chondro-
cytic markers COL2, aggrecan (AGC) and SOX9, indicating that the osteoarthritic 
cells became more chondrogenic. This role of Cn and the effects of Cn inhibition 
on human adult osteoarthritic cells are consistent with other publications. Yoo et 
al. also described that Cn is highly expressed in chondrocytes of OA patients and 
that inhibition of Cn by Cyclosporin A (CsA) decreased the interleukin-1β (IL1β) 
stimulated production of nitric oxide (NO) and matrix metalloproteinases (MMP) 
1 and 3 (4). In addition, in a mouse model for OA cyclosporin A decreased the 
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extent and severity of cartilage damage (4). Nakamura et al. described increased 
production of Col2 and Col10 in mouse costal chondrocytes after treatment with 
FK506 (5). 
The effects of FK506 and CsA on chondrocytic marker expression has more exten-
sively been studied in other cell types, like mesenchymal stem cells, chondropro-
genitor cell lines (ATDC5, RCJ3.1C5.18) and human synovial stromal cells. FK506 
induced expression of Col2, Col10 and proteoglycans in the chondroprogenitor 
ATDC5 cell line and in human synovial stromal cells (5-7). 
However, the mechanism by which Cn inhibition leads to increased chondrocytic 
marker expression and the role of the NFAT1-4 transcription factors in this process 
remains mostly unclarified. Cn inhibitors are known to induce TGFβ signaling in 
renal cells, vascular smooth muscle cells and lymphocytic B cells (8-11). In chapter 
2 we demonstrated that increased endogenous TGFβ1 production was respon-
sible for the effect of FK506 on COL2 expression in osteoarthritic chondrocytes. 
TGFβ is a secreted protein that controls proliferation, cellular differentiation, and 
other functions in many cell types. The TGFβ family is part of a superfamily, which 
includes, besides TGFβ, activins and bone morphogenetic proteins (BMPs). In 
mammalian cells there are three isotypes of TGFβ: β1, β2 and β3. Activated TGFβ 
induces gene transcription by phosphorylation of intracellular Smads. TGFβ has 
been shown to be beneficial for cartilage as it stimulates chondrocytes to elevate 
proteoglycan and COL2 production (12-14). In human synovial stromal cells FK506 
induced glycosaminoglycan and COL2 production via Smad 1/5/8 and Smad 3 
(7). There are different mechanisms reported by which FK506 and/or CsA induce 
endogenous TGFβ. The FK506 binding protein, FKBP12, is known to inhibit TGFβ1-
receptors (15). FK506 can block this inhibition and enhances the ligand activity of 
the TGFβ1-receptor. This mechanism could explain the effects of FK506 on TGFβ 
signaling, but not the effect of CsA. An other possible mechanism is regulation of 
the TGFβ1 promotor activity by the Cn-dependent NFAT transcription factors (16). 
The role of NFAT1-4 in regulating chondrogenic marker expression remains insuf-
ficiently clear. Tomita et al. showed that Cn and NFAT4 stimulate chondrogenesis 
via BMP2 in a rat mesenchymal cell line (17). However, most evidence is directed 
toward a role for NFAT1. In one study NFAT1 knock-out mice showed increased 
endochondral ossification and expression of chondrogenic markers, and the 
authors concluded that NFAT1 serves as a repressor of cartilage cell growth and 
differentiation (18). However, other studies have shown opposite roles for NFAT1. 
NFAT1 promoted ADAMTS-4 expression (19) and NFAT2 activates ADMTS-9 in 
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chondrocytes (20), which are both catabolic effects. Mice lacking NFAT1 exhibited 
normal skeletal development but displayed loss of specific anabolic factors (such 
as BMPs and TGFβ) with over-expression of specific matrix-degrading proteinases 
(MMPs and ADAMTSs) and proinflammatory cytokines (interleukins) in young adult 
articular cartilage of load-bearing joints. These initial changes were followed by 
articular chondrocyte proliferation/clustering, progressive articular surface de-
struction, periarticular chondro-osteophyte formation and exposure of thickened 
subchondral bone, all of which resemble human OA (21, 22). NFAT1-/-NFAT2col2 
double knockout mice displayed severe cartilage degradation with increased 
expression of genes encoding many matrix-degrading proteinases and increased 
expression of hypertrophic chondrocyte marker COL10. Expression of Sox9 and 
lubricin were reduced in the double knockout mice (23). These data suggest that 
NFAT1 supresses catabolic metabolism and hypertrophy in articular chondrocytes 
and thereby the development of OA. We examined the gene expression of NFAT1-
4 during the dedifferentiation of osteoarthritic chondrocytes in the experiments 
of chapter 2. Consistent with most of the data above, we measured decreased 
expression of NFAT1 during dedifferentiation and increased expression of NFAT3, 
while NFAT2 and NFAT4 were not significantly regulated (data not shown). Un-
fortunately, we were not able to evaluate the expression and activity of NFATs on 
protein level, which would provide more valuable information.
Physiological omsolarity improves matrix synthesis by 
chondrocytes
Chondrocytes experience a hyperosmotic environment in vivo compared with 
plasma (280 mOsm) due to the high fixed negative charge density of the glycosami-
noglycan side chains of proteoglycans (24). The extracellular osmolarity of healthy 
articular cartilage ranges between 350 and 480 mOsm (25, 26). As mentioned be-
fore, during cartilage degeneration in OA, the extracellular osmolarity decreases 
as a result of matrix breakdown (27). Standard isolation of chondrocytes removes 
the hyperosmotic matrix, exposing the cells to nonphysiological conditions in stan-
dard culture medium of 280 mOsm. In chapter 3 we report a simple, yet effective 
method to improve chondrogenic marker expression by osteoarthritic and healthy 
human chondrocytes in vitro. Increasing the medium osmolarity from 280 mOsm up 
to physiological levels (here: 380 mOsm) by adding sterile sodium chloride during 
isolation and monolayer expansion increased levels of COL2, aggrecan and SOX9, 
while it decreased the unwanted COL1. Several studies have shown that nonhuman 
chondrocytes are tonicity responsive and react with changes in matrix synthesis. 
In 1993, incorporation of [35S]sulphate and 3H-proline into glycosaminoglycans 
(GAGs) was reported to be maximized between 350 and 400 mOsm (within cartilage 
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physiological range) for both freshly isolated chondrocytes and for chondrocytes 
in cartilage (26). GAG production was largest in 370 mOsm and the capacity for 
GAG production and cell metabolism was low under hypo- and hyperosmotic 
conditions (28). Palmer et al. described that hyperosmotic (supraphysiological, 580-
680mOsm) loading of bovine articular chondrocytes decreased aggrecan promoter 
activity and mRNA expression. Osmotic regulation of aggrecan gene expression 
was time-dependent and correlated with cell shrinkage and swelling (29). This was 
further investigated by Hung et al. who showed that aggrecan gene expression 
was elevated in monolayer chondrocytes subjected to osmotic solutions below 360 
mOsm (relative cell swelling) and suppressed above 360 mOsm (cell shrinking). 
Interestingly, there appeared to be a direct correlation between early cell size 
change (shrinking) and suppression of aggrecan transcription under hyperosmotic 
loading, while this correlation was absent under hypotonic loading (30). These data 
suggest that both the osmotic environment and the applied force (cell deformation 
or membrane folding) regulate the transcriptional response.
Besides the effects of hyperosmotic conditions on aggrecan production, Tew et 
al. revealed an osmotically driven increase in post-transcriptional stability of SOX9 
and activity of a COL2A1 enhancer-driven reporter (31). Cyclical osmotic loading of 
healthy dedifferentiated and primary OA chondrocytes but not of primary healthy 
chondrocytes led to an increase in SOX9 gene expression (32), indicating that the 
response to osmotic loading of SOX9 mRNA is dependent on the nature of the 
osmotic stimulation and the chondrocyte phenotype.
The molecular mechanism by which physiological osmolarity improves matrix 
synthesis by human articular chondrocytes has not been completely clarified. In 
chapter 3 we first identified the role of NFAT5 (TonEBP) in this process. NFAT5 was 
abundantly expressed in both healthy and OA chondrocytes throughout passages 
at standard osmolarity (280 mOsm) and further increased by physiological osmo-
larity (380 mOsm). Unfortunately, we failed to show NFAT5 protein expression. 
Whether this failure is due to low protein abundance or technical issues remains to 
be elucidated. However, mRNA levels of well accepted NFAT5 target genes, S100A4 
and SLC6A12, were induced accordingly after physiological osmotic challenge. In 
addition, knockdown of NFAT5 inhibited the osmolarity-induced expression of 
both the chondrogenic markers and S100A4/SLC6A12. So, aside from regulating 
intracellular osmolarity, NFAT5 seems to be a key regulator of matrix synthesis in 
response to osmotic changes in the extracellular environment. However, the down-
stream effect of NFAT5 needs to be further investigated. The human aggrecan 
promoter sequence has been shown to contain a conserved NFAT5 binding site 
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in nucleus pulposus cells and suppression of NFAT5 activity decreased aggrecan 
promoter activity (33). NFAT5 also regulated BMP2 and TGFβ mediated induction 
of β1,3-glucoronosyltransferase, an enzyme required for the synthesis of chondroi-
tin sulfate chains of aggrecan (34, 35). On the other hand, we showed that SOX9, 
a known regulator of aggrecan and COL2 expression, increased by physiological 
osmolarity and was decreased by NFAT5 knockdown (chapter 3 and 5) (31). There-
fore, it is also possible that NFAT5 regulates COL2 and aggecran expression in 
a SOX9-dependent manner rather than direct regulation of the promoter activity 
of COL2 and aggrecan. Details of the downstream effects of NFAT5 in regulating 
chondrogenic marker expression require further investigation. 
Calcineurin inhibition at physiological osmolarity: effects on 
catabolic enzymes
In chapter 4 we combined treatments from chapter 2 and 3 and showed that Cn 
inhibition by FK506 at physiological osmolarity exerts a superior effect. Adding 
FK506 to medium of physiological osmolarity (380 mOsm) dose-dependently 
enhanced chondrogenic markers to a much greater extent than FK506 or physi-
ological osmolarity alone. In both monolayer (2D) and explant (3D) cultures, COL2 
mRNA and protein expression profited relatively more from this combined treat-
ment effect than aggrecan mRNA and GAG expression did. However, our data 
indicated that the combined treatment could only delay, but not prevent chondro-
cyte de-differentiation in vitro. 
As OA is characterized by increased expression of catabolic enzymes, like metal-
loproteinases (MMPs) and aggrecanases ADAMTS4 and -5 (36-39), we also inves-
tigated the regulation of these enzymes in chapter 4. ADAMTS4 and -5 were not 
influenced by 380 mOsm or FK506 alone, but the combination decreased their ex-
pression. Interestingly, the catabolic enzymes MMP1, MMP8 and MMP13, and the 
hypertrophic markers COL10 and alkaline phosphatase (ALPL) were increased by 
physiological osmolarity in osteoarthritic human chondrocytes. Especially MMP13 
is thought to be the major type II collagen-degrading collagenase in OA, that not 
only contributes to irreversible joint damage (progression) in OA, but importantly, 
also to the initiation/onset phase, wherein chondrocytes in articular cartilage leave 
their natural growth- and differentiation-arrested state (38). Continued overload-
ing, stress and pro-inflammatory cytokines activate NF-κB-dependent pathways 
(via Toll-like receptors (TLRs) and specific protein kinase C (PKC) isoforms) and ERK/
p38, which are known to activate MMP13 via other regulatory transcription factors 
(like ELF3 and HIF2A), facilitating the progression of articular chondrocytes to a 
hypertrophic-like differentiated state in vivo, thereby also contributing to OA onset 
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and/or progression (38). The role of NFAT5 in the osmolarity-induced upregula-
tion of MMP13 and other MMPs and aggrecanases remains to be elucidated. In a 
murine fibroblast cell line it was discovered that NFAT5 binds to the TNF-promoter, 
in a pattern distinct from NFAT1 (a key factor involved in TNF gene regulation in 
T and B cells) and activates transcription of the pro-inflammatory cytokine TNF 
during hyperosmotic stress (40). In addition, NFAT5 is reported to mediate the 
effects of TLRs in macrophages by up-regulating IL-6, NOS2, VCAN and MMP13 
(41). In inflammatory arthritis, TLR activation of NFAT5 seems to occur in a p38/
MAPK-dependent manner rather than a hyperosmotic-dependent manner (42). On 
the other hand, hyperosmolarity-stimulated p38 activated NFAT5, which in turn 
directly enhances the activity of the NF-κB pathway (43). Taken together, these 
data suggest that besides the role of NFAT5 in protecting against cellular damage 
during hyperosmotic stress, it also plays a role in mediating TLR- and NF-κB activa-
tion of pro-inflammatory targets under pathological conditions (figure 1). Thereby, 
NFAT5 might contribute to increased expression of catabolic enzymes, like MMPs 
and aggrecanases, in the onset of OA.
Interestingly, in chapter 4 we discovered that FK506 had a suppressing effect on 
the osmolarity/NFAT5-induced expression of the unwanted catabolic and hyper-
trophic markers. This data is in agreement with CsA inhibiting the IL1β-induced 
MMP1 and MMP3 expression in a murine model for OA (4) and with CsA inhibiting 
IL1α-induced MMP13, ADAMTS4 and ADAMTS5 in articular cartilage explants (45). 
FK506 is capable of suppressing MMP-13 synthesis via JNK pathway in rheumatoid 
synovium (46). Both FK506 and CsA are well known for their immunosuppressive 
effects. Inhibition of Cn leads to inhibition of NFAT translocation to the nucleus, 
Figure 1. Adopted from Johnson et al. Matrix Biology 40 (2014) 10-16 (44).
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where NFATs initiate transcription of pro-inflammatory cytokines through binding 
to DNA in conjuction with AP-1 (47). However, some studies have linked inhibition 
of the Cn pathway to suppression of NF-κB signaling (48) and suppressive effects 
of FK506 on NF-κB signaling in peripheral human T-cells has been described (49). 
In addition, both CsA and FK506 are reported to impair TLR function after liver 
transplantation in comparison with healthy controls and there are direct correlations 
between serum levels and TLR function in peripheral immune cells (50). Whether 
FK506 suppressed the osmolarity-induced catabolic and hypertrophic markers via 
a Cn/NFAT-dependent or rather a TLR/NF-κB-dependent manner would be of 
interest in further research. Although controversial, NFAT5 might also be induced 
by a Cn-regulated but NFATc-independent mechanism, and NFAT5-dependent 
transcription can be inhibited by CsA and FK506 in T-cells (51). However, in our 
experiments induction of NFAT5 by a osmotic stimulus was not blocked by inhibi-
tion of Cn (51).
Treatment effects on chondroprogenitor cells
Chondrogenic differentiation of progenitor cells plays an essential role during 
endochondral ossification for skeletal growth and bone fracture healing. More-
over, mesenchymal progenitor cells are also used as an alternative cell source 
for cell-based cartilage regeneration. Therefore, new methodologies improving 
chondrogenic differentiation of mesenchymal progenitor and stem cells into 
chondrocytes are of interest for cartilage and bone regenerative medicine ap-
proaches. In chapter 5, the ATDC5 chondroprogenitor cell line and human bone 
marrow stem cells were used as in vitro models for chondrogenic differentiation 
and the effect of physiological osmolarity was studied. We found that cartilage 
physiological osmolarity (410 ±5 mOsm) improved chondrogenic differentiation of 
ATDC5 cells. Both chondrogenic (Sox9, Col2 and aggrecan, GAG content) and 
hypertropic (RunX2 and Col10) markers were increased. When the osmolarity 
was further increased up to non-physiological cartilage levels of 510 ±5 mOsm, 
chondrogenic differentiation was inhibited compared to control conditions (310 
±5 mOsm). In addition, we found that human bone marrow derived mesenchymal 
stem cells (hBMCs) responded similarly to physiological osmolarity as ATDC5 cells. 
Bertram et al. (52) showed that synovial fluid harvested from healthy joints ranged 
from 295-340 mOsm, while values from OA joints ranged from 249-277 mOsm and 
rheumatoid arthritis (RA) joints ranged from 273-283 mOsm. By harvesting mesen-
chymal progenitor cells (expressing CD90) from the synovial fluid of OA and RA 
joints and culturing them under different osmolarities they concluded that the cells 
retained increased chondrogenic potential if differentiated under the same tonicity 
for which they were derived within. These data confirms our results that osmolarity 
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regulates the chondrogenic potential of mesencymal progenitor cells. However, 
where healthy progenitor cells improve their chondrogenic potential at physiologi-
cal (healthy) osmolarity (chapter 5 and (52)), arthritic synovial progenitor cells did 
not and preferred pathological osmolarity of 264 mOsm (52). Healthy synovial fluid 
mesenchymal progenitor cells showed increased chondrogenic capacity compared 
to arthritic cells. Pathological changes in in vivo osmolarity of the synovial fluid 
may lead to a selection of a subpopulation of progenitor cells with decreased 
chondrogenic potential.
In chapter 5 we also show that knockdown of NFAT5 under both control (plasma 
level) and cartilage physiological osmolarity decreased chondrogenic differen-
tiation of healthy progenitor cells and suppressed the osmolarity-induced chon-
drogenic induction. Early expression of Sox9 in the differentiation process was 
decreased by NFAT5 knockdown, while knockdown of Sox9 in early differentiation 
did not decrease NFAT5 expression. These data suggest that NFAT5 is involved in 
regulating chondrogenic differentiation of chondroprogenitor cells under control 
and physiological osmolarity and may regulate its chondrogenic effects, at least in 
part, through transcription factor Sox9. Post-transcriptional stabilization of Sox9 
mRNA is controlled by p38 MAPK signaling (53), which is also known to be involved 
in the hyperosmotic activation of NFAT5 (43, 54). The transcriptional mechanism 
through which NFAT5 acts upstream of Sox9 has to be addressed in future studies. 
The stimulating effect of physiological osmolarity on the expression of hypertrophic 
and terminal differentiation markers is a favourable event in improving endochon-
dral regeneration medicine approaches, but unfavourable in improving cartilage 
regenerative medicine treatments. Therefore, in chapter 6 we investigated the 
effects of FK506 on osmolarity-induced chondrogenic and terminal differentiation 
markers in chondroprogenitor cells. We found that physiological osmolarity pro-
moted chondrocytic and hypertrophic differentiation of pre-chondrocytes, without 
altering differentiation from hypertrophic to terminally differentiated chondrocytes 
expressing mineralization markers. FK506 inhibited Cn activity at both control and 
physiological osmolarity, but only improved chondrogenic differentiation markers 
Col9 and Col 11 at physiological osmolarity. This might indicate that the effect of 
FK506 on differentiation of progenitor cells is (partially) dependent on the osmolar-
ity and not fully dependent on Cn. This is in line with the study by Nishigaki et al. 
(6) where FK506 but not CsA induced chondrogenic differentiation of ATDC5 cells 
after binding to FKBP. 
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However, the effects of FK506 on chondrogenic differentiation of ATDC5 cells in 
physiological osmolarity differ from the effects of FK506 on osteoarthritic mature 
chondrocytes in monolayer or explant cultures at physiological osmolarity. Where 
FK506 at physiological osmolarity further increased most chondrogenic markers 
and the COL2:COL1 ratio in osteoarthritic cells (chapter 4, figure 1+5; chapter 7, 
figure 2), it only increased Col9 and Col11 and did not increase the Col2:Col1 ratio 
in ATDC5 cells at physiological osmolarity (chapter 6, figure 1). In addition, FK506 
could not decrease hypertrophic and terminal differentiation markers in ATDC5 
cells at physiological osmolarity (chapter 6, figure 2+3), which is in contrast to the 
inhibiting effect of FK506 on hypertrophy in osteoarthritic chondrocytes (chapter 
4, figure 3+5; chapter 7, figure 2). The ATDC5 cell line in these experiments is used 
as a model for the multistep differentiation process of chondroprogenitor cells 
during endochondral bone formation, which is a different process than redifferen-
tiation of osteoarthritic mature chondrocytes. This could explain why the effects of 
FK506 on chondroprogenitor cells differ from the effects on osteoarthritic mature 
chondrocytes. 
In conclusion, we found evidence that FK506 may be therapeutically useful in 
repairing focal articular cartilage lesions or in joints with osteoarthritis, where it can 
act on mature chondrocytes. The results of chapter 6 and those of other studies (5, 
7) indicate that FK506 also promotes early chondrogenic differentiation of chon-
droprogenitor cells, without altering differentiation to hypertrophic and terminally 
differentiated cells. Future studies should investigate whether changes in FK506 
concentration or timing during chondrogenic differentiation of chondroprogenitor 
cells could achieve an inhibiting effect on cell hypertrophy, making FK506 also more 
useful for cartilage tissue engineering approaches using chondroprogenitor cells.
Clinical application and future directions
FK506 has proven to be useful in reducing inflammation and alleviating symptoms 
in patients with inflammatory (rheumatoid) joint disease (55, 56). To investigate 
whether patients with non-inflammatory joint diseases, like OA, also benefit from 
treatment with FK506, we examined in chapter 7 the effects of systemic FK506 
in a rat model for OA. FK506 treatment protected extracellular matrix integrity in 
vivo by markedly decreasing subchondral sclerosis, reducing development of sub-
chondral pores, depletion of synovial macrophage activation and less osteophyte 
formation. FK506 treatment did not protect against sGAG loss in the OA model, 
but did protect against structural matrix degradation. OA is a complex disease and 
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disturbed balance between anabolic and catabolic activity of chondrocytes is an 
early event leading to matrix degradation. Progression of OA finally results in severe 
detoriation of articular cartilage and involves pathological changes throughout the 
joint, like extensive subchondral bone remodelling and activation of macrophages. 
We found indications that FK506 might not only affect chondrocytes, but may also 
directly modulate osteoblast and osteoclast activity and macrophage activity.
Although being a lot more potent than CsA and therefore more effective and safer 
at lower concentrations, even FK506 is known to cause cytotoxic effects when 
applied systemically. Calcineurin protein is expressed in for example the brain, 
spleen, thymus, heart, liver, pancreas and kidney. Both CsA and FK506 therefore 
induce considerable toxicity, like nephrotoxicity, neurotoxicity, glucose intolerance 
and diabetes, hypertension, hepatotoxicity and gastrointestinal disturbances (57). 
In our study the used dose of systemic FK506 did not influence liver and kidney 
function at the end of the 12-week experiment. Liver and kidney histology gave no 
indication for induced fibrosis. Several clinical trials have attempted to evaluate the 
efficacy and toxicity of add-on FK506 in patients with active Rheumatoid Arthritis 
(RA) who failed to show an adequate response to DMARDs. FK506 at dosages of 
mean 1.3 mg/day for 24 weeks appeared to be well tolerated and induced infection 
in 2.3% out of 172 patients, renal impairment in 1.2%, cardiac dysfunction in 0.6% 
and glucose intolerance in 0.6% (58). Minor adverse effects like gastrointestinal 
disorders (abdominal pain, diarrhea) occurred in 4.1% of patients. However, the 
systemic dosage used in these experiments is much lower than the dose used 
in our rat experiments (1 mg/kg/day). Therefore, despite the promising findings, 
systemic FK506 treatment cannot be translated toward clinical OA care directly. 
The possible induced side effects and toxicity are unacceptable for treating a non-
life-threatening disease like OA. To reduce toxicity, local intra-articular treatment 
is preferable. Repetitive intra-articular injections increase the risk of iatrogenic 
arthritis and should be avoided. Sustained intra-articular drug delivery by loaded 
biodegradable hydrogels (59, 60) might be a promising solution and is of interest 
for future research. 
In this dissertation we also showed that physiological osmolarity can be used for 
optimizing the in vitro culture conditions for cell transplantation techniques for 
cartilage repair. However, the in vivo use toward a treatment for OA or chondral 
lesions is again challenging and needs to be investigated. As stated before, re-
petitive intra-articular injections of saline upto physiological osmolarity should be 
avoided. The use of a hyperosmotic rinsing solution during orthopaedic surgery 
(61) or the use of hydrogels to deliver a sustained hyperosmotic solution in the 
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articular joint might be promising tools to influence the extracellular osmolarity of 
the damaged cartilage and hopefully leading to an increase in extracellular matrix 
production by the chondrocytes in situ to modulate the progression of OA. This, 
especially in combination with local controlled release of FK506 or more specific 
newer Cn- or NFAT-regulating small molecular compounds, holds potential to alter 
the course of OA in the future.
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The research that is reported in this dissertation aimed at finding new potential 
targets or tools for improving cartilage matrix synthesis by chondrocytes and pro-
genitor cells, either in vitro for cell transplantation techniques or in vivo toward a 
treatment for osteoarthritis (OA). The studies focus on influencing the calcineurin-
dependent NFAT1-4 pathway and the osmolarity-dependent NFAT5 pathway. 
In chapter 2 we identified calcineurin (Cn) as a potential target to improve chon-
drogenic phenotype of culture-expanded osteoarthritic chondrocytes. During in 
vitro expansion, required for cell-based therapies, loss of chondrocyte phenotype 
takes place (dedifferentiation). Chondrocytes convert into a flattened, fibroblast-
like state, accompanied by a shift from collagen type II to collagen type I expres-
sion, reducing the quality of the extracellular matrix (ECM). Calcineurin activity in 
human articular chondrocytes was significantly increased during dedifferentiation 
and decreased during redifferentiation in vitro. Inhibition of Cn activity by FK506 
increased the expression of chondrogenic markers via stimulation of endogenous 
transforming growth factor β1 (TGFβ1). FK506 thereby became an interesting drug 
to promote chondrocytic phenotype for cell-based cartilage repair procedures. 
Next, we focused on the effects of osmolarity on chondrocytic phenotype of 
culture-expanded cells. During cartilage degeneration as in OA, the extracellular 
osmolarity decreases as a result of matrix breakdown, in particular the loss of 
proteoglycans. Chondrocyte in vitro expansion is mostly performed in medium of 
non-physiological tonicity of 270 mOsm, which corresponds to physiological os-
molarity of blood. Cartilage is normally characterized by a much higher interstitial 
osmolarity, in the range of 350 to 400 mOsm. Chapter 3 describes the effects of 
chondrocyte isolation and expansion at cartilage-specific physiological osmolarity 
of 380 mOsm, by adding sterile sodiumchloride to the cell culture medium. Physio-
logical osmolarity improved expression of chondrogenic markers via nuclear factor 
of activated T-cells 5 (NFAT5) in both osteoarthritic and normal (nonosteoartrhritic) 
human chondrocytes in vitro. These results can be used for the development of 
improved cell-based repair strategies for chondral lesions and provide important 
insights into the mechanisms underlying the progression of OA. 
In chapter 4 both treatments (FK506 and physiological osmolarity) were combined 
and we discovered that Cn inhibition by FK506 at physiological osmolarity exerted 
a superior effect than either treatment alone. The combination treatment increased 
anabolic, but now also suppressed unwanted catabolic and hypertrophic markers 
in osteoarthritic and normal (nonosteoartrhritic) human chondrocytes. 
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Mesenchymal progenitor cells have been introduced as alternative cell source 
for cell-based cartilage regeneration. Therefore, new methodologies improving 
chondrogenic differentiation of mesenchymal progenitor and stem cells into chon-
drocytes are of interest for cartilage and bone regenerative medicine approaches. 
In chapter 5, the chondroprogenitor cell line ATDC5 and human bone marrow 
stem cells were used as in vitro models for chondrogenic differentiation. Increas-
ing the osmolarity to cartilage physiological levels also significantly increased the 
chondrogenic capacity of these progenitor cells. Again, we found a regulating role 
for NFAT5 in the chondrogenic differentiation process. 
Terminal differentiation of mesenchymal progenitor cells into hypertrophic 
chondrocytes and mineralization of the tissue is favorable for bone regenerative 
medicine, but unfavorable for cartilage purposes. Based on the results of chapter 
4 and 5, we wondered whether FK506 addition to physiological osmolarity medium 
would be able to inhibit hypertrophic differentiation of progenitor cells. In chapter 
6 we show that FK506 also improved chondrogenic differentiation of progenitor 
cells at physiological osmolarity. Unfortunately, FK506 could not decrease hyper-
trophic and terminal differentiation markers in progenitor cells. These data sug-
gest that FK506 promotes early chondrogenic differentiation of progenitor cells, 
without altering differentiation to hypertrophic and terminally differentiated cells. 
The latter is in contrast to the inhibiting effect of FK506 on hypertrophy in human 
osteoarthritic chondrocytes. 
Chapter 7 describes the in vivo effects of oral FK506 in an animal model for OA. 
FK506 clearly protected against articular cartilage collagenous matrix degradation 
in this model. In addition, it markedly decreased subchondral sclerosis and led to 
less development of subchondral pores as well as depletion of synovial macro-
phage activation and less osteophyte formation. 
In conclusion, we found evidence that FK506 may be therapeutically useful in re-
pairing articular cartilage lesions or in joints with osteoarthritis, where it can act on 
human chondrocytes. Future studies should investigate whether changes in FK506 
concentration or timing during chondrogenic differentiation of progenitor cells 
could achieve an inhibiting effect on cell hypertrophy, making FK506 also more 
useful for cartilage tissue engineering approaches using progenitor cells.
In this dissertation we also showed that physiological osmolarity can be used for 
optimizing the in vitro culture conditions in cell transplantation techniques for 
cartilage repair. The use of a hyperosmotic rinsing solution during orthopaedic 
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surgery or the use of hydrogels to deliver a sustained hyperosmotic solution in 
the articular joint might be a tool to influence the extracellular osmolarity of the 
damaged cartilage. This, especially in combination with local controlled release of 
FK506, holds potential to alter the course of OA in the future.
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Samenvatting
Dit proefschrift beschrijft een aantal onderzoeken gericht op het ontdekken van 
nieuwe technieken of aangrijpingspunten om de synthese van kraakbeenmatrix 
door kraakbeencellen (chondrocyten) en stamcellen te verbeteren, zowel in vitro 
tijdens cel transplantatie technieken, als in vivo voor een behandeling voor artrose. 
De onderzoeken zijn gericht op het beïnvloeden van de calcineurine afhankelijke 
NFAT1-4 en de calcineurine onafhankelijke NFAT5 signaal transductie cascade. 
In hoofdstuk 2 identificeerden we calcineurine (Cn) als potentieel doelwit om het 
kraakbeen fenotype van chondrocyten, verkregen uit een artrotisch gewricht, in 
een kweekcultuur te verbeteren. Tijdens het kweken en vermenigvuldigen van cel-
len voor cel therapieën, verliezen de chondrocyten hun specifieke fenotype (dedif-
ferentiatie). De chondrocyten veranderen in plattere, fibroblast-achtige cellen. Dit 
gaat gepaard met minder collageen type 2 en meer collageen type 1 expressie, 
waardoor de kwaliteit van de extracellulaire matrix vermindert. De calcineurine 
activiteit was significant hoger tijdens de dedifferentiatie van de chondrocyten in 
vitro en was juist lager tijdens redifferentiatie. Remming van de Cn activiteit door 
FK506 leidde tot een hogere expressie van kraakbeen-specifieke markers door-
middel van stimulatie van de endogene groeifactor TGFβ1. FK506 lijkt hierdoor 
een interessant middel om het fenotype van chondrocyten bij celtherapie voor 
kraakbeenherstel te verbeteren. 
In het volgende onderzoek bestudeerden we het effect van osmolariteit op het fe-
notype van chondrocyten in een kweekcultuur. Tijdens degeneratie van het kraak-
been, zoals bij artrose, daalt de extracellulaire osmolariteit door de afbraak van de 
matrix, met name door afbraak van proteoglycanen. Het kweken van chondrocyten 
gebeurt doorgaans in een kweekmedium met een niet-fysiologische osmolariteit 
van 270 mOsm, wat overeenkomt met de osmolariteit van bloed. Gezond kraak-
been heeft echter een veel hogere interstitiële osmolariteit van 350 tot 400 mOsm. 
Hoofdstuk 3 beschrijft het effect van het kweken van chondrocyten in medium 
met een kraakbeen-specifieke fysiologische osmolariteit van 380 mOsm. Deze 
osmolariteit werd bereikt door het toevoegen van steriel natriumchloride aan het 
medium. Deze fysiologische osmolariteit gaf een hogere expressie van kraakbeen 
markers door middel van stimulatie van de transcriptie factor NFAT5, zowel in ar-
trotische als normale (gezonde) kraakbeencellen. Deze resultaten kunnen gebruikt 
worden in de ontwikkeling van betere celtherapieën voor kraakbeendefecten en 
bieden belangrijke inzichten in de onderliggende mechanismen bij de progressie 
van artrose. 
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In hoofdstuk 4 worden beide behandelingen (FK506 en fysiologische osmolariteit) 
gecombineerd en ontdekten we dat remming van Cn door FK506 in een fysiolo-
gische osmolariteit een superieur effect heeft ten opzichte van de afzonderlijke 
behandelingen. De combinatietherapie verhoogde de anabole, maar verlaagde de 
katabole en hypertrofie markers in artrotische en normale humane chondrocyten. 
Mesenchymale stamcellen worden regelmatig gebruikt als alternatieve cel bron 
voor celtherapie voor kraakbeenherstel. Nieuwe methoden om chondrogene 
differentiatie van mesenchymale stamcellen richting chondrocyten te verbeteren, 
zijn daarom interessant voor celtherapieën voor kraakbeen- en botregeneratie. 
In hoofdstuk 5 worden de chondrogene stamcellijn ATDC5 en humane been-
mergstamcellen gebruikt als in vitro model voor chondrogene differentiatie. Het 
verhogen van de osmolariteit van het kweekmedium naar de kraakbeen specifieke 
fysiologische waarde had een significant positief effect op de chondrogene capa-
citeit van deze stamcellen. Ook hier vonden we een belangrijk regulerende rol voor 
NFAT5 in het chondrogene differentiatie proces. 
Terminale chondrogene differentiatie van stamcellen naar hypertrofe chondrocyten 
en mineralisatie van het weefsel is gunstig voor botregeneratie therapieën, maar 
ongunstig voor kraakbeen behandeling. Op basis van de resultaten van hoofdstuk 
4 en 5, vroegen we ons af of FK506 de hypertrofe differentiatie van de stamcellen 
in fysiologische osmolariteit kon remmen. In hoofdstuk 6 werd waargenomen 
dat FK506 ook de chondrogene differentiatie van stamcellen in fysiologische 
osmolariteit verder verbeterde. FK506 had helaas geen remmend effect op de 
hypertrofe en terminale differentiatie markers. Deze resultaten suggereren dat 
FK506 de vroege chondrogene differentiatie van stamcellen stimuleert, zonder de 
differentiatie richting hypertrofe en terminale cellen te beïnvloeden. Dit laatste is 
in tegenstelling tot het remmende effect van FK506 op hypertrofie van humane 
artrose chondrocyten.
Hoofdstuk 7 beschrijft de in vivo effecten van oraal FK506 in een diermodel voor 
artrose. FK506 had een duidelijk beschermend effect tegen de afbraak van de 
collagene kraakbeenmatrix in dit model. Daarnaast verminderde de subchondrale 
sclerose, ontstonden er minder subchondrale poriën, werden synoviale macrofa-
gen minder geactiveerd en werden minder osteofyten gevormd. 
Samengevat vonden we bewijs dat FK506 mogelijk therapeutisch gebruikt kan wor-
den voor het herstel van kraakbeendefecten of in gewrichten met artrose, gezien 
het effect op humane chondrocyten. Toekomstige onderzoeken zullen moeten 
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uitwijzen of aanpassingen in de dosering of het moment van toedienen van FK506 
tijdens chondrogene differentiatie van stamcellen ook een remmend effect op cel-
hypertrofie kunnen bewerkstelligen, waardoor FK506 ook beter toepasbaar wordt 
voor kraakbeenregeneratie therapieën met behulp van stamcellen. 
Dit proefschrift toont ook aan dat fysiologische osmolariteit gebruikt kan worden 
voor het optimaliseren van de in vitro kweekcondities in celtransplantatie thera-
pieën voor kraakbeenherstel. Het gebruik van een hyperosmotische spoelvloeistof 
tijdens orthopaedische operaties of het gebruik van hydrogels die langdurig een 
hyperosmotische vloeistof afgeven in het gewricht, kunnen methoden zijn om de 
extracellulaire osmolariteit van beschadigd kraakbeen te beïnvloeden. Dit, en 
vooral in combinatie met lokale gecontroleerde afgifte van FK506, is een potenti-
ele manier om het beloop van artrose in de toekomst te kunnen veranderen. 
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